#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Orbitofrontal cortex connectivity as a mechanism of adolescent behavior change
#Text=An increasing number of studies have implicated network functional connectivity with addiction.
1-1	0-13	Orbitofrontal	_	
1-2	14-20	cortex	_	
1-3	21-33	connectivity	_	
1-4	34-36	as	_	
1-5	37-38	a	_	
1-6	39-48	mechanism	_	
1-7	49-51	of	_	
1-8	52-62	adolescent	_	
1-9	63-71	behavior	_	
1-10	72-78	change	_	
1-11	79-81	An	_	
1-12	82-92	increasing	_	
1-13	93-99	number	_	
1-14	100-102	of	_	
1-15	103-110	studies	_	
1-16	111-115	have	_	
1-17	116-126	implicated	_	
1-18	127-134	network	_	
1-19	135-145	functional	_	
1-20	146-158	connectivity	_	
1-21	159-163	with	_	
1-22	164-173	addiction	_	
1-23	173-174	.	_	

#Text=Yet, none have examined functional connectivity as a potential mechanism of adolescent behavior change.
2-1	175-178	Yet	_	
2-2	178-179	,	_	
2-3	180-184	none	_	
2-4	185-189	have	_	
2-5	190-198	examined	_	
2-6	199-209	functional	_	
2-7	210-222	connectivity	_	
2-8	223-225	as	_	
2-9	226-227	a	_	
2-10	228-237	potential	_	
2-11	238-247	mechanism	_	
2-12	248-250	of	_	
2-13	251-261	adolescent	_	
2-14	262-270	behavior	_	
2-15	271-277	change	_	
2-16	277-278	.	_	

#Text=We examined the underlying neural mechanisms of a promising treatment for adolescents, motivational interviewing (MI).
3-1	279-281	We	_	
3-2	282-290	examined	_	
3-3	291-294	the	_	
3-4	295-305	underlying	_	
3-5	306-312	neural	_	
3-6	313-323	mechanisms	_	
3-7	324-326	of	_	
3-8	327-328	a	_	
3-9	329-338	promising	_	
3-10	339-348	treatment	_	
3-11	349-352	for	_	
3-12	353-364	adolescents	_	
3-13	364-365	,	_	
3-14	366-378	motivational	_	
3-15	379-391	interviewing	_	
3-16	392-393	(	_	
3-17	393-395	MI	_	
3-18	395-396	)	_	
3-19	396-397	.	_	

#Text=We began by employing psychophysiological interaction (PPI) to evaluate network response in a sample of adolescent cannabis users (N = 30).
4-1	398-400	We	_	
4-2	401-406	began	_	
4-3	407-409	by	_	
4-4	410-419	employing	_	
4-5	420-439	psychophysiological	_	
4-6	440-451	interaction	_	
4-7	452-453	(	_	
4-8	453-456	PPI	_	
4-9	456-457	)	_	
4-10	458-460	to	_	
4-11	461-469	evaluate	_	
4-12	470-477	network	_	
4-13	478-486	response	_	
4-14	487-489	in	_	
4-15	490-491	a	_	
4-16	492-498	sample	_	
4-17	499-501	of	_	
4-18	502-512	adolescent	_	
4-19	513-521	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
4-20	522-527	users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
4-21	528-529	(	_	
4-22	529-530	N	_	
4-23	531-532	=	_	
4-24	533-535	30	_	
4-25	535-536	)	_	
4-26	536-537	.	_	

#Text=Next, we examined correlations between network connectivity and clinical metrics of treatment outcome.
5-1	538-542	Next	_	
5-2	542-543	,	_	
5-3	544-546	we	_	
5-4	547-555	examined	_	
5-5	556-568	correlations	_	
5-6	569-576	between	_	
5-7	577-584	network	_	
5-8	585-597	connectivity	_	
5-9	598-601	and	_	
5-10	602-610	clinical	_	
5-11	611-618	metrics	_	
5-12	619-621	of	_	
5-13	622-631	treatment	_	
5-14	632-639	outcome	_	
5-15	639-640	.	_	

#Text=PPI analyses seeded on the orbitofrontal cortex (OFC) showed significant increases in functional connectivity across the inferior frontal gyrus (IFG), precentral gyrus, anterior and posterior cingulate gyrus, supplementary motor area (SMA), superior frontal gyrus, pallidus, caudate, and parahippocampal gyrus.
6-1	641-644	PPI	_	
6-2	645-653	analyses	_	
6-3	654-660	seeded	_	
6-4	661-663	on	_	
6-5	664-667	the	_	
6-6	668-681	orbitofrontal	_	
6-7	682-688	cortex	_	
6-8	689-690	(	_	
6-9	690-693	OFC	_	
6-10	693-694	)	_	
6-11	695-701	showed	_	
6-12	702-713	significant	_	
6-13	714-723	increases	_	
6-14	724-726	in	_	
6-15	727-737	functional	_	
6-16	738-750	connectivity	_	
6-17	751-757	across	_	
6-18	758-761	the	_	
6-19	762-770	inferior	_	
6-20	771-778	frontal	_	
6-21	779-784	gyrus	_	
6-22	785-786	(	_	
6-23	786-789	IFG	_	
6-24	789-790	)	_	
6-25	790-791	,	_	
6-26	792-802	precentral	_	
6-27	803-808	gyrus	_	
6-28	808-809	,	_	
6-29	810-818	anterior	_	
6-30	819-822	and	_	
6-31	823-832	posterior	_	
6-32	833-842	cingulate	_	
6-33	843-848	gyrus	_	
6-34	848-849	,	_	
6-35	850-863	supplementary	_	
6-36	864-869	motor	_	
6-37	870-874	area	_	
6-38	875-876	(	_	
6-39	876-879	SMA	_	
6-40	879-880	)	_	
6-41	880-881	,	_	
6-42	882-890	superior	_	
6-43	891-898	frontal	_	
6-44	899-904	gyrus	_	
6-45	904-905	,	_	
6-46	906-914	pallidus	_	
6-47	914-915	,	_	
6-48	916-923	caudate	_	
6-49	923-924	,	_	
6-50	925-928	and	_	
6-51	929-944	parahippocampal	_	
6-52	945-950	gyrus	_	
6-53	950-951	.	_	

#Text=Further, greater functional connectivity between the OFC and anterior cingulate/medial frontal gyrus was associated with less behavior change (e.g., greater post-treatment cannabis problems).
7-1	952-959	Further	_	
7-2	959-960	,	_	
7-3	961-968	greater	_	
7-4	969-979	functional	_	
7-5	980-992	connectivity	_	
7-6	993-1000	between	_	
7-7	1001-1004	the	_	
7-8	1005-1008	OFC	_	
7-9	1009-1012	and	_	
7-10	1013-1021	anterior	_	
7-11	1022-1031	cingulate	_	
7-12	1031-1032	/	_	
7-13	1032-1038	medial	_	
7-14	1039-1046	frontal	_	
7-15	1047-1052	gyrus	_	
7-16	1053-1056	was	_	
7-17	1057-1067	associated	_	
7-18	1068-1072	with	_	
7-19	1073-1077	less	_	
7-20	1078-1086	behavior	_	
7-21	1087-1093	change	_	
7-22	1094-1095	(	_	
7-23	1095-1098	e.g	_	
7-24	1098-1099	.	_	
7-25	1099-1100	,	_	
7-26	1101-1108	greater	_	
7-27	1109-1123	post-treatment	_	
7-28	1124-1132	cannabis	_	
7-29	1133-1141	problems	_	
7-30	1141-1142	)	_	
7-31	1142-1143	.	_	

#Text=These data support the role of the OFC network as a mechanism of adolescent addiction treatment response.
8-1	1144-1149	These	_	
8-2	1150-1154	data	_	
8-3	1155-1162	support	_	
8-4	1163-1166	the	_	
8-5	1167-1171	role	_	
8-6	1172-1174	of	_	
8-7	1175-1178	the	_	
8-8	1179-1182	OFC	_	
8-9	1183-1190	network	_	
8-10	1191-1193	as	_	
8-11	1194-1195	a	_	
8-12	1196-1205	mechanism	_	
8-13	1206-1208	of	_	
8-14	1209-1219	adolescent	_	
8-15	1220-1229	addiction	_	
8-16	1230-1239	treatment	_	
8-17	1240-1248	response	_	
8-18	1248-1249	.	_	

#Text=Introduction
#Text=Cannabis and alcohol are two of the most widely abused substances among adolescents.
9-1	1250-1262	Introduction	_	
9-2	1263-1271	Cannabis	_	
9-3	1272-1275	and	_	
9-4	1276-1283	alcohol	_	
9-5	1284-1287	are	_	
9-6	1288-1291	two	_	
9-7	1292-1294	of	_	
9-8	1295-1298	the	_	
9-9	1299-1303	most	_	
9-10	1304-1310	widely	_	
9-11	1311-1317	abused	_	
9-12	1318-1328	substances	_	
9-13	1329-1334	among	_	
9-14	1335-1346	adolescents	_	
9-15	1346-1347	.	_	

#Text=Though it remains to be seen whether newly instantiated changes in United States (U.S.) cannabis legislation will cause rates of adolescent misuse to escalate , rates of daily cannabis use have steadily been on the rise for youth .
10-1	1348-1354	Though	_	
10-2	1355-1357	it	_	
10-3	1358-1365	remains	_	
10-4	1366-1368	to	_	
10-5	1369-1371	be	_	
10-6	1372-1376	seen	_	
10-7	1377-1384	whether	_	
10-8	1385-1390	newly	_	
10-9	1391-1403	instantiated	_	
10-10	1404-1411	changes	_	
10-11	1412-1414	in	_	
10-12	1415-1421	United	_	
10-13	1422-1428	States	_	
10-14	1429-1430	(	_	
10-15	1430-1433	U.S	_	
10-16	1433-1434	.	_	
10-17	1434-1435	)	_	
10-18	1436-1444	cannabis	_	
10-19	1445-1456	legislation	_	
10-20	1457-1461	will	_	
10-21	1462-1467	cause	_	
10-22	1468-1473	rates	_	
10-23	1474-1476	of	_	
10-24	1477-1487	adolescent	_	
10-25	1488-1494	misuse	_	
10-26	1495-1497	to	_	
10-27	1498-1506	escalate	_	
10-28	1507-1508	,	_	
10-29	1509-1514	rates	_	
10-30	1515-1517	of	_	
10-31	1518-1523	daily	_	
10-32	1524-1532	cannabis	_	
10-33	1533-1536	use	_	
10-34	1537-1541	have	_	
10-35	1542-1550	steadily	_	
10-36	1551-1555	been	_	
10-37	1556-1558	on	_	
10-38	1559-1562	the	_	
10-39	1563-1567	rise	_	
10-40	1568-1571	for	_	
10-41	1572-1577	youth	_	
10-42	1578-1579	.	_	

#Text=By the start of high school, 26% of U.S. youth have used cannabis, a proportion that increases to 50% by graduation .
11-1	1580-1582	By	_	
11-2	1583-1586	the	_	
11-3	1587-1592	start	_	
11-4	1593-1595	of	_	
11-5	1596-1600	high	_	
11-6	1601-1607	school	_	
11-7	1607-1608	,	_	
11-8	1609-1612	26%	_	
11-9	1613-1615	of	_	
11-10	1616-1619	U.S	_	
11-11	1619-1620	.	_	
11-12	1621-1626	youth	_	
11-13	1627-1631	have	_	
11-14	1632-1636	used	_	
11-15	1637-1645	cannabis	_	
11-16	1645-1646	,	_	
11-17	1647-1648	a	_	
11-18	1649-1659	proportion	_	
11-19	1660-1664	that	_	
11-20	1665-1674	increases	_	
11-21	1675-1677	to	_	
11-22	1678-1681	50%	_	
11-23	1682-1684	by	_	
11-24	1685-1695	graduation	_	
11-25	1696-1697	.	_	

#Text=Similarly, most adolescents experiment with alcohol during the high school years, with 51% reporting drinking alcohol at least one time by the time they start high school, a percent that rises to 73% by senior year .
12-1	1698-1707	Similarly	_	
12-2	1707-1708	,	_	
12-3	1709-1713	most	_	
12-4	1714-1725	adolescents	_	
12-5	1726-1736	experiment	_	
12-6	1737-1741	with	_	
12-7	1742-1749	alcohol	_	
12-8	1750-1756	during	_	
12-9	1757-1760	the	_	
12-10	1761-1765	high	_	
12-11	1766-1772	school	_	
12-12	1773-1778	years	_	
12-13	1778-1779	,	_	
12-14	1780-1784	with	_	
12-15	1785-1788	51%	_	
12-16	1789-1798	reporting	_	
12-17	1799-1807	drinking	_	
12-18	1808-1815	alcohol	_	
12-19	1816-1818	at	_	
12-20	1819-1824	least	_	
12-21	1825-1828	one	_	
12-22	1829-1833	time	_	
12-23	1834-1836	by	_	
12-24	1837-1840	the	_	
12-25	1841-1845	time	_	
12-26	1846-1850	they	_	
12-27	1851-1856	start	_	
12-28	1857-1861	high	_	
12-29	1862-1868	school	_	
12-30	1868-1869	,	_	
12-31	1870-1871	a	_	
12-32	1872-1879	percent	_	
12-33	1880-1884	that	_	
12-34	1885-1890	rises	_	
12-35	1891-1893	to	_	
12-36	1894-1897	73%	_	
12-37	1898-1900	by	_	
12-38	1901-1907	senior	_	
12-39	1908-1912	year	_	
12-40	1913-1914	.	_	

#Text=These levels of use are consequential, as cannabis and alcohol use are a key contributor to accidents and injuries, the number one source of morbidity and mortality for this age group .
13-1	1915-1920	These	_	
13-2	1921-1927	levels	_	
13-3	1928-1930	of	_	
13-4	1931-1934	use	_	
13-5	1935-1938	are	_	
13-6	1939-1952	consequential	_	
13-7	1952-1953	,	_	
13-8	1954-1956	as	_	
13-9	1957-1965	cannabis	_	
13-10	1966-1969	and	_	
13-11	1970-1977	alcohol	_	
13-12	1978-1981	use	_	
13-13	1982-1985	are	_	
13-14	1986-1987	a	_	
13-15	1988-1991	key	_	
13-16	1992-2003	contributor	_	
13-17	2004-2006	to	_	
13-18	2007-2016	accidents	_	
13-19	2017-2020	and	_	
13-20	2021-2029	injuries	_	
13-21	2029-2030	,	_	
13-22	2031-2034	the	_	
13-23	2035-2041	number	_	
13-24	2042-2045	one	_	
13-25	2046-2052	source	_	
13-26	2053-2055	of	_	
13-27	2056-2065	morbidity	_	
13-28	2066-2069	and	_	
13-29	2070-2079	mortality	_	
13-30	2080-2083	for	_	
13-31	2084-2088	this	_	
13-32	2089-2092	age	_	
13-33	2093-2098	group	_	
13-34	2099-2100	.	_	

#Text=Notably, most adolescents see little connection between their substance use and substance-related problems .
14-1	2101-2108	Notably	_	
14-2	2108-2109	,	_	
14-3	2110-2114	most	_	
14-4	2115-2126	adolescents	_	
14-5	2127-2130	see	_	
14-6	2131-2137	little	_	
14-7	2138-2148	connection	_	
14-8	2149-2156	between	_	
14-9	2157-2162	their	_	
14-10	2163-2172	substance	_	
14-11	2173-2176	use	_	
14-12	2177-2180	and	_	
14-13	2181-2198	substance-related	_	
14-14	2199-2207	problems	_	
14-15	2208-2209	.	_	

#Text=Motivational interviewing is an addiction treatment focused on catalyzing and enhancing an individual’s intrinsic motivation and movement toward behavior change; this is one reason why it represents a particularly good fit with non-treatment seeking youth .
15-1	2210-2222	Motivational	_	
15-2	2223-2235	interviewing	_	
15-3	2236-2238	is	_	
15-4	2239-2241	an	_	
15-5	2242-2251	addiction	_	
15-6	2252-2261	treatment	_	
15-7	2262-2269	focused	_	
15-8	2270-2272	on	_	
15-9	2273-2283	catalyzing	_	
15-10	2284-2287	and	_	
15-11	2288-2297	enhancing	_	
15-12	2298-2300	an	_	
15-13	2301-2311	individual	_	
15-14	2311-2312	’	_	
15-15	2312-2313	s	_	
15-16	2314-2323	intrinsic	_	
15-17	2324-2334	motivation	_	
15-18	2335-2338	and	_	
15-19	2339-2347	movement	_	
15-20	2348-2354	toward	_	
15-21	2355-2363	behavior	_	
15-22	2364-2370	change	_	
15-23	2370-2371	;	_	
15-24	2372-2376	this	_	
15-25	2377-2379	is	_	
15-26	2380-2383	one	_	
15-27	2384-2390	reason	_	
15-28	2391-2394	why	_	
15-29	2395-2397	it	_	
15-30	2398-2408	represents	_	
15-31	2409-2410	a	_	
15-32	2411-2423	particularly	_	
15-33	2424-2428	good	_	
15-34	2429-2432	fit	_	
15-35	2433-2437	with	_	
15-36	2438-2451	non-treatment	_	
15-37	2452-2459	seeking	_	
15-38	2460-2465	youth	_	
15-39	2466-2467	.	_	

#Text=MI is one of the strongest evidence-based treatments for adolescent cannabis and alcohol use (SAMHSA; http://www.nrepp.samhsa.gov/), and clinically, it is well received by adolescents .
16-1	2468-2470	MI	_	
16-2	2471-2473	is	_	
16-3	2474-2477	one	_	
16-4	2478-2480	of	_	
16-5	2481-2484	the	_	
16-6	2485-2494	strongest	_	
16-7	2495-2509	evidence-based	_	
16-8	2510-2520	treatments	_	
16-9	2521-2524	for	_	
16-10	2525-2535	adolescent	_	
16-11	2536-2544	cannabis	_	
16-12	2545-2548	and	_	
16-13	2549-2556	alcohol	_	
16-14	2557-2560	use	_	
16-15	2561-2562	(	_	
16-16	2562-2568	SAMHSA	_	
16-17	2568-2569	;	_	
16-18	2570-2574	http	_	
16-19	2574-2575	:	_	
16-20	2575-2576	/	_	
16-21	2576-2577	/	_	
16-22	2577-2597	www.nrepp.samhsa.gov	_	
16-23	2597-2598	/	_	
16-24	2598-2599	)	_	
16-25	2599-2600	,	_	
16-26	2601-2604	and	_	
16-27	2605-2615	clinically	_	
16-28	2615-2616	,	_	
16-29	2617-2619	it	_	
16-30	2620-2622	is	_	
16-31	2623-2627	well	_	
16-32	2628-2636	received	_	
16-33	2637-2639	by	_	
16-34	2640-2651	adolescents	_	
16-35	2652-2653	.	_	

#Text=A single session of MI generates observable behavior change, with weighted effect sizes approaching d = 0.8 (M d = 0.17), and the strongest effect sizes observed within 6 months post-treatment (d = 0.32) .
17-1	2654-2655	A	_	
17-2	2656-2662	single	_	
17-3	2663-2670	session	_	
17-4	2671-2673	of	_	
17-5	2674-2676	MI	_	
17-6	2677-2686	generates	_	
17-7	2687-2697	observable	_	
17-8	2698-2706	behavior	_	
17-9	2707-2713	change	_	
17-10	2713-2714	,	_	
17-11	2715-2719	with	_	
17-12	2720-2728	weighted	_	
17-13	2729-2735	effect	_	
17-14	2736-2741	sizes	_	
17-15	2742-2753	approaching	_	
17-16	2754-2755	d	_	
17-17	2756-2757	=	_	
17-18	2758-2761	0.8	_	
17-19	2762-2763	(	_	
17-20	2763-2764	M	_	
17-21	2765-2766	d	_	
17-22	2767-2768	=	_	
17-23	2769-2773	0.17	_	
17-24	2773-2774	)	_	
17-25	2774-2775	,	_	
17-26	2776-2779	and	_	
17-27	2780-2783	the	_	
17-28	2784-2793	strongest	_	
17-29	2794-2800	effect	_	
17-30	2801-2806	sizes	_	
17-31	2807-2815	observed	_	
17-32	2816-2822	within	_	
17-33	2823-2824	6	_	
17-34	2825-2831	months	_	
17-35	2832-2846	post-treatment	_	
17-36	2847-2848	(	_	
17-37	2848-2849	d	_	
17-38	2850-2851	=	_	
17-39	2852-2856	0.32	_	
17-40	2856-2857	)	_	
17-41	2858-2859	.	_	

#Text=Contrasting with other types of adolescent addiction treatment , ambivalence is one of the central tenets of the clinical framework of MI .
18-1	2860-2871	Contrasting	_	
18-2	2872-2876	with	_	
18-3	2877-2882	other	_	
18-4	2883-2888	types	_	
18-5	2889-2891	of	_	
18-6	2892-2902	adolescent	_	
18-7	2903-2912	addiction	_	
18-8	2913-2922	treatment	_	
18-9	2923-2924	,	_	
18-10	2925-2936	ambivalence	_	
18-11	2937-2939	is	_	
18-12	2940-2943	one	_	
18-13	2944-2946	of	_	
18-14	2947-2950	the	_	
18-15	2951-2958	central	_	
18-16	2959-2965	tenets	_	
18-17	2966-2968	of	_	
18-18	2969-2972	the	_	
18-19	2973-2981	clinical	_	
18-20	2982-2991	framework	_	
18-21	2992-2994	of	_	
18-22	2995-2997	MI	_	
18-23	2998-2999	.	_	

#Text=Ambivalence represents a client’s experience of simultaneously wanting to make a change while also being reticent to do so.
19-1	3000-3011	Ambivalence	_	
19-2	3012-3022	represents	_	
19-3	3023-3024	a	_	
19-4	3025-3031	client	_	
19-5	3031-3032	’	_	
19-6	3032-3033	s	_	
19-7	3034-3044	experience	_	
19-8	3045-3047	of	_	
19-9	3048-3062	simultaneously	_	
19-10	3063-3070	wanting	_	
19-11	3071-3073	to	_	
19-12	3074-3078	make	_	
19-13	3079-3080	a	_	
19-14	3081-3087	change	_	
19-15	3088-3093	while	_	
19-16	3094-3098	also	_	
19-17	3099-3104	being	_	
19-18	3105-3113	reticent	_	
19-19	3114-3116	to	_	
19-20	3117-3119	do	_	
19-21	3120-3122	so	_	
19-22	3122-3123	.	_	

#Text=Concretely, within MI, ambivalence is operationalized as client expressions in favor of changing (change talk; CT), which most often co-occur with client expressions in favor of maintaining a target behavior (sustain talk; ST)  [e.g., “I know I shouldn’t drink (CT), but it is so fun!”
20-1	3124-3134	Concretely	_	
20-2	3134-3135	,	_	
20-3	3136-3142	within	_	
20-4	3143-3145	MI	_	
20-5	3145-3146	,	_	
20-6	3147-3158	ambivalence	_	
20-7	3159-3161	is	_	
20-8	3162-3177	operationalized	_	
20-9	3178-3180	as	_	
20-10	3181-3187	client	_	
20-11	3188-3199	expressions	_	
20-12	3200-3202	in	_	
20-13	3203-3208	favor	_	
20-14	3209-3211	of	_	
20-15	3212-3220	changing	_	
20-16	3221-3222	(	_	
20-17	3222-3228	change	_	
20-18	3229-3233	talk	_	
20-19	3233-3234	;	_	
20-20	3235-3237	CT	_	
20-21	3237-3238	)	_	
20-22	3238-3239	,	_	
20-23	3240-3245	which	_	
20-24	3246-3250	most	_	
20-25	3251-3256	often	_	
20-26	3257-3265	co-occur	_	
20-27	3266-3270	with	_	
20-28	3271-3277	client	_	
20-29	3278-3289	expressions	_	
20-30	3290-3292	in	_	
20-31	3293-3298	favor	_	
20-32	3299-3301	of	_	
20-33	3302-3313	maintaining	_	
20-34	3314-3315	a	_	
20-35	3316-3322	target	_	
20-36	3323-3331	behavior	_	
20-37	3332-3333	(	_	
20-38	3333-3340	sustain	_	
20-39	3341-3345	talk	_	
20-40	3345-3346	;	_	
20-41	3347-3349	ST	_	
20-42	3349-3350	)	_	
20-43	3352-3353	[	_	
20-44	3353-3356	e.g	_	
20-45	3356-3357	.	_	
20-46	3357-3358	,	_	
20-47	3359-3360	“	_	
20-48	3360-3361	I	_	
20-49	3362-3366	know	_	
20-50	3367-3368	I	_	
20-51	3369-3376	shouldn	_	
20-52	3376-3377	’	_	
20-53	3377-3378	t	_	
20-54	3379-3384	drink	_	
20-55	3385-3386	(	_	
20-56	3386-3388	CT	_	
20-57	3388-3389	)	_	
20-58	3389-3390	,	_	
20-59	3391-3394	but	_	
20-60	3395-3397	it	_	
20-61	3398-3400	is	_	
20-62	3401-3403	so	_	
20-63	3404-3407	fun	_	
20-64	3407-3408	!	_	
20-65	3408-3409	”	_	

#Text=(ST)].
21-1	3410-3411	(	_	
21-2	3411-3413	ST	_	
21-3	3413-3414	)	_	
21-4	3414-3415	]	_	
21-5	3415-3416	.	_	

#Text=In practice, therapists must navigate the key challenge of MI: helping clients “resolve” their ambivalence in the direction of behavior change .
22-1	3417-3419	In	_	
22-2	3420-3428	practice	_	
22-3	3428-3429	,	_	
22-4	3430-3440	therapists	_	
22-5	3441-3445	must	_	
22-6	3446-3454	navigate	_	
22-7	3455-3458	the	_	
22-8	3459-3462	key	_	
22-9	3463-3472	challenge	_	
22-10	3473-3475	of	_	
22-11	3476-3478	MI	_	
22-12	3478-3479	:	_	
22-13	3480-3487	helping	_	
22-14	3488-3495	clients	_	
22-15	3496-3497	“	_	
22-16	3497-3504	resolve	_	
22-17	3504-3505	”	_	
22-18	3506-3511	their	_	
22-19	3512-3523	ambivalence	_	
22-20	3524-3526	in	_	
22-21	3527-3530	the	_	
22-22	3531-3540	direction	_	
22-23	3541-3543	of	_	
22-24	3544-3552	behavior	_	
22-25	3553-3559	change	_	
22-26	3560-3561	.	_	

#Text=Therapists can measure their degree of success in this effort by observing clients’ in-session increase expressions of “change talk” and in-session decreased expressions of “sustain talk” .
23-1	3562-3572	Therapists	_	
23-2	3573-3576	can	_	
23-3	3577-3584	measure	_	
23-4	3585-3590	their	_	
23-5	3591-3597	degree	_	
23-6	3598-3600	of	_	
23-7	3601-3608	success	_	
23-8	3609-3611	in	_	
23-9	3612-3616	this	_	
23-10	3617-3623	effort	_	
23-11	3624-3626	by	_	
23-12	3627-3636	observing	_	
23-13	3637-3644	clients	_	
23-14	3644-3645	’	_	
23-15	3646-3656	in-session	_	
23-16	3657-3665	increase	_	
23-17	3666-3677	expressions	_	
23-18	3678-3680	of	_	
23-19	3681-3682	“	_	
23-20	3682-3688	change	_	
23-21	3689-3693	talk	_	
23-22	3693-3694	”	_	
23-23	3695-3698	and	_	
23-24	3699-3709	in-session	_	
23-25	3710-3719	decreased	_	
23-26	3720-3731	expressions	_	
23-27	3732-3734	of	_	
23-28	3735-3736	“	_	
23-29	3736-3743	sustain	_	
23-30	3744-3748	talk	_	
23-31	3748-3749	”	_	
23-32	3750-3751	.	_	

#Text=Yet, much of the knowledge base on MI was generated from samples of treatment-seeking adults who were actively trying to quit drinking (e.g., COMBINE; MATCH; UKATT) .
24-1	3752-3755	Yet	_	
24-2	3755-3756	,	_	
24-3	3757-3761	much	_	
24-4	3762-3764	of	_	
24-5	3765-3768	the	_	
24-6	3769-3778	knowledge	_	
24-7	3779-3783	base	_	
24-8	3784-3786	on	_	
24-9	3787-3789	MI	_	
24-10	3790-3793	was	_	
24-11	3794-3803	generated	_	
24-12	3804-3808	from	_	
24-13	3809-3816	samples	_	
24-14	3817-3819	of	_	
24-15	3820-3837	treatment-seeking	_	
24-16	3838-3844	adults	_	
24-17	3845-3848	who	_	
24-18	3849-3853	were	_	
24-19	3854-3862	actively	_	
24-20	3863-3869	trying	_	
24-21	3870-3872	to	_	
24-22	3873-3877	quit	_	
24-23	3878-3886	drinking	_	
24-24	3887-3888	(	_	
24-25	3888-3891	e.g	_	
24-26	3891-3892	.	_	
24-27	3892-3893	,	_	
24-28	3894-3901	COMBINE	_	
24-29	3901-3902	;	_	
24-30	3903-3908	MATCH	_	
24-31	3908-3909	;	_	
24-32	3910-3915	UKATT	_	
24-33	3915-3916	)	_	
24-34	3917-3918	.	_	

#Text=In contrast, most youth in addiction treatment are non-treatment-seeking (e.g., “opportunistic” clients ), who arrive at the clinician’s office because treatment is either an integrated component of their other medical  or service system care , or because an adult brought them.
25-1	3919-3921	In	_	
25-2	3922-3930	contrast	_	
25-3	3930-3931	,	_	
25-4	3932-3936	most	_	
25-5	3937-3942	youth	_	
25-6	3943-3945	in	_	
25-7	3946-3955	addiction	_	
25-8	3956-3965	treatment	_	
25-9	3966-3969	are	_	
25-10	3970-3991	non-treatment-seeking	_	
25-11	3992-3993	(	_	
25-12	3993-3996	e.g	_	
25-13	3996-3997	.	_	
25-14	3997-3998	,	_	
25-15	3999-4000	“	_	
25-16	4000-4013	opportunistic	_	
25-17	4013-4014	”	_	
25-18	4015-4022	clients	_	
25-19	4023-4024	)	_	
25-20	4024-4025	,	_	
25-21	4026-4029	who	_	
25-22	4030-4036	arrive	_	
25-23	4037-4039	at	_	
25-24	4040-4043	the	_	
25-25	4044-4053	clinician	_	
25-26	4053-4054	’	_	
25-27	4054-4055	s	_	
25-28	4056-4062	office	_	
25-29	4063-4070	because	_	
25-30	4071-4080	treatment	_	
25-31	4081-4083	is	_	
25-32	4084-4090	either	_	
25-33	4091-4093	an	_	
25-34	4094-4104	integrated	_	
25-35	4105-4114	component	_	
25-36	4115-4117	of	_	
25-37	4118-4123	their	_	
25-38	4124-4129	other	_	
25-39	4130-4137	medical	_	
25-40	4139-4141	or	_	
25-41	4142-4149	service	_	
25-42	4150-4156	system	_	
25-43	4157-4161	care	_	
25-44	4162-4163	,	_	
25-45	4164-4166	or	_	
25-46	4167-4174	because	_	
25-47	4175-4177	an	_	
25-48	4178-4183	adult	_	
25-49	4184-4191	brought	_	
25-50	4192-4196	them	_	
25-51	4196-4197	.	_	

#Text=Meta-analytic data on MI with adolescents [(Cohen’s d = 0.17, 95% CI [.09, .25], n = 21) ; (Hedge’s g = .16; 95% CI [.05, .27], n = 8) ; (Hedge’s g = 0.28; 95% CI [0.242, 0.323], n = 37)]  support that youth still show positive behavior change after receiving MI, despite limited interest in receiving addiction treatment.
26-1	4198-4211	Meta-analytic	_	
26-2	4212-4216	data	_	
26-3	4217-4219	on	_	
26-4	4220-4222	MI	_	
26-5	4223-4227	with	_	
26-6	4228-4239	adolescents	_	
26-7	4240-4241	[	_	
26-8	4241-4242	(	_	
26-9	4242-4247	Cohen	_	
26-10	4247-4248	’	_	
26-11	4248-4249	s	_	
26-12	4250-4251	d	_	
26-13	4252-4253	=	_	
26-14	4254-4258	0.17	_	
26-15	4258-4259	,	_	
26-16	4260-4263	95%	_	
26-17	4264-4266	CI	_	
26-18	4267-4268	[	_	
26-19	4268-4271	.09	_	
26-20	4271-4272	,	_	
26-21	4273-4276	.25	_	
26-22	4276-4277	]	_	
26-23	4277-4278	,	_	
26-24	4279-4280	n	_	
26-25	4281-4282	=	_	
26-26	4283-4285	21	_	
26-27	4285-4286	)	_	
26-28	4287-4288	;	_	
26-29	4289-4290	(	_	
26-30	4290-4295	Hedge	_	
26-31	4295-4296	’	_	
26-32	4296-4297	s	_	
26-33	4298-4299	g	_	
26-34	4300-4301	=	_	
26-35	4302-4305	.16	_	
26-36	4305-4306	;	_	
26-37	4307-4310	95%	_	
26-38	4311-4313	CI	_	
26-39	4314-4315	[	_	
26-40	4315-4318	.05	_	
26-41	4318-4319	,	_	
26-42	4320-4323	.27	_	
26-43	4323-4324	]	_	
26-44	4324-4325	,	_	
26-45	4326-4327	n	_	
26-46	4328-4329	=	_	
26-47	4330-4331	8	_	
26-48	4331-4332	)	_	
26-49	4333-4334	;	_	
26-50	4335-4336	(	_	
26-51	4336-4341	Hedge	_	
26-52	4341-4342	’	_	
26-53	4342-4343	s	_	
26-54	4344-4345	g	_	
26-55	4346-4347	=	_	
26-56	4348-4352	0.28	_	
26-57	4352-4353	;	_	
26-58	4354-4357	95%	_	
26-59	4358-4360	CI	_	
26-60	4361-4362	[	_	
26-61	4362-4367	0.242	_	
26-62	4367-4368	,	_	
26-63	4369-4374	0.323	_	
26-64	4374-4375	]	_	
26-65	4375-4376	,	_	
26-66	4377-4378	n	_	
26-67	4379-4380	=	_	
26-68	4381-4383	37	_	
26-69	4383-4384	)	_	
26-70	4384-4385	]	_	
26-71	4387-4394	support	_	
26-72	4395-4399	that	_	
26-73	4400-4405	youth	_	
26-74	4406-4411	still	_	
26-75	4412-4416	show	_	
26-76	4417-4425	positive	_	
26-77	4426-4434	behavior	_	
26-78	4435-4441	change	_	
26-79	4442-4447	after	_	
26-80	4448-4457	receiving	_	
26-81	4458-4460	MI	_	
26-82	4460-4461	,	_	
26-83	4462-4469	despite	_	
26-84	4470-4477	limited	_	
26-85	4478-4486	interest	_	
26-86	4487-4489	in	_	
26-87	4490-4499	receiving	_	
26-88	4500-4509	addiction	_	
26-89	4510-4519	treatment	_	
26-90	4519-4520	.	_	

#Text=One avenue to understand how adolescents respond to this intervention is to examine the mechanisms of treatment response .
27-1	4521-4524	One	_	
27-2	4525-4531	avenue	_	
27-3	4532-4534	to	_	
27-4	4535-4545	understand	_	
27-5	4546-4549	how	_	
27-6	4550-4561	adolescents	_	
27-7	4562-4569	respond	_	
27-8	4570-4572	to	_	
27-9	4573-4577	this	_	
27-10	4578-4590	intervention	_	
27-11	4591-4593	is	_	
27-12	4594-4596	to	_	
27-13	4597-4604	examine	_	
27-14	4605-4608	the	_	
27-15	4609-4619	mechanisms	_	
27-16	4620-4622	of	_	
27-17	4623-4632	treatment	_	
27-18	4633-4641	response	_	
27-19	4642-4643	.	_	

#Text=Defined by Morgenstern (p. 860; ), mechanisms represent “processes occurring within the client” that facilitate or interfere with an individual’s movement toward successful behavior change during treatment.
28-1	4644-4651	Defined	_	
28-2	4652-4654	by	_	
28-3	4655-4666	Morgenstern	_	
28-4	4667-4668	(	_	
28-5	4668-4669	p	_	
28-6	4669-4670	.	_	
28-7	4671-4674	860	_	
28-8	4674-4675	;	_	
28-9	4676-4677	)	_	
28-10	4677-4678	,	_	
28-11	4679-4689	mechanisms	_	
28-12	4690-4699	represent	_	
28-13	4700-4701	“	_	
28-14	4701-4710	processes	_	
28-15	4711-4720	occurring	_	
28-16	4721-4727	within	_	
28-17	4728-4731	the	_	
28-18	4732-4738	client	_	
28-19	4738-4739	”	_	
28-20	4740-4744	that	_	
28-21	4745-4755	facilitate	_	
28-22	4756-4758	or	_	
28-23	4759-4768	interfere	_	
28-24	4769-4773	with	_	
28-25	4774-4776	an	_	
28-26	4777-4787	individual	_	
28-27	4787-4788	’	_	
28-28	4788-4789	s	_	
28-29	4790-4798	movement	_	
28-30	4799-4805	toward	_	
28-31	4806-4816	successful	_	
28-32	4817-4825	behavior	_	
28-33	4826-4832	change	_	
28-34	4833-4839	during	_	
28-35	4840-4849	treatment	_	
28-36	4849-4850	.	_	

#Text=Unfortunately, at this time, examinations of behavioral factors (only) have languished.
29-1	4851-4864	Unfortunately	_	
29-2	4864-4865	,	_	
29-3	4866-4868	at	_	
29-4	4869-4873	this	_	
29-5	4874-4878	time	_	
29-6	4878-4879	,	_	
29-7	4880-4892	examinations	_	
29-8	4893-4895	of	_	
29-9	4896-4906	behavioral	_	
29-10	4907-4914	factors	_	
29-11	4915-4916	(	_	
29-12	4916-4920	only	_	
29-13	4920-4921	)	_	
29-14	4922-4926	have	_	
29-15	4927-4937	languished	_	
29-16	4937-4938	.	_	

#Text=In addiction, numerous studies have tried to isolate behavioral drivers of individual change, but have failed to identify reliable factors upon which to “match” individuals to effective treatment .
30-1	4939-4941	In	_	
30-2	4942-4951	addiction	_	
30-3	4951-4952	,	_	
30-4	4953-4961	numerous	_	
30-5	4962-4969	studies	_	
30-6	4970-4974	have	_	
30-7	4975-4980	tried	_	
30-8	4981-4983	to	_	
30-9	4984-4991	isolate	_	
30-10	4992-5002	behavioral	_	
30-11	5003-5010	drivers	_	
30-12	5011-5013	of	_	
30-13	5014-5024	individual	_	
30-14	5025-5031	change	_	
30-15	5031-5032	,	_	
30-16	5033-5036	but	_	
30-17	5037-5041	have	_	
30-18	5042-5048	failed	_	
30-19	5049-5051	to	_	
30-20	5052-5060	identify	_	
30-21	5061-5069	reliable	_	
30-22	5070-5077	factors	_	
30-23	5078-5082	upon	_	
30-24	5083-5088	which	_	
30-25	5089-5091	to	_	
30-26	5092-5093	“	_	
30-27	5093-5098	match	_	
30-28	5098-5099	”	_	
30-29	5100-5111	individuals	_	
30-30	5112-5114	to	_	
30-31	5115-5124	effective	_	
30-32	5125-5134	treatment	_	
30-33	5135-5136	.	_	

#Text=To strengthen the examination of potential treatment mechanisms, investigators are increasingly integrating basic biological approaches into this field of inquiry , including MRI .
31-1	5137-5139	To	_	
31-2	5140-5150	strengthen	_	
31-3	5151-5154	the	_	
31-4	5155-5166	examination	_	
31-5	5167-5169	of	_	
31-6	5170-5179	potential	_	
31-7	5180-5189	treatment	_	
31-8	5190-5200	mechanisms	_	
31-9	5200-5201	,	_	
31-10	5202-5215	investigators	_	
31-11	5216-5219	are	_	
31-12	5220-5232	increasingly	_	
31-13	5233-5244	integrating	_	
31-14	5245-5250	basic	_	
31-15	5251-5261	biological	_	
31-16	5262-5272	approaches	_	
31-17	5273-5277	into	_	
31-18	5278-5282	this	_	
31-19	5283-5288	field	_	
31-20	5289-5291	of	_	
31-21	5292-5299	inquiry	_	
31-22	5300-5301	,	_	
31-23	5302-5311	including	_	
31-24	5312-5315	MRI	_	
31-25	5316-5317	.	_	

#Text=Compellingly, work within our lab has generated support for this translational approach .
32-1	5318-5330	Compellingly	_	
32-2	5330-5331	,	_	
32-3	5332-5336	work	_	
32-4	5337-5343	within	_	
32-5	5344-5347	our	_	
32-6	5348-5351	lab	_	
32-7	5352-5355	has	_	
32-8	5356-5365	generated	_	
32-9	5366-5373	support	_	
32-10	5374-5377	for	_	
32-11	5378-5382	this	_	
32-12	5383-5396	translational	_	
32-13	5397-5405	approach	_	
32-14	5406-5407	.	_	

#Text=For example, among our adolescent samples, we have found greater BOLD response for client speech in favor of reducing substance use (change talk) relative to client speech in favor of continuing to use (sustain talk) .
33-1	5408-5411	For	_	
33-2	5412-5419	example	_	
33-3	5419-5420	,	_	
33-4	5421-5426	among	_	
33-5	5427-5430	our	_	
33-6	5431-5441	adolescent	_	
33-7	5442-5449	samples	_	
33-8	5449-5450	,	_	
33-9	5451-5453	we	_	
33-10	5454-5458	have	_	
33-11	5459-5464	found	_	
33-12	5465-5472	greater	_	
33-13	5473-5477	BOLD	_	
33-14	5478-5486	response	_	
33-15	5487-5490	for	_	
33-16	5491-5497	client	_	
33-17	5498-5504	speech	_	
33-18	5505-5507	in	_	
33-19	5508-5513	favor	_	
33-20	5514-5516	of	_	
33-21	5517-5525	reducing	_	
33-22	5526-5535	substance	_	
33-23	5536-5539	use	_	
33-24	5540-5541	(	_	
33-25	5541-5547	change	_	
33-26	5548-5552	talk	_	
33-27	5552-5553	)	_	
33-28	5554-5562	relative	_	
33-29	5563-5565	to	_	
33-30	5566-5572	client	_	
33-31	5573-5579	speech	_	
33-32	5580-5582	in	_	
33-33	5583-5588	favor	_	
33-34	5589-5591	of	_	
33-35	5592-5602	continuing	_	
33-36	5603-5605	to	_	
33-37	5606-5609	use	_	
33-38	5610-5611	(	_	
33-39	5611-5618	sustain	_	
33-40	5619-5623	talk	_	
33-41	5623-5624	)	_	
33-42	5625-5626	.	_	

#Text=Our lab and others’ have found support for several regions in successful behavior change, including the precuneus, middle and superior frontal gyrus, inferior frontal gyrus (IFG), insula, and posterior cingulate/cingulate gyrus .
34-1	5627-5630	Our	_	
34-2	5631-5634	lab	_	
34-3	5635-5638	and	_	
34-4	5639-5645	others	_	
34-5	5645-5646	’	_	
34-6	5647-5651	have	_	
34-7	5652-5657	found	_	
34-8	5658-5665	support	_	
34-9	5666-5669	for	_	
34-10	5670-5677	several	_	
34-11	5678-5685	regions	_	
34-12	5686-5688	in	_	
34-13	5689-5699	successful	_	
34-14	5700-5708	behavior	_	
34-15	5709-5715	change	_	
34-16	5715-5716	,	_	
34-17	5717-5726	including	_	
34-18	5727-5730	the	_	
34-19	5731-5740	precuneus	_	
34-20	5740-5741	,	_	
34-21	5742-5748	middle	_	
34-22	5749-5752	and	_	
34-23	5753-5761	superior	_	
34-24	5762-5769	frontal	_	
34-25	5770-5775	gyrus	_	
34-26	5775-5776	,	_	
34-27	5777-5785	inferior	_	
34-28	5786-5793	frontal	_	
34-29	5794-5799	gyrus	_	
34-30	5800-5801	(	_	
34-31	5801-5804	IFG	_	
34-32	5804-5805	)	_	
34-33	5805-5806	,	_	
34-34	5807-5813	insula	_	
34-35	5813-5814	,	_	
34-36	5815-5818	and	_	
34-37	5819-5828	posterior	_	
34-38	5829-5838	cingulate	_	
34-39	5838-5839	/	_	
34-40	5839-5848	cingulate	_	
34-41	5849-5854	gyrus	_	
34-42	5855-5856	.	_	

#Text=While recent reviews have highlighted the extensive network of neural systems that respond to drug cues , it is not known how functional networks, or communication between these neural regions, may drive successful treatment response .
35-1	5857-5862	While	_	
35-2	5863-5869	recent	_	
35-3	5870-5877	reviews	_	
35-4	5878-5882	have	_	
35-5	5883-5894	highlighted	_	
35-6	5895-5898	the	_	
35-7	5899-5908	extensive	_	
35-8	5909-5916	network	_	
35-9	5917-5919	of	_	
35-10	5920-5926	neural	_	
35-11	5927-5934	systems	_	
35-12	5935-5939	that	_	
35-13	5940-5947	respond	_	
35-14	5948-5950	to	_	
35-15	5951-5955	drug	_	
35-16	5956-5960	cues	_	
35-17	5961-5962	,	_	
35-18	5963-5965	it	_	
35-19	5966-5968	is	_	
35-20	5969-5972	not	_	
35-21	5973-5978	known	_	
35-22	5979-5982	how	_	
35-23	5983-5993	functional	_	
35-24	5994-6002	networks	_	
35-25	6002-6003	,	_	
35-26	6004-6006	or	_	
35-27	6007-6020	communication	_	
35-28	6021-6028	between	_	
35-29	6029-6034	these	_	
35-30	6035-6041	neural	_	
35-31	6042-6049	regions	_	
35-32	6049-6050	,	_	
35-33	6051-6054	may	_	
35-34	6055-6060	drive	_	
35-35	6061-6071	successful	_	
35-36	6072-6081	treatment	_	
35-37	6082-6090	response	_	
35-38	6091-6092	.	_	

#Text=These are important clinical questions, and highly informative in terms of the less-than-intuitive translation of “bench-to-bedside”, the use of neuroscience data to guide real-world clinical practice .
36-1	6093-6098	These	_	
36-2	6099-6102	are	_	
36-3	6103-6112	important	_	
36-4	6113-6121	clinical	_	
36-5	6122-6131	questions	_	
36-6	6131-6132	,	_	
36-7	6133-6136	and	_	
36-8	6137-6143	highly	_	
36-9	6144-6155	informative	_	
36-10	6156-6158	in	_	
36-11	6159-6164	terms	_	
36-12	6165-6167	of	_	
36-13	6168-6171	the	_	
36-14	6172-6191	less-than-intuitive	_	
36-15	6192-6203	translation	_	
36-16	6204-6206	of	_	
36-17	6207-6208	“	_	
36-18	6208-6224	bench-to-bedside	_	
36-19	6224-6225	”	_	
36-20	6225-6226	,	_	
36-21	6227-6230	the	_	
36-22	6231-6234	use	_	
36-23	6235-6237	of	_	
36-24	6238-6250	neuroscience	_	
36-25	6251-6255	data	_	
36-26	6256-6258	to	_	
36-27	6259-6264	guide	_	
36-28	6265-6275	real-world	_	
36-29	6276-6284	clinical	_	
36-30	6285-6293	practice	_	
36-31	6294-6295	.	_	

#Text=Learning how networks within the adolescent brain process clinical elements, and evaluating the predictive validity of those neural network processes is integral in guiding clinicians’ selection of which approaches to use in clinical settings.
37-1	6296-6304	Learning	_	
37-2	6305-6308	how	_	
37-3	6309-6317	networks	_	
37-4	6318-6324	within	_	
37-5	6325-6328	the	_	
37-6	6329-6339	adolescent	_	
37-7	6340-6345	brain	_	
37-8	6346-6353	process	_	
37-9	6354-6362	clinical	_	
37-10	6363-6371	elements	_	
37-11	6371-6372	,	_	
37-12	6373-6376	and	_	
37-13	6377-6387	evaluating	_	
37-14	6388-6391	the	_	
37-15	6392-6402	predictive	_	
37-16	6403-6411	validity	_	
37-17	6412-6414	of	_	
37-18	6415-6420	those	_	
37-19	6421-6427	neural	_	
37-20	6428-6435	network	_	
37-21	6436-6445	processes	_	
37-22	6446-6448	is	_	
37-23	6449-6457	integral	_	
37-24	6458-6460	in	_	
37-25	6461-6468	guiding	_	
37-26	6469-6479	clinicians	_	
37-27	6479-6480	’	_	
37-28	6481-6490	selection	_	
37-29	6491-6493	of	_	
37-30	6494-6499	which	_	
37-31	6500-6510	approaches	_	
37-32	6511-6513	to	_	
37-33	6514-6517	use	_	
37-34	6518-6520	in	_	
37-35	6521-6529	clinical	_	
37-36	6530-6538	settings	_	
37-37	6538-6539	.	_	

#Text=Given that prior investigations of adolescent addiction treatment response have primarily focused on regional activation, we sought to expand our investigation to examine functional organization of these systems.
38-1	6540-6545	Given	_	
38-2	6546-6550	that	_	
38-3	6551-6556	prior	_	
38-4	6557-6571	investigations	_	
38-5	6572-6574	of	_	
38-6	6575-6585	adolescent	_	
38-7	6586-6595	addiction	_	
38-8	6596-6605	treatment	_	
38-9	6606-6614	response	_	
38-10	6615-6619	have	_	
38-11	6620-6629	primarily	_	
38-12	6630-6637	focused	_	
38-13	6638-6640	on	_	
38-14	6641-6649	regional	_	
38-15	6650-6660	activation	_	
38-16	6660-6661	,	_	
38-17	6662-6664	we	_	
38-18	6665-6671	sought	_	
38-19	6672-6674	to	_	
38-20	6675-6681	expand	_	
38-21	6682-6685	our	_	
38-22	6686-6699	investigation	_	
38-23	6700-6702	to	_	
38-24	6703-6710	examine	_	
38-25	6711-6721	functional	_	
38-26	6722-6734	organization	_	
38-27	6735-6737	of	_	
38-28	6738-6743	these	_	
38-29	6744-6751	systems	_	
38-30	6751-6752	.	_	

#Text=Specifically, by generating an empirically-derived seed region, we identified the locus and nature of network cohesion as a relevant mechanism of change in adolescent treatment response.
39-1	6753-6765	Specifically	_	
39-2	6765-6766	,	_	
39-3	6767-6769	by	_	
39-4	6770-6780	generating	_	
39-5	6781-6783	an	_	
39-6	6784-6803	empirically-derived	_	
39-7	6804-6808	seed	_	
39-8	6809-6815	region	_	
39-9	6815-6816	,	_	
39-10	6817-6819	we	_	
39-11	6820-6830	identified	_	
39-12	6831-6834	the	_	
39-13	6835-6840	locus	_	
39-14	6841-6844	and	_	
39-15	6845-6851	nature	_	
39-16	6852-6854	of	_	
39-17	6855-6862	network	_	
39-18	6863-6871	cohesion	_	
39-19	6872-6874	as	_	
39-20	6875-6876	a	_	
39-21	6877-6885	relevant	_	
39-22	6886-6895	mechanism	_	
39-23	6896-6898	of	_	
39-24	6899-6905	change	_	
39-25	6906-6908	in	_	
39-26	6909-6919	adolescent	_	
39-27	6920-6929	treatment	_	
39-28	6930-6938	response	_	
39-29	6938-6939	.	_	

#Text=We sought to query the functional connectivity, or temporal correlation, of BOLD response with other relevant regions within the brain during the in-session proxy for adolescent movement on the key clinical construct of ambivalence: client change talk.
40-1	6940-6942	We	_	
40-2	6943-6949	sought	_	
40-3	6950-6952	to	_	
40-4	6953-6958	query	_	
40-5	6959-6962	the	_	
40-6	6963-6973	functional	_	
40-7	6974-6986	connectivity	_	
40-8	6986-6987	,	_	
40-9	6988-6990	or	_	
40-10	6991-6999	temporal	_	
40-11	7000-7011	correlation	_	
40-12	7011-7012	,	_	
40-13	7013-7015	of	_	
40-14	7016-7020	BOLD	_	
40-15	7021-7029	response	_	
40-16	7030-7034	with	_	
40-17	7035-7040	other	_	
40-18	7041-7049	relevant	_	
40-19	7050-7057	regions	_	
40-20	7058-7064	within	_	
40-21	7065-7068	the	_	
40-22	7069-7074	brain	_	
40-23	7075-7081	during	_	
40-24	7082-7085	the	_	
40-25	7086-7096	in-session	_	
40-26	7097-7102	proxy	_	
40-27	7103-7106	for	_	
40-28	7107-7117	adolescent	_	
40-29	7118-7126	movement	_	
40-30	7127-7129	on	_	
40-31	7130-7133	the	_	
40-32	7134-7137	key	_	
40-33	7138-7146	clinical	_	
40-34	7147-7156	construct	_	
40-35	7157-7159	of	_	
40-36	7160-7171	ambivalence	_	
40-37	7171-7172	:	_	
40-38	7173-7179	client	_	
40-39	7180-7186	change	_	
40-40	7187-7191	talk	_	
40-41	7191-7192	.	_	

#Text=To determine the association between network connectivity and adolescent treatment response, we evaluated the correlation between network connectivity and adolescent post-treatment behavior change.
41-1	7193-7195	To	_	
41-2	7196-7205	determine	_	
41-3	7206-7209	the	_	
41-4	7210-7221	association	_	
41-5	7222-7229	between	_	
41-6	7230-7237	network	_	
41-7	7238-7250	connectivity	_	
41-8	7251-7254	and	_	
41-9	7255-7265	adolescent	_	
41-10	7266-7275	treatment	_	
41-11	7276-7284	response	_	
41-12	7284-7285	,	_	
41-13	7286-7288	we	_	
41-14	7289-7298	evaluated	_	
41-15	7299-7302	the	_	
41-16	7303-7314	correlation	_	
41-17	7315-7322	between	_	
41-18	7323-7330	network	_	
41-19	7331-7343	connectivity	_	
41-20	7344-7347	and	_	
41-21	7348-7358	adolescent	_	
41-22	7359-7373	post-treatment	_	
41-23	7374-7382	behavior	_	
41-24	7383-7389	change	_	
41-25	7389-7390	.	_	

#Text=Finally, to determine the degree of generalizability of these networks across other types of adolescent substance abuse, we employed conjunction analysis with a de novo sample of adolescent alcohol abusers.
42-1	7391-7398	Finally	_	
42-2	7398-7399	,	_	
42-3	7400-7402	to	_	
42-4	7403-7412	determine	_	
42-5	7413-7416	the	_	
42-6	7417-7423	degree	_	
42-7	7424-7426	of	_	
42-8	7427-7443	generalizability	_	
42-9	7444-7446	of	_	
42-10	7447-7452	these	_	
42-11	7453-7461	networks	_	
42-12	7462-7468	across	_	
42-13	7469-7474	other	_	
42-14	7475-7480	types	_	
42-15	7481-7483	of	_	
42-16	7484-7494	adolescent	_	
42-17	7495-7504	substance	_	
42-18	7505-7510	abuse	_	
42-19	7510-7511	,	_	
42-20	7512-7514	we	_	
42-21	7515-7523	employed	_	
42-22	7524-7535	conjunction	_	
42-23	7536-7544	analysis	_	
42-24	7545-7549	with	_	
42-25	7550-7551	a	_	
42-26	7552-7554	de	_	
42-27	7555-7559	novo	_	
42-28	7560-7566	sample	_	
42-29	7567-7569	of	_	
42-30	7570-7580	adolescent	_	
42-31	7581-7588	alcohol	_	
42-32	7589-7596	abusers	_	
42-33	7596-7597	.	_	

#Text=Our aims were thus three-fold: (1) Employ psychophysiological interaction (PPI) analyses to evaluate network response in a large sample of adolescent cannabis users, (2) utilize correlations to evaluate the link between network connectivity and treatment response within this sample, and (3) conduct an exploratory conjunction analysis to assess congruence of these networks across different substances of abuse.
43-1	7598-7601	Our	_	
43-2	7602-7606	aims	_	
43-3	7607-7611	were	_	
43-4	7612-7616	thus	_	
43-5	7617-7627	three-fold	_	
43-6	7627-7628	:	_	
43-7	7629-7630	(	_	
43-8	7630-7631	1	_	
43-9	7631-7632	)	_	
43-10	7633-7639	Employ	_	
43-11	7640-7659	psychophysiological	_	
43-12	7660-7671	interaction	_	
43-13	7672-7673	(	_	
43-14	7673-7676	PPI	_	
43-15	7676-7677	)	_	
43-16	7678-7686	analyses	_	
43-17	7687-7689	to	_	
43-18	7690-7698	evaluate	_	
43-19	7699-7706	network	_	
43-20	7707-7715	response	_	
43-21	7716-7718	in	_	
43-22	7719-7720	a	_	
43-23	7721-7726	large	_	
43-24	7727-7733	sample	_	
43-25	7734-7736	of	_	
43-26	7737-7747	adolescent	_	
43-27	7748-7756	cannabis	_	
43-28	7757-7762	users	_	
43-29	7762-7763	,	_	
43-30	7764-7765	(	_	
43-31	7765-7766	2	_	
43-32	7766-7767	)	_	
43-33	7768-7775	utilize	_	
43-34	7776-7788	correlations	_	
43-35	7789-7791	to	_	
43-36	7792-7800	evaluate	_	
43-37	7801-7804	the	_	
43-38	7805-7809	link	_	
43-39	7810-7817	between	_	
43-40	7818-7825	network	_	
43-41	7826-7838	connectivity	_	
43-42	7839-7842	and	_	
43-43	7843-7852	treatment	_	
43-44	7853-7861	response	_	
43-45	7862-7868	within	_	
43-46	7869-7873	this	_	
43-47	7874-7880	sample	_	
43-48	7880-7881	,	_	
43-49	7882-7885	and	_	
43-50	7886-7887	(	_	
43-51	7887-7888	3	_	
43-52	7888-7889	)	_	
43-53	7890-7897	conduct	_	
43-54	7898-7900	an	_	
43-55	7901-7912	exploratory	_	
43-56	7913-7924	conjunction	_	
43-57	7925-7933	analysis	_	
43-58	7934-7936	to	_	
43-59	7937-7943	assess	_	
43-60	7944-7954	congruence	_	
43-61	7955-7957	of	_	
43-62	7958-7963	these	_	
43-63	7964-7972	networks	_	
43-64	7973-7979	across	_	
43-65	7980-7989	different	_	
43-66	7990-8000	substances	_	
43-67	8001-8003	of	_	
43-68	8004-8009	abuse	_	
43-69	8009-8010	.	_	

#Text=Materials and Methods
#Text=1.1 Participants
#Text=For this evaluation, 45 unique adolescent substance users (ages 14–19; n = 30 in the cannabis sample, and n = 15 in the alcohol sample) were recruited through community and/or high-risk (justice) centers in the Southwestern United States.
44-1	8011-8020	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-2	8021-8024	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-3	8025-8032	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
44-4	8033-8036	1.1	_	
44-5	8037-8049	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-6	8050-8053	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-7	8054-8058	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-8	8059-8069	evaluation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-9	8069-8070	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-10	8071-8073	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-11	8074-8080	unique	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-12	8081-8091	adolescent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-13	8092-8101	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-14	8102-8107	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-15	8108-8109	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-16	8109-8113	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-17	8114-8116	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-18	8116-8117	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-19	8117-8119	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-20	8119-8120	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-21	8121-8122	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-22	8123-8124	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-23	8125-8127	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-24	8128-8130	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-25	8131-8134	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-26	8135-8143	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[4]	
44-27	8144-8150	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[4]	
44-28	8150-8151	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-29	8152-8155	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-30	8156-8157	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-31	8158-8159	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-32	8160-8162	15	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-33	8163-8165	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-34	8166-8169	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-35	8170-8177	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
44-36	8178-8184	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[6]	
44-37	8184-8185	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-38	8186-8190	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-39	8191-8200	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-40	8201-8208	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-41	8209-8218	community	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-42	8219-8222	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-43	8222-8223	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-44	8223-8225	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-45	8226-8235	high-risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-46	8236-8237	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-47	8237-8244	justice	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-48	8244-8245	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-49	8246-8253	centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-50	8254-8256	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-51	8257-8260	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-52	8261-8273	Southwestern	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-53	8274-8280	United	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-54	8281-8287	States	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
44-55	8287-8288	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=For sample demographics, see Table 1.
45-1	8289-8292	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-2	8293-8299	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-3	8300-8312	demographics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-4	8312-8313	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-5	8314-8317	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-6	8318-8323	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-7	8324-8325	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-8	8325-8326	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=All adolescents agreed to participate in a translational study aimed at reducing adolescent health risk behavior.
46-1	8327-8330	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-2	8331-8342	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-3	8343-8349	agreed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-4	8350-8352	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-5	8353-8364	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-6	8365-8367	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-7	8368-8369	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-8	8370-8383	translational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-9	8384-8389	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-10	8390-8395	aimed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-11	8396-8398	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-12	8399-8407	reducing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-13	8408-8418	adolescent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-14	8419-8425	health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-15	8426-8430	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-16	8431-8439	behavior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-17	8439-8440	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Written consent was obtained from participants ages >18.
47-1	8441-8448	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-2	8449-8456	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-3	8457-8460	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-4	8461-8469	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-5	8470-8474	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-6	8475-8487	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-7	8488-8492	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-8	8493-8494	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-9	8494-8496	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
47-10	8496-8497	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=For youth <age 18, adolescents provided written assent and parent/guardian informed consent was obtained via telephone following youth assent.
48-1	8498-8501	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-2	8502-8507	youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-3	8508-8509	<	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-4	8509-8512	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-5	8513-8515	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-6	8515-8516	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-7	8517-8528	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-8	8529-8537	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-9	8538-8545	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-10	8546-8552	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-11	8553-8556	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-12	8557-8563	parent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-13	8563-8564	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-14	8564-8572	guardian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-15	8573-8581	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-16	8582-8589	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-17	8590-8593	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-18	8594-8602	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-19	8603-8606	via	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-20	8607-8616	telephone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-21	8617-8626	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-22	8627-8632	youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-23	8633-8639	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
48-24	8639-8640	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=All consent conversations were audio-recorded and logged.
49-1	8641-8644	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-2	8645-8652	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-3	8653-8666	conversations	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-4	8667-8671	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-5	8672-8686	audio-recorded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-6	8687-8690	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-7	8691-8697	logged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
49-8	8697-8698	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Study procedures were conducted with institutional review board approval and with a federal Certificate of Confidentiality.
50-1	8699-8704	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-2	8705-8715	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-3	8716-8720	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-4	8721-8730	conducted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-5	8731-8735	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-6	8736-8749	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-7	8750-8756	review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-8	8757-8762	board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-9	8763-8771	approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-10	8772-8775	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-11	8776-8780	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-12	8781-8782	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-13	8783-8790	federal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-14	8791-8802	Certificate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-15	8803-8805	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-16	8806-8821	Confidentiality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
50-17	8821-8822	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Inclusion criteria required that youth be current users of alcohol and/or cannabis (defined as > 7 past-month cannabis use episodes for the cannabis sample; > 3 past-month binge-drinking episodes for the alcohol sample), and meet requisite MRI safety criteria .
51-1	8823-8832	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-2	8833-8841	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-3	8842-8850	required	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-4	8851-8855	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-5	8856-8861	youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-6	8862-8864	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-7	8865-8872	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-8	8873-8878	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-9	8879-8881	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-10	8882-8889	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[14]	
51-11	8890-8893	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-12	8893-8894	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-13	8894-8896	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-14	8897-8905	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[15]	
51-15	8906-8907	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-16	8907-8914	defined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-17	8915-8917	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-18	8918-8919	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-19	8920-8921	7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-20	8922-8932	past-month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-21	8933-8941	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-22	8942-8945	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
51-23	8946-8954	episodes	_	
51-24	8955-8958	for	_	
51-25	8959-8962	the	_	
51-26	8963-8971	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-27	8972-8978	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-28	8978-8979	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-29	8980-8981	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-30	8982-8983	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-31	8984-8994	past-month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-32	8995-9009	binge-drinking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-33	9010-9018	episodes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-34	9019-9022	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-35	9023-9026	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-36	9027-9034	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-37	9035-9041	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-38	9041-9042	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge[17]	
51-39	9042-9043	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-40	9044-9047	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-41	9048-9052	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-42	9053-9062	requisite	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-43	9063-9066	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[18]	
51-44	9067-9073	safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-45	9074-9082	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
51-46	9083-9084	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Youth were excluded if they reported serious medical conditions (e.g., loss of consciousness >5 minutes in the last 6 months, history of brain disease or brain illness), current psychosis, and/or serious psychopathology (as measured by current prescription medications for these disorders).
#Text=2.1 Procedure
#Text=Adolescents completed a psychosocial assessment, two MI sessions focused on reducing the target substance of abuse (cannabis or alcohol, respectively), an MRI scan that included an fMRI paradigm to assess the neural correlates of client language, and a behavioral follow-up at one month post-treatment.
52-1	9085-9090	Youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-2	9091-9095	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-3	9096-9104	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-4	9105-9107	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-5	9108-9112	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-6	9113-9121	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-7	9122-9129	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-8	9130-9137	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-9	9138-9148	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-10	9149-9150	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-11	9150-9153	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-12	9153-9154	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-13	9154-9155	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-14	9156-9160	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-15	9161-9163	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-16	9164-9177	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-17	9178-9179	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-18	9179-9180	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-19	9181-9188	minutes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-20	9189-9191	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-21	9192-9195	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-22	9196-9200	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-23	9201-9202	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-24	9203-9209	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-25	9209-9210	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-26	9211-9218	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-27	9219-9221	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-28	9222-9227	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]	
52-29	9228-9235	disease	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-30	9236-9238	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-31	9239-9244	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-32	9245-9252	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-33	9252-9253	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-34	9253-9254	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-35	9255-9262	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-36	9263-9272	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-37	9272-9273	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-38	9274-9277	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-39	9277-9278	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-40	9278-9280	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-41	9281-9288	serious	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-42	9289-9304	psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-43	9305-9306	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-44	9306-9308	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-45	9309-9317	measured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-46	9318-9320	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-47	9321-9328	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-48	9329-9341	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-49	9342-9353	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-50	9354-9357	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-51	9358-9363	these	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-52	9364-9373	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-53	9373-9374	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
52-54	9374-9375	.	_	
52-55	9376-9379	2.1	_	
52-56	9380-9389	Procedure	_	
52-57	9390-9401	Adolescents	_	
52-58	9402-9411	completed	_	
52-59	9412-9413	a	_	
52-60	9414-9426	psychosocial	_	
52-61	9427-9437	assessment	_	
52-62	9437-9438	,	_	
52-63	9439-9442	two	_	
52-64	9443-9445	MI	_	
52-65	9446-9454	sessions	_	
52-66	9455-9462	focused	_	
52-67	9463-9465	on	_	
52-68	9466-9474	reducing	_	
52-69	9475-9478	the	_	
52-70	9479-9485	target	_	
52-71	9486-9495	substance	_	
52-72	9496-9498	of	_	
52-73	9499-9504	abuse	_	
52-74	9505-9506	(	_	
52-75	9506-9514	cannabis	_	
52-76	9515-9517	or	_	
52-77	9518-9525	alcohol	_	
52-78	9525-9526	,	_	
52-79	9527-9539	respectively	_	
52-80	9539-9540	)	_	
52-81	9540-9541	,	_	
52-82	9542-9544	an	_	
52-83	9545-9548	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
52-84	9549-9553	scan	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
52-85	9554-9558	that	_	
52-86	9559-9567	included	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[22]	
52-87	9568-9570	an	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[22]	
52-88	9571-9575	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[22]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
52-89	9576-9584	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[22]	
52-90	9585-9587	to	_	
52-91	9588-9594	assess	_	
52-92	9595-9598	the	_	
52-93	9599-9605	neural	_	
52-94	9606-9616	correlates	_	
52-95	9617-9619	of	_	
52-96	9620-9626	client	_	
52-97	9627-9635	language	_	
52-98	9635-9636	,	_	
52-99	9637-9640	and	_	
52-100	9641-9642	a	_	
52-101	9643-9653	behavioral	_	
52-102	9654-9663	follow-up	_	
52-103	9664-9666	at	_	
52-104	9667-9670	one	_	
52-105	9671-9676	month	_	
52-106	9677-9691	post-treatment	_	
52-107	9691-9692	.	_	

#Text=All youth completed the baseline behavioral assessment and the first MI session during their first appointment.
53-1	9693-9696	All	_	
53-2	9697-9702	youth	_	
53-3	9703-9712	completed	_	
53-4	9713-9716	the	_	
53-5	9717-9725	baseline	_	
53-6	9726-9736	behavioral	_	
53-7	9737-9747	assessment	_	
53-8	9748-9751	and	_	
53-9	9752-9755	the	_	
53-10	9756-9761	first	_	
53-11	9762-9764	MI	_	
53-12	9765-9772	session	_	
53-13	9773-9779	during	_	
53-14	9780-9785	their	_	
53-15	9786-9791	first	_	
53-16	9792-9803	appointment	_	
53-17	9803-9804	.	_	

#Text=One week later, youth completed an MRI scan, immediately followed by their second MI session.
54-1	9805-9808	One	_	
54-2	9809-9813	week	_	
54-3	9814-9819	later	_	
54-4	9819-9820	,	_	
54-5	9821-9826	youth	_	
54-6	9827-9836	completed	_	
54-7	9837-9839	an	_	
54-8	9840-9843	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
54-9	9844-9848	scan	_	
54-10	9848-9849	,	_	
54-11	9850-9861	immediately	_	
54-12	9862-9870	followed	_	
54-13	9871-9873	by	_	
54-14	9874-9879	their	_	
54-15	9880-9886	second	_	
54-16	9887-9889	MI	_	
54-17	9890-9897	session	_	
54-18	9897-9898	.	_	

#Text=One month after the scan session, youth completed their final behavioral follow-up.
55-1	9899-9902	One	_	
55-2	9903-9908	month	_	
55-3	9909-9914	after	_	
55-4	9915-9918	the	_	
55-5	9919-9923	scan	_	
55-6	9924-9931	session	_	
55-7	9931-9932	,	_	
55-8	9933-9938	youth	_	
55-9	9939-9948	completed	_	
55-10	9949-9954	their	_	
55-11	9955-9960	final	_	
55-12	9961-9971	behavioral	_	
55-13	9972-9981	follow-up	_	
55-14	9981-9982	.	_	

#Text=All youth completed measures of demographics, substance use, and an MRI scan.
56-1	9983-9986	All	_	
56-2	9987-9992	youth	_	
56-3	9993-10002	completed	_	
56-4	10003-10011	measures	_	
56-5	10012-10014	of	_	
56-6	10015-10027	demographics	_	
56-7	10027-10028	,	_	
56-8	10029-10038	substance	_	
56-9	10039-10042	use	_	
56-10	10042-10043	,	_	
56-11	10044-10047	and	_	
56-12	10048-10050	an	_	
56-13	10051-10054	MRI	_	
56-14	10055-10059	scan	_	
56-15	10059-10060	.	_	

#Text=In terms of accuracy, recent adolescent studies support the reliability and validity of adolescent self-report in assessing substance use behavior .
57-1	10061-10063	In	_	
57-2	10064-10069	terms	_	
57-3	10070-10072	of	_	
57-4	10073-10081	accuracy	_	
57-5	10081-10082	,	_	
57-6	10083-10089	recent	_	
57-7	10090-10100	adolescent	_	
57-8	10101-10108	studies	_	
57-9	10109-10116	support	_	
57-10	10117-10120	the	_	
57-11	10121-10132	reliability	_	
57-12	10133-10136	and	_	
57-13	10137-10145	validity	_	
57-14	10146-10148	of	_	
57-15	10149-10159	adolescent	_	
57-16	10160-10171	self-report	_	
57-17	10172-10174	in	_	
57-18	10175-10184	assessing	_	
57-19	10185-10194	substance	_	
57-20	10195-10198	use	_	
57-21	10199-10207	behavior	_	
57-22	10208-10209	.	_	

#Text=Adolescents also completed the Timeline Followback (TLFB; ), an interviewer-administered measure that utilizes a calendar format to assess adolescents’ quantity and frequency of substance use during the past month.
58-1	10210-10221	Adolescents	_	
58-2	10222-10226	also	_	
58-3	10227-10236	completed	_	
58-4	10237-10240	the	_	
58-5	10241-10249	Timeline	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-6	10250-10260	Followback	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-7	10261-10262	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-8	10262-10266	TLFB	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-9	10266-10267	;	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-10	10268-10269	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire[24]	
58-11	10269-10270	,	_	
58-12	10271-10273	an	_	
58-13	10274-10298	interviewer-administered	_	
58-14	10299-10306	measure	_	
58-15	10307-10311	that	_	
58-16	10312-10320	utilizes	_	
58-17	10321-10322	a	_	
58-18	10323-10331	calendar	_	
58-19	10332-10338	format	_	
58-20	10339-10341	to	_	
58-21	10342-10348	assess	_	
58-22	10349-10360	adolescents	_	
58-23	10360-10361	’	_	
58-24	10362-10370	quantity	_	
58-25	10371-10374	and	_	
58-26	10375-10384	frequency	_	
58-27	10385-10387	of	_	
58-28	10388-10397	substance	_	
58-29	10398-10401	use	_	
58-30	10402-10408	during	_	
58-31	10409-10412	the	_	
58-32	10413-10417	past	_	
58-33	10418-10423	month	_	
58-34	10423-10424	.	_	

#Text=From this measure, we derived past month totals for overall number of cannabis and alcohol use days at each assessment point.
59-1	10425-10429	From	_	
59-2	10430-10434	this	_	
59-3	10435-10442	measure	_	
59-4	10442-10443	,	_	
59-5	10444-10446	we	_	
59-6	10447-10454	derived	_	
59-7	10455-10459	past	_	
59-8	10460-10465	month	_	
59-9	10466-10472	totals	_	
59-10	10473-10476	for	_	
59-11	10477-10484	overall	_	
59-12	10485-10491	number	_	
59-13	10492-10494	of	_	
59-14	10495-10503	cannabis	_	
59-15	10504-10507	and	_	
59-16	10508-10515	alcohol	_	
59-17	10516-10519	use	_	
59-18	10520-10524	days	_	
59-19	10525-10527	at	_	
59-20	10528-10532	each	_	
59-21	10533-10543	assessment	_	
59-22	10544-10549	point	_	
59-23	10549-10550	.	_	

#Text=For the first sample (cannabis using youth), we employed a clinical metric of treatment response, a 58-item measure evaluating past-month cannabis-related problems (e.g., “Have you had a persistent chest infection or cough?”
60-1	10551-10554	For	_	
60-2	10555-10558	the	_	
60-3	10559-10564	first	_	
60-4	10565-10571	sample	_	
60-5	10572-10573	(	_	
60-6	10573-10581	cannabis	_	
60-7	10582-10587	using	_	
60-8	10588-10593	youth	_	
60-9	10593-10594	)	_	
60-10	10594-10595	,	_	
60-11	10596-10598	we	_	
60-12	10599-10607	employed	_	
60-13	10608-10609	a	_	
60-14	10610-10618	clinical	_	
60-15	10619-10625	metric	_	
60-16	10626-10628	of	_	
60-17	10629-10638	treatment	_	
60-18	10639-10647	response	_	
60-19	10647-10648	,	_	
60-20	10649-10650	a	_	
60-21	10651-10653	58	_	
60-22	10653-10654	-	_	
60-23	10654-10658	item	_	
60-24	10659-10666	measure	_	
60-25	10667-10677	evaluating	_	
60-26	10678-10688	past-month	_	
60-27	10689-10705	cannabis-related	_	
60-28	10706-10714	problems	_	
60-29	10715-10716	(	_	
60-30	10716-10719	e.g	_	
60-31	10719-10720	.	_	
60-32	10720-10721	,	_	
60-33	10722-10723	“	_	
60-34	10723-10727	Have	_	
60-35	10728-10731	you	_	
60-36	10732-10735	had	_	
60-37	10736-10737	a	_	
60-38	10738-10748	persistent	_	
60-39	10749-10754	chest	_	
60-40	10755-10764	infection	_	
60-41	10765-10767	or	_	
60-42	10768-10773	cough	_	
60-43	10773-10774	?	_	
60-44	10774-10775	”	_	

#Text=, “Have you driven while stoned?”
61-1	10775-10776	,	_	
61-2	10777-10778	“	_	
61-3	10778-10782	Have	_	
61-4	10783-10786	you	_	
61-5	10787-10793	driven	_	
61-6	10794-10799	while	_	
61-7	10800-10806	stoned	_	
61-8	10806-10807	?	_	
61-9	10807-10808	”	_	

#Text=; CPQ-A; ).
62-1	10808-10809	;	_	
62-2	10810-10815	CPQ-A	_	
62-3	10815-10816	;	_	
62-4	10817-10818	)	_	
62-5	10818-10819	.	_	

#Text=The MI treatment followed a manualized approach .
63-1	10820-10823	The	_	
63-2	10824-10826	MI	_	
63-3	10827-10836	treatment	_	
63-4	10837-10845	followed	_	
63-5	10846-10847	a	_	
63-6	10848-10858	manualized	_	
63-7	10859-10867	approach	_	
63-8	10868-10869	.	_	

#Text=A master’s level therapist administered all treatment sessions.
64-1	10870-10871	A	_	
64-2	10872-10878	master	_	
64-3	10878-10879	’	_	
64-4	10879-10880	s	_	
64-5	10881-10886	level	_	
64-6	10887-10896	therapist	_	
64-7	10897-10909	administered	_	
64-8	10910-10913	all	_	
64-9	10914-10923	treatment	_	
64-10	10924-10932	sessions	_	
64-11	10932-10933	.	_	

#Text=The first author, via random audio-recorded session review during weekly supervision, monitored treatment integrity and fidelity.
65-1	10934-10937	The	_	
65-2	10938-10943	first	_	
65-3	10944-10950	author	_	
65-4	10950-10951	,	_	
65-5	10952-10955	via	_	
65-6	10956-10962	random	_	
65-7	10963-10977	audio-recorded	_	
65-8	10978-10985	session	_	
65-9	10986-10992	review	_	
65-10	10993-10999	during	_	
65-11	11000-11006	weekly	_	
65-12	11007-11018	supervision	_	
65-13	11018-11019	,	_	
65-14	11020-11029	monitored	_	
65-15	11030-11039	treatment	_	
65-16	11040-11049	integrity	_	
65-17	11050-11053	and	_	
65-18	11054-11062	fidelity	_	
65-19	11062-11063	.	_	

#Text=Across both sessions, therapists relied on MI-consistent approaches, including use of complex reflections, open-ended questions, affirmations, accurate empathy, support of youths’ self-efficacy, and efforts to reduce youth resistance.
66-1	11064-11070	Across	_	
66-2	11071-11075	both	_	
66-3	11076-11084	sessions	_	
66-4	11084-11085	,	_	
66-5	11086-11096	therapists	_	
66-6	11097-11103	relied	_	
66-7	11104-11106	on	_	
66-8	11107-11120	MI-consistent	_	
66-9	11121-11131	approaches	_	
66-10	11131-11132	,	_	
66-11	11133-11142	including	_	
66-12	11143-11146	use	_	
66-13	11147-11149	of	_	
66-14	11150-11157	complex	_	
66-15	11158-11169	reflections	_	
66-16	11169-11170	,	_	
66-17	11171-11181	open-ended	_	
66-18	11182-11191	questions	_	
66-19	11191-11192	,	_	
66-20	11193-11205	affirmations	_	
66-21	11205-11206	,	_	
66-22	11207-11215	accurate	_	
66-23	11216-11223	empathy	_	
66-24	11223-11224	,	_	
66-25	11225-11232	support	_	
66-26	11233-11235	of	_	
66-27	11236-11242	youths	_	
66-28	11242-11243	’	_	
66-29	11244-11257	self-efficacy	_	
66-30	11257-11258	,	_	
66-31	11259-11262	and	_	
66-32	11263-11270	efforts	_	
66-33	11271-11273	to	_	
66-34	11274-11280	reduce	_	
66-35	11281-11286	youth	_	
66-36	11287-11297	resistance	_	
66-37	11297-11298	.	_	

#Text=All sessions were audio-recorded to gather requisite statements for the neuroimaging paradigm and to maintain treatment integrity and fidelity.
#Text=2.3 fMRI data acquisition
#Text=Participants were instructed to abstain from all substance use for a minimum of 24 hours prior to the MRI scan, which was verified by self-report prior to the scan session.
67-1	11299-11302	All	_	
67-2	11303-11311	sessions	_	
67-3	11312-11316	were	_	
67-4	11317-11331	audio-recorded	_	
67-5	11332-11334	to	_	
67-6	11335-11341	gather	_	
67-7	11342-11351	requisite	_	
67-8	11352-11362	statements	_	
67-9	11363-11366	for	_	
67-10	11367-11370	the	_	
67-11	11371-11383	neuroimaging	_	
67-12	11384-11392	paradigm	_	
67-13	11393-11396	and	_	
67-14	11397-11399	to	_	
67-15	11400-11408	maintain	_	
67-16	11409-11418	treatment	_	
67-17	11419-11428	integrity	_	
67-18	11429-11432	and	_	
67-19	11433-11441	fidelity	_	
67-20	11441-11442	.	_	
67-21	11443-11446	2.3	_	
67-22	11447-11451	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
67-23	11452-11456	data	_	
67-24	11457-11468	acquisition	_	
67-25	11469-11481	Participants	_	
67-26	11482-11486	were	_	
67-27	11487-11497	instructed	_	
67-28	11498-11500	to	_	
67-29	11501-11508	abstain	_	
67-30	11509-11513	from	_	
67-31	11514-11517	all	_	
67-32	11518-11527	substance	_	
67-33	11528-11531	use	_	
67-34	11532-11535	for	_	
67-35	11536-11537	a	_	
67-36	11538-11545	minimum	_	
67-37	11546-11548	of	_	
67-38	11549-11551	24	_	
67-39	11552-11557	hours	_	
67-40	11558-11563	prior	_	
67-41	11564-11566	to	_	
67-42	11567-11570	the	_	
67-43	11571-11574	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[25]	
67-44	11575-11579	scan	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[25]	
67-45	11579-11580	,	_	
67-46	11581-11586	which	_	
67-47	11587-11590	was	_	
67-48	11591-11599	verified	_	
67-49	11600-11602	by	_	
67-50	11603-11614	self-report	_	
67-51	11615-11620	prior	_	
67-52	11621-11623	to	_	
67-53	11624-11627	the	_	
67-54	11628-11632	scan	_	
67-55	11633-11640	session	_	
67-56	11640-11641	.	_	

#Text=Youth were screened for indicators of acute intoxication; no individuals were non-compliant, and no youth needed to be rescheduled.
68-1	11642-11647	Youth	_	
68-2	11648-11652	were	_	
68-3	11653-11661	screened	_	
68-4	11662-11665	for	_	
68-5	11666-11676	indicators	_	
68-6	11677-11679	of	_	
68-7	11680-11685	acute	_	
68-8	11686-11698	intoxication	_	
68-9	11698-11699	;	_	
68-10	11700-11702	no	_	
68-11	11703-11714	individuals	_	
68-12	11715-11719	were	_	
68-13	11720-11733	non-compliant	_	
68-14	11733-11734	,	_	
68-15	11735-11738	and	_	
68-16	11739-11741	no	_	
68-17	11742-11747	youth	_	
68-18	11748-11754	needed	_	
68-19	11755-11757	to	_	
68-20	11758-11760	be	_	
68-21	11761-11772	rescheduled	_	
68-22	11772-11773	.	_	

#Text=Once comfortable with the MRI procedures, youth were placed into the scanner for a high-resolution structural scan.
69-1	11774-11778	Once	_	
69-2	11779-11790	comfortable	_	
69-3	11791-11795	with	_	
69-4	11796-11799	the	_	
69-5	11800-11803	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
69-6	11804-11814	procedures	_	
69-7	11814-11815	,	_	
69-8	11816-11821	youth	_	
69-9	11822-11826	were	_	
69-10	11827-11833	placed	_	
69-11	11834-11838	into	_	
69-12	11839-11842	the	_	
69-13	11843-11850	scanner	_	
69-14	11851-11854	for	_	
69-15	11855-11856	a	_	
69-16	11857-11872	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
69-17	11873-11883	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
69-18	11884-11888	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[26]	
69-19	11888-11889	.	_	

#Text=This scan provided image registration and normalization.
70-1	11890-11894	This	_	
70-2	11895-11899	scan	_	
70-3	11900-11908	provided	_	
70-4	11909-11914	image	_	
70-5	11915-11927	registration	_	
70-6	11928-11931	and	_	
70-7	11932-11945	normalization	_	
70-8	11945-11946	.	_	

#Text=We utilized the standard audio volume setting for all participants, which was monitored by our MR technicians.
71-1	11947-11949	We	_	
71-2	11950-11958	utilized	_	
71-3	11959-11962	the	_	
71-4	11963-11971	standard	_	
71-5	11972-11977	audio	_	
71-6	11978-11984	volume	_	
71-7	11985-11992	setting	_	
71-8	11993-11996	for	_	
71-9	11997-12000	all	_	
71-10	12001-12013	participants	_	
71-11	12013-12014	,	_	
71-12	12015-12020	which	_	
71-13	12021-12024	was	_	
71-14	12025-12034	monitored	_	
71-15	12035-12037	by	_	
71-16	12038-12041	our	_	
71-17	12042-12044	MR	_	
71-18	12045-12056	technicians	_	
71-19	12056-12057	.	_	

#Text=As verified in our post-scan questionnaire, no youth reported difficulties hearing the audio statements within the fMRI paradigm.
72-1	12058-12060	As	_	
72-2	12061-12069	verified	_	
72-3	12070-12072	in	_	
72-4	12073-12076	our	_	
72-5	12077-12086	post-scan	_	
72-6	12087-12100	questionnaire	_	
72-7	12100-12101	,	_	
72-8	12102-12104	no	_	
72-9	12105-12110	youth	_	
72-10	12111-12119	reported	_	
72-11	12120-12132	difficulties	_	
72-12	12133-12140	hearing	_	
72-13	12141-12144	the	_	
72-14	12145-12150	audio	_	
72-15	12151-12161	statements	_	
72-16	12162-12168	within	_	
72-17	12169-12172	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
72-18	12173-12177	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
72-19	12178-12186	paradigm	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[27]	
72-20	12186-12187	.	_	

#Text=MRI images were collected using a 3T Siemens Trio whole body scanner equipped with Sonata gradient subsystem (40 mT/m amplitude, 200 µs rise time, 100% duty cycle) with a 12-channel coil combined with body coil transmission to achieve greater sensitivity in cortical areas.
73-1	12188-12191	MRI	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument	
73-2	12192-12198	images	_	
73-3	12199-12203	were	_	
73-4	12204-12213	collected	_	
73-5	12214-12219	using	_	
73-6	12220-12221	a	_	
73-7	12222-12224	3T	_	
73-8	12225-12232	Siemens	_	
73-9	12233-12237	Trio	_	
73-10	12238-12243	whole	_	
73-11	12244-12248	body	_	
73-12	12249-12256	scanner	_	
73-13	12257-12265	equipped	_	
73-14	12266-12270	with	_	
73-15	12271-12277	Sonata	_	
73-16	12278-12286	gradient	_	
73-17	12287-12296	subsystem	_	
73-18	12297-12298	(	_	
73-19	12298-12300	40	_	
73-20	12301-12303	mT	_	
73-21	12303-12304	/	_	
73-22	12304-12305	m	_	
73-23	12306-12315	amplitude	_	
73-24	12315-12316	,	_	
73-25	12317-12320	200	_	
73-26	12321-12323	µs	_	
73-27	12324-12328	rise	_	
73-28	12329-12333	time	_	
73-29	12333-12334	,	_	
73-30	12335-12339	100%	_	
73-31	12340-12344	duty	_	
73-32	12345-12350	cycle	_	
73-33	12350-12351	)	_	
73-34	12352-12356	with	_	
73-35	12357-12358	a	_	
73-36	12359-12361	12	_	
73-37	12361-12362	-	_	
73-38	12362-12369	channel	_	
73-39	12370-12374	coil	_	
73-40	12375-12383	combined	_	
73-41	12384-12388	with	_	
73-42	12389-12393	body	_	
73-43	12394-12398	coil	_	
73-44	12399-12411	transmission	_	
73-45	12412-12414	to	_	
73-46	12415-12422	achieve	_	
73-47	12423-12430	greater	_	
73-48	12431-12442	sensitivity	_	
73-49	12443-12445	in	_	
73-50	12446-12454	cortical	_	
73-51	12455-12460	areas	_	
73-52	12460-12461	.	_	

#Text=A high resolution whole brain anatomical MRI scan was also collected with a T1-weighted multi-echo Magnetization Prepared Rapid Gradient Echo or MPRAGE (MEMPR) sequence with the following parameters: TR/TE/TI = 2300/2.74/900 ms, flip angle = 8°, 192 sagittal slices, FOV = 256×256 mm, slab thickness = 176 mm, matrix = 256×256×176, voxel size =1×1×1 mm, number of echos = 4, pixel bandwidth = 650 Hz.
74-1	12462-12463	A	_	
74-2	12464-12468	high	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-3	12469-12479	resolution	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-4	12480-12485	whole	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-5	12486-12491	brain	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-6	12492-12502	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-7	12503-12506	MRI	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-8	12507-12511	scan	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
74-9	12512-12515	was	_	
74-10	12516-12520	also	_	
74-11	12521-12530	collected	_	
74-12	12531-12535	with	_	
74-13	12536-12537	a	_	
74-14	12538-12540	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-15	12540-12541	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-16	12541-12549	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
74-17	12550-12560	multi-echo	_	
74-18	12561-12574	Magnetization	_	
74-19	12575-12583	Prepared	_	
74-20	12584-12589	Rapid	_	
74-21	12590-12598	Gradient	_	
74-22	12599-12603	Echo	_	
74-23	12604-12606	or	_	
74-24	12607-12613	MPRAGE	_	
74-25	12614-12615	(	_	
74-26	12615-12620	MEMPR	_	
74-27	12620-12621	)	_	
74-28	12622-12630	sequence	_	
74-29	12631-12635	with	_	
74-30	12636-12639	the	_	
74-31	12640-12649	following	_	
74-32	12650-12660	parameters	_	
74-33	12660-12661	:	_	
74-34	12662-12664	TR	_	
74-35	12664-12665	/	_	
74-36	12665-12667	TE	_	
74-37	12667-12668	/	_	
74-38	12668-12670	TI	_	
74-39	12671-12672	=	_	
74-40	12673-12677	2300	_	
74-41	12677-12678	/	_	
74-42	12678-12682	2.74	_	
74-43	12682-12683	/	_	
74-44	12683-12686	900	_	
74-45	12687-12689	ms	_	
74-46	12689-12690	,	_	
74-47	12691-12695	flip	_	
74-48	12696-12701	angle	_	
74-49	12702-12703	=	_	
74-50	12704-12705	8	_	
74-51	12705-12706	°	_	
74-52	12706-12707	,	_	
74-53	12708-12711	192	_	
74-54	12712-12720	sagittal	_	
74-55	12721-12727	slices	_	
74-56	12727-12728	,	_	
74-57	12729-12732	FOV	_	
74-58	12733-12734	=	_	
74-59	12735-12738	256	_	
74-60	12738-12739	×	_	
74-61	12739-12742	256	_	
74-62	12743-12745	mm	_	
74-63	12745-12746	,	_	
74-64	12747-12751	slab	_	
74-65	12752-12761	thickness	_	
74-66	12762-12763	=	_	
74-67	12764-12767	176	_	
74-68	12768-12770	mm	_	
74-69	12770-12771	,	_	
74-70	12772-12778	matrix	_	
74-71	12779-12780	=	_	
74-72	12781-12784	256	_	
74-73	12784-12785	×	_	
74-74	12785-12788	256	_	
74-75	12788-12789	×	_	
74-76	12789-12792	176	_	
74-77	12792-12793	,	_	
74-78	12794-12799	voxel	_	
74-79	12800-12804	size	_	
74-80	12805-12806	=	_	
74-81	12806-12807	1	_	
74-82	12807-12808	×	_	
74-83	12808-12809	1	_	
74-84	12809-12810	×	_	
74-85	12810-12811	1	_	
74-86	12812-12814	mm	_	
74-87	12814-12815	,	_	
74-88	12816-12822	number	_	
74-89	12823-12825	of	_	
74-90	12826-12831	echos	_	
74-91	12832-12833	=	_	
74-92	12834-12835	4	_	
74-93	12835-12836	,	_	
74-94	12837-12842	pixel	_	
74-95	12843-12852	bandwidth	_	
74-96	12853-12854	=	_	
74-97	12855-12858	650	_	
74-98	12859-12861	Hz	_	
74-99	12861-12862	.	_	

#Text=Whole brain fMRI scans were collected using a gradient echo, echoplanar (EPI) sequence with ramp sampling correction using the inter-commissural line (AC-PC) as a reference (TR: 2.0 s, TE: 27ms, α: 70°, matrix size: 64×64, 32 slices, voxel size: 3×3×4 mm for the cannabis study; TR: 2.0 s, TE: 27 ms, flip angle= 75°, matrix size: 64 × 64, 33 slices, voxel size: 3.75 × 3.27 × 4.55 mm for the alcohol study) ventral to the surface of the OFC.
75-1	12863-12868	Whole	_	
75-2	12869-12874	brain	_	
75-3	12875-12879	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
75-4	12880-12885	scans	_	
75-5	12886-12890	were	_	
75-6	12891-12900	collected	_	
75-7	12901-12906	using	_	
75-8	12907-12908	a	_	
75-9	12909-12917	gradient	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-10	12918-12922	echo	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-11	12922-12923	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-12	12924-12934	echoplanar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-13	12935-12936	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-14	12936-12939	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-15	12939-12940	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-16	12941-12949	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[30]	
75-17	12950-12954	with	_	
75-18	12955-12959	ramp	_	
75-19	12960-12968	sampling	_	
75-20	12969-12979	correction	_	
75-21	12980-12985	using	_	
75-22	12986-12989	the	_	
75-23	12990-13007	inter-commissural	_	
75-24	13008-13012	line	_	
75-25	13013-13014	(	_	
75-26	13014-13019	AC-PC	_	
75-27	13019-13020	)	_	
75-28	13021-13023	as	_	
75-29	13024-13025	a	_	
75-30	13026-13035	reference	_	
75-31	13036-13037	(	_	
75-32	13037-13039	TR	_	
75-33	13039-13040	:	_	
75-34	13041-13044	2.0	_	
75-35	13045-13046	s	_	
75-36	13046-13047	,	_	
75-37	13048-13050	TE	_	
75-38	13050-13051	:	_	
75-39	13052-13056	27ms	_	
75-40	13056-13057	,	_	
75-41	13058-13059	α	_	
75-42	13059-13060	:	_	
75-43	13061-13063	70	_	
75-44	13063-13064	°	_	
75-45	13064-13065	,	_	
75-46	13066-13072	matrix	_	
75-47	13073-13077	size	_	
75-48	13077-13078	:	_	
75-49	13079-13081	64	_	
75-50	13081-13082	×	_	
75-51	13082-13084	64	_	
75-52	13084-13085	,	_	
75-53	13086-13088	32	_	
75-54	13089-13095	slices	_	
75-55	13095-13096	,	_	
75-56	13097-13102	voxel	_	
75-57	13103-13107	size	_	
75-58	13107-13108	:	_	
75-59	13109-13110	3	_	
75-60	13110-13111	×	_	
75-61	13111-13112	3	_	
75-62	13112-13113	×	_	
75-63	13113-13114	4	_	
75-64	13115-13117	mm	_	
75-65	13118-13121	for	_	
75-66	13122-13125	the	_	
75-67	13126-13134	cannabis	_	
75-68	13135-13140	study	_	
75-69	13140-13141	;	_	
75-70	13142-13144	TR	_	
75-71	13144-13145	:	_	
75-72	13146-13149	2.0	_	
75-73	13150-13151	s	_	
75-74	13151-13152	,	_	
75-75	13153-13155	TE	_	
75-76	13155-13156	:	_	
75-77	13157-13159	27	_	
75-78	13160-13162	ms	_	
75-79	13162-13163	,	_	
75-80	13164-13168	flip	_	
75-81	13169-13174	angle	_	
75-82	13174-13175	=	_	
75-83	13176-13178	75	_	
75-84	13178-13179	°	_	
75-85	13179-13180	,	_	
75-86	13181-13187	matrix	_	
75-87	13188-13192	size	_	
75-88	13192-13193	:	_	
75-89	13194-13196	64	_	
75-90	13197-13198	×	_	
75-91	13199-13201	64	_	
75-92	13201-13202	,	_	
75-93	13203-13205	33	_	
75-94	13206-13212	slices	_	
75-95	13212-13213	,	_	
75-96	13214-13219	voxel	_	
75-97	13220-13224	size	_	
75-98	13224-13225	:	_	
75-99	13226-13230	3.75	_	
75-100	13231-13232	×	_	
75-101	13233-13237	3.27	_	
75-102	13238-13239	×	_	
75-103	13240-13244	4.55	_	
75-104	13245-13247	mm	_	
75-105	13248-13251	for	_	
75-106	13252-13255	the	_	
75-107	13256-13263	alcohol	_	
75-108	13264-13269	study	_	
75-109	13269-13270	)	_	
75-110	13271-13278	ventral	_	
75-111	13279-13281	to	_	
75-112	13282-13285	the	_	
75-113	13286-13293	surface	_	
75-114	13294-13296	of	_	
75-115	13297-13300	the	_	
75-116	13301-13304	OFC	_	
75-117	13304-13305	.	_	

#Text=A tilting acquisition previously described in Filbey et al.
76-1	13306-13307	A	_	
76-2	13308-13315	tilting	_	
76-3	13316-13327	acquisition	_	
76-4	13328-13338	previously	_	
76-5	13339-13348	described	_	
76-6	13349-13351	in	_	
76-7	13352-13358	Filbey	_	
76-8	13359-13361	et	_	
76-9	13362-13364	al	_	
76-10	13364-13365	.	_	

#Text=was applied to increase the signal-to-noise ratio in the OFC.
77-1	13367-13370	was	_	
77-2	13371-13378	applied	_	
77-3	13379-13381	to	_	
77-4	13382-13390	increase	_	
77-5	13391-13394	the	_	
77-6	13395-13410	signal-to-noise	_	
77-7	13411-13416	ratio	_	
77-8	13417-13419	in	_	
77-9	13420-13423	the	_	
77-10	13424-13427	OFC	_	
77-11	13427-13428	.	_	

#Text=Our task (Figure 1) was designed to assess the impact of in-session client statements on brain response.
78-1	13429-13432	Our	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-2	13433-13437	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-3	13438-13439	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-4	13439-13445	Figure	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-5	13446-13447	1	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-6	13447-13448	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-7	13449-13452	was	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-8	13453-13461	designed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-9	13462-13464	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-10	13465-13471	assess	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-11	13472-13475	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-12	13476-13482	impact	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-13	13483-13485	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-14	13486-13496	in-session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-15	13497-13503	client	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-16	13504-13514	statements	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-17	13515-13517	on	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-18	13518-13523	brain	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-19	13524-13532	response	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	
78-20	13532-13533	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]	

#Text=Throughout the past decade, this task has demonstrated the ability to extract relevant regional brain activation during client language across three different age groups (adolescents, young adults, and adults) and across two different substances of abuse (alcohol and cannabis) .
79-1	13534-13544	Throughout	_	
79-2	13545-13548	the	_	
79-3	13549-13553	past	_	
79-4	13554-13560	decade	_	
79-5	13560-13561	,	_	
79-6	13562-13566	this	_	
79-7	13567-13571	task	_	
79-8	13572-13575	has	_	
79-9	13576-13588	demonstrated	_	
79-10	13589-13592	the	_	
79-11	13593-13600	ability	_	
79-12	13601-13603	to	_	
79-13	13604-13611	extract	_	
79-14	13612-13620	relevant	_	
79-15	13621-13629	regional	_	
79-16	13630-13635	brain	_	
79-17	13636-13646	activation	_	
79-18	13647-13653	during	_	
79-19	13654-13660	client	_	
79-20	13661-13669	language	_	
79-21	13670-13676	across	_	
79-22	13677-13682	three	_	
79-23	13683-13692	different	_	
79-24	13693-13696	age	_	
79-25	13697-13703	groups	_	
79-26	13704-13705	(	_	
79-27	13705-13716	adolescents	_	
79-28	13716-13717	,	_	
79-29	13718-13723	young	_	
79-30	13724-13730	adults	_	
79-31	13730-13731	,	_	
79-32	13732-13735	and	_	
79-33	13736-13742	adults	_	
79-34	13742-13743	)	_	
79-35	13744-13747	and	_	
79-36	13748-13754	across	_	
79-37	13755-13758	two	_	
79-38	13759-13768	different	_	
79-39	13769-13779	substances	_	
79-40	13780-13782	of	_	
79-41	13783-13788	abuse	_	
79-42	13789-13790	(	_	
79-43	13790-13797	alcohol	_	
79-44	13798-13801	and	_	
79-45	13802-13810	cannabis	_	
79-46	13810-13811	)	_	
79-47	13812-13813	.	_	

#Text=For this task, we extracted 5 client “change talk” statements (CT; “I need to cut back my use”) and 5 client “sustain talk” statements (ST; “I like using - it’s fun!”)
80-1	13814-13817	For	_	
80-2	13818-13822	this	_	
80-3	13823-13827	task	_	
80-4	13827-13828	,	_	
80-5	13829-13831	we	_	
80-6	13832-13841	extracted	_	
80-7	13842-13843	5	_	
80-8	13844-13850	client	_	
80-9	13851-13852	“	_	
80-10	13852-13858	change	_	
80-11	13859-13863	talk	_	
80-12	13863-13864	”	_	
80-13	13865-13875	statements	_	
80-14	13876-13877	(	_	
80-15	13877-13879	CT	_	
80-16	13879-13880	;	_	
80-17	13881-13882	“	_	
80-18	13882-13883	I	_	
80-19	13884-13888	need	_	
80-20	13889-13891	to	_	
80-21	13892-13895	cut	_	
80-22	13896-13900	back	_	
80-23	13901-13903	my	_	
80-24	13904-13907	use	_	
80-25	13907-13908	”	_	
80-26	13908-13909	)	_	
80-27	13910-13913	and	_	
80-28	13914-13915	5	_	
80-29	13916-13922	client	_	
80-30	13923-13924	“	_	
80-31	13924-13931	sustain	_	
80-32	13932-13936	talk	_	
80-33	13936-13937	”	_	
80-34	13938-13948	statements	_	
80-35	13949-13950	(	_	
80-36	13950-13952	ST	_	
80-37	13952-13953	;	_	
80-38	13954-13955	“	_	
80-39	13955-13956	I	_	
80-40	13957-13961	like	_	
80-41	13962-13967	using	_	
80-42	13968-13969	-	_	
80-43	13970-13972	it	_	
80-44	13972-13973	’	_	
80-45	13973-13974	s	_	
80-46	13975-13978	fun	_	
80-47	13978-13979	!	_	
80-48	13979-13980	”	_	
80-49	13980-13981	)	_	

#Text=from participants’ therapy sessions.
81-1	13982-13986	from	_	
81-2	13987-13999	participants	_	
81-3	13999-14000	’	_	
81-4	14001-14008	therapy	_	
81-5	14009-14017	sessions	_	
81-6	14017-14018	.	_	

#Text=Each type of client statement (change talk; sustain talk) was presented in 4 counterbalanced runs consisting of 10 × 65 second trials (TR 2s/volume; 1 run = 10 trials × 65 seconds/30 TRs per trial = 325 TRs/10 minutes).
82-1	14019-14023	Each	_	
82-2	14024-14028	type	_	
82-3	14029-14031	of	_	
82-4	14032-14038	client	_	
82-5	14039-14048	statement	_	
82-6	14049-14050	(	_	
82-7	14050-14056	change	_	
82-8	14057-14061	talk	_	
82-9	14061-14062	;	_	
82-10	14063-14070	sustain	_	
82-11	14071-14075	talk	_	
82-12	14075-14076	)	_	
82-13	14077-14080	was	_	
82-14	14081-14090	presented	_	
82-15	14091-14093	in	_	
82-16	14094-14095	4	_	
82-17	14096-14111	counterbalanced	_	
82-18	14112-14116	runs	_	
82-19	14117-14127	consisting	_	
82-20	14128-14130	of	_	
82-21	14131-14133	10	_	
82-22	14134-14135	×	_	
82-23	14136-14138	65	_	
82-24	14139-14145	second	_	
82-25	14146-14152	trials	_	
82-26	14153-14154	(	_	
82-27	14154-14156	TR	_	
82-28	14157-14159	2s	_	
82-29	14159-14160	/	_	
82-30	14160-14166	volume	_	
82-31	14166-14167	;	_	
82-32	14168-14169	1	_	
82-33	14170-14173	run	_	
82-34	14174-14175	=	_	
82-35	14176-14178	10	_	
82-36	14179-14185	trials	_	
82-37	14186-14187	×	_	
82-38	14188-14190	65	_	
82-39	14191-14198	seconds	_	
82-40	14198-14199	/	_	
82-41	14199-14201	30	_	
82-42	14202-14205	TRs	_	
82-43	14206-14209	per	_	
82-44	14210-14215	trial	_	
82-45	14216-14217	=	_	
82-46	14218-14221	325	_	
82-47	14222-14225	TRs	_	
82-48	14225-14226	/	_	
82-49	14226-14228	10	_	
82-50	14229-14236	minutes	_	
82-51	14236-14237	)	_	
82-52	14237-14238	.	_	

#Text=Across the 4 counterbalanced runs, the subjects were presented with each of the 10 CT and 10 ST trials twice for a total of 40 trials (20 CT and 20 ST).
83-1	14239-14245	Across	_	
83-2	14246-14249	the	_	
83-3	14250-14251	4	_	
83-4	14252-14267	counterbalanced	_	
83-5	14268-14272	runs	_	
83-6	14272-14273	,	_	
83-7	14274-14277	the	_	
83-8	14278-14286	subjects	_	
83-9	14287-14291	were	_	
83-10	14292-14301	presented	_	
83-11	14302-14306	with	_	
83-12	14307-14311	each	_	
83-13	14312-14314	of	_	
83-14	14315-14318	the	_	
83-15	14319-14321	10	_	
83-16	14322-14324	CT	_	
83-17	14325-14328	and	_	
83-18	14329-14331	10	_	
83-19	14332-14334	ST	_	
83-20	14335-14341	trials	_	
83-21	14342-14347	twice	_	
83-22	14348-14351	for	_	
83-23	14352-14353	a	_	
83-24	14354-14359	total	_	
83-25	14360-14362	of	_	
83-26	14363-14365	40	_	
83-27	14366-14372	trials	_	
83-28	14373-14374	(	_	
83-29	14374-14376	20	_	
83-30	14377-14379	CT	_	
83-31	14380-14383	and	_	
83-32	14384-14386	20	_	
83-33	14387-14389	ST	_	
83-34	14389-14390	)	_	
83-35	14390-14391	.	_	

#Text=During the presentation of the CT and ST statements, participants were instructed to silently read their visually presented words and listen to their audio-recorded voice.
84-1	14392-14398	During	_	
84-2	14399-14402	the	_	
84-3	14403-14415	presentation	_	
84-4	14416-14418	of	_	
84-5	14419-14422	the	_	
84-6	14423-14425	CT	_	
84-7	14426-14429	and	_	
84-8	14430-14432	ST	_	
84-9	14433-14443	statements	_	
84-10	14443-14444	,	_	
84-11	14445-14457	participants	_	
84-12	14458-14462	were	_	
84-13	14463-14473	instructed	_	
84-14	14474-14476	to	_	
84-15	14477-14485	silently	_	
84-16	14486-14490	read	_	
84-17	14491-14496	their	_	
84-18	14497-14505	visually	_	
84-19	14506-14515	presented	_	
84-20	14516-14521	words	_	
84-21	14522-14525	and	_	
84-22	14526-14532	listen	_	
84-23	14533-14535	to	_	
84-24	14536-14541	their	_	
84-25	14542-14556	audio-recorded	_	
84-26	14557-14562	voice	_	
84-27	14562-14563	.	_	

#Text=For a single run, each trial started with their 6 second audio clip (recorded from the participant’s therapy session) with a simultaneous visual presentation (seeing the written words) of their CT or ST statement.
85-1	14564-14567	For	_	
85-2	14568-14569	a	_	
85-3	14570-14576	single	_	
85-4	14577-14580	run	_	
85-5	14580-14581	,	_	
85-6	14582-14586	each	_	
85-7	14587-14592	trial	_	
85-8	14593-14600	started	_	
85-9	14601-14605	with	_	
85-10	14606-14611	their	_	
85-11	14612-14613	6	_	
85-12	14614-14620	second	_	
85-13	14621-14626	audio	_	
85-14	14627-14631	clip	_	
85-15	14632-14633	(	_	
85-16	14633-14641	recorded	_	
85-17	14642-14646	from	_	
85-18	14647-14650	the	_	
85-19	14651-14662	participant	_	
85-20	14662-14663	’	_	
85-21	14663-14664	s	_	
85-22	14665-14672	therapy	_	
85-23	14673-14680	session	_	
85-24	14680-14681	)	_	
85-25	14682-14686	with	_	
85-26	14687-14688	a	_	
85-27	14689-14701	simultaneous	_	
85-28	14702-14708	visual	_	
85-29	14709-14721	presentation	_	
85-30	14722-14723	(	_	
85-31	14723-14729	seeing	_	
85-32	14730-14733	the	_	
85-33	14734-14741	written	_	
85-34	14742-14747	words	_	
85-35	14747-14748	)	_	
85-36	14749-14751	of	_	
85-37	14752-14757	their	_	
85-38	14758-14760	CT	_	
85-39	14761-14763	or	_	
85-40	14764-14766	ST	_	
85-41	14767-14776	statement	_	
85-42	14776-14777	.	_	

#Text=Statement presentations were then followed by a 4–20 second washout period with a fixation cross on the screen during which no audio was presented.
86-1	14778-14787	Statement	_	
86-2	14788-14801	presentations	_	
86-3	14802-14806	were	_	
86-4	14807-14811	then	_	
86-5	14812-14820	followed	_	
86-6	14821-14823	by	_	
86-7	14824-14825	a	_	
86-8	14826-14827	4	_	
86-9	14827-14828	–	_	
86-10	14828-14830	20	_	
86-11	14831-14837	second	_	
86-12	14838-14845	washout	_	
86-13	14846-14852	period	_	
86-14	14853-14857	with	_	
86-15	14858-14859	a	_	
86-16	14860-14868	fixation	_	
86-17	14869-14874	cross	_	
86-18	14875-14877	on	_	
86-19	14878-14881	the	_	
86-20	14882-14888	screen	_	
86-21	14889-14895	during	_	
86-22	14896-14901	which	_	
86-23	14902-14904	no	_	
86-24	14905-14910	audio	_	
86-25	14911-14914	was	_	
86-26	14915-14924	presented	_	
86-27	14924-14925	.	_	

#Text=The task was presented using a front projection to a mirror system mounted on the head coil.
87-1	14926-14929	The	_	
87-2	14930-14934	task	_	
87-3	14935-14938	was	_	
87-4	14939-14948	presented	_	
87-5	14949-14954	using	_	
87-6	14955-14956	a	_	
87-7	14957-14962	front	_	
87-8	14963-14973	projection	_	
87-9	14974-14976	to	_	
87-10	14977-14978	a	_	
87-11	14979-14985	mirror	_	
87-12	14986-14992	system	_	
87-13	14993-15000	mounted	_	
87-14	15001-15003	on	_	
87-15	15004-15007	the	_	
87-16	15008-15012	head	_	
87-17	15013-15017	coil	_	
87-18	15017-15018	.	_	

#Text=Stimulus presentations were delivered using E-Prime (cannabis study) and Presentation (alcohol study).
88-1	15019-15027	Stimulus	_	
88-2	15028-15041	presentations	_	
88-3	15042-15046	were	_	
88-4	15047-15056	delivered	_	
88-5	15057-15062	using	_	
88-6	15063-15070	E-Prime	_	
88-7	15071-15072	(	_	
88-8	15072-15080	cannabis	_	
88-9	15081-15086	study	_	
88-10	15086-15087	)	_	
88-11	15088-15091	and	_	
88-12	15092-15104	Presentation	_	
88-13	15105-15106	(	_	
88-14	15106-15113	alcohol	_	
88-15	15114-15119	study	_	
88-16	15119-15120	)	_	
88-17	15120-15121	.	_	

#Text=The timing of the stimulus presentation was synchronized with trigger pulses from the scanner to ensure precise temporal integration of stimulus presentation and fMRI data acquisition.
89-1	15122-15125	The	_	
89-2	15126-15132	timing	_	
89-3	15133-15135	of	_	
89-4	15136-15139	the	_	
89-5	15140-15148	stimulus	_	
89-6	15149-15161	presentation	_	
89-7	15162-15165	was	_	
89-8	15166-15178	synchronized	_	
89-9	15179-15183	with	_	
89-10	15184-15191	trigger	_	
89-11	15192-15198	pulses	_	
89-12	15199-15203	from	_	
89-13	15204-15207	the	_	
89-14	15208-15215	scanner	_	
89-15	15216-15218	to	_	
89-16	15219-15225	ensure	_	
89-17	15226-15233	precise	_	
89-18	15234-15242	temporal	_	
89-19	15243-15254	integration	_	
89-20	15255-15257	of	_	
89-21	15258-15266	stimulus	_	
89-22	15267-15279	presentation	_	
89-23	15280-15283	and	_	
89-24	15284-15288	fMRI	_	
89-25	15289-15293	data	_	
89-26	15294-15305	acquisition	_	
89-27	15305-15306	.	_	

#Text=Given our interest on the expression of client language as a potential marker of in-session behavior change, all analyses herein focused on the comparison of client language condition relative to baseline.
90-1	15307-15312	Given	_	
90-2	15313-15316	our	_	
90-3	15317-15325	interest	_	
90-4	15326-15328	on	_	
90-5	15329-15332	the	_	
90-6	15333-15343	expression	_	
90-7	15344-15346	of	_	
90-8	15347-15353	client	_	
90-9	15354-15362	language	_	
90-10	15363-15365	as	_	
90-11	15366-15367	a	_	
90-12	15368-15377	potential	_	
90-13	15378-15384	marker	_	
90-14	15385-15387	of	_	
90-15	15388-15398	in-session	_	
90-16	15399-15407	behavior	_	
90-17	15408-15414	change	_	
90-18	15414-15415	,	_	
90-19	15416-15419	all	_	
90-20	15420-15428	analyses	_	
90-21	15429-15435	herein	_	
90-22	15436-15443	focused	_	
90-23	15444-15446	on	_	
90-24	15447-15450	the	_	
90-25	15451-15461	comparison	_	
90-26	15462-15464	of	_	
90-27	15465-15471	client	_	
90-28	15472-15480	language	_	
90-29	15481-15490	condition	_	
90-30	15491-15499	relative	_	
90-31	15500-15502	to	_	
90-32	15503-15511	baseline	_	
90-33	15511-15512	.	_	

#Text=This facilitated a way for us to elucidate how the brain responds to this widely accepted mechanism of change in the behavioral treatment literature .
91-1	15513-15517	This	_	
91-2	15518-15529	facilitated	_	
91-3	15530-15531	a	_	
91-4	15532-15535	way	_	
91-5	15536-15539	for	_	
91-6	15540-15542	us	_	
91-7	15543-15545	to	_	
91-8	15546-15555	elucidate	_	
91-9	15556-15559	how	_	
91-10	15560-15563	the	_	
91-11	15564-15569	brain	_	
91-12	15570-15578	responds	_	
91-13	15579-15581	to	_	
91-14	15582-15586	this	_	
91-15	15587-15593	widely	_	
91-16	15594-15602	accepted	_	
91-17	15603-15612	mechanism	_	
91-18	15613-15615	of	_	
91-19	15616-15622	change	_	
91-20	15623-15625	in	_	
91-21	15626-15629	the	_	
91-22	15630-15640	behavioral	_	
91-23	15641-15650	treatment	_	
91-24	15651-15661	literature	_	
91-25	15662-15663	.	_	

#Text=The baseline included the washout/fixation period.
#Text=2.4 fMRI Data Preprocessing and First-level Analyses
#Text=All analyses were performed offline using SPM8 (Wellcome Department of Imaging Neuroscience, London, UK).
92-1	15664-15667	The	_	
92-2	15668-15676	baseline	_	
92-3	15677-15685	included	_	
92-4	15686-15689	the	_	
92-5	15690-15697	washout	_	
92-6	15697-15698	/	_	
92-7	15698-15706	fixation	_	
92-8	15707-15713	period	_	
92-9	15713-15714	.	_	
92-10	15715-15718	2.4	_	
92-11	15719-15723	fMRI	_	
92-12	15724-15728	Data	_	
92-13	15729-15742	Preprocessing	_	
92-14	15743-15746	and	_	
92-15	15747-15758	First-level	_	
92-16	15759-15767	Analyses	_	
92-17	15768-15771	All	_	
92-18	15772-15780	analyses	_	
92-19	15781-15785	were	_	
92-20	15786-15795	performed	_	
92-21	15796-15803	offline	_	
92-22	15804-15809	using	_	
92-23	15810-15814	SPM8	_	
92-24	15815-15816	(	_	
92-25	15816-15824	Wellcome	_	
92-26	15825-15835	Department	_	
92-27	15836-15838	of	_	
92-28	15839-15846	Imaging	_	
92-29	15847-15859	Neuroscience	_	
92-30	15859-15860	,	_	
92-31	15861-15867	London	_	
92-32	15867-15868	,	_	
92-33	15869-15871	UK	_	
92-34	15871-15872	)	_	
92-35	15872-15873	.	_	

#Text=Before starting statistical analysis, the first six volumes of each EPI run were discarded to allow the MR signal to reach steady state.
93-1	15874-15880	Before	_	
93-2	15881-15889	starting	_	
93-3	15890-15901	statistical	_	
93-4	15902-15910	analysis	_	
93-5	15910-15911	,	_	
93-6	15912-15915	the	_	
93-7	15916-15921	first	_	
93-8	15922-15925	six	_	
93-9	15926-15933	volumes	_	
93-10	15934-15936	of	_	
93-11	15937-15941	each	_	
93-12	15942-15945	EPI	_	
93-13	15946-15949	run	_	
93-14	15950-15954	were	_	
93-15	15955-15964	discarded	_	
93-16	15965-15967	to	_	
93-17	15968-15973	allow	_	
93-18	15974-15977	the	_	
93-19	15978-15980	MR	_	
93-20	15981-15987	signal	_	
93-21	15988-15990	to	_	
93-22	15991-15996	reach	_	
93-23	15997-16003	steady	_	
93-24	16004-16009	state	_	
93-25	16009-16010	.	_	

#Text=Pre-processing of these volumes started with motion correction using SPM’s realignment module .
94-1	16011-16025	Pre-processing	_	
94-2	16026-16028	of	_	
94-3	16029-16034	these	_	
94-4	16035-16042	volumes	_	
94-5	16043-16050	started	_	
94-6	16051-16055	with	_	
94-7	16056-16062	motion	_	
94-8	16063-16073	correction	_	
94-9	16074-16079	using	_	
94-10	16080-16083	SPM	_	
94-11	16083-16084	’	_	
94-12	16084-16085	s	_	
94-13	16086-16097	realignment	_	
94-14	16098-16104	module	_	
94-15	16105-16106	.	_	

#Text=This was followed by slice timing correction, which corrected for temporal differences in acquisition time of the BOLD signal across slices within each volume.
95-1	16107-16111	This	_	
95-2	16112-16115	was	_	
95-3	16116-16124	followed	_	
95-4	16125-16127	by	_	
95-5	16128-16133	slice	_	
95-6	16134-16140	timing	_	
95-7	16141-16151	correction	_	
95-8	16151-16152	,	_	
95-9	16153-16158	which	_	
95-10	16159-16168	corrected	_	
95-11	16169-16172	for	_	
95-12	16173-16181	temporal	_	
95-13	16182-16193	differences	_	
95-14	16194-16196	in	_	
95-15	16197-16208	acquisition	_	
95-16	16209-16213	time	_	
95-17	16214-16216	of	_	
95-18	16217-16220	the	_	
95-19	16221-16225	BOLD	_	
95-20	16226-16232	signal	_	
95-21	16233-16239	across	_	
95-22	16240-16246	slices	_	
95-23	16247-16253	within	_	
95-24	16254-16258	each	_	
95-25	16259-16265	volume	_	
95-26	16265-16266	.	_	

#Text=The functional data were then normalized  into the Montreal Neurological Institute (MNI) standard space using the template provided in SPM.
96-1	16267-16270	The	_	
96-2	16271-16281	functional	_	
96-3	16282-16286	data	_	
96-4	16287-16291	were	_	
96-5	16292-16296	then	_	
96-6	16297-16307	normalized	_	
96-7	16309-16313	into	_	
96-8	16314-16317	the	_	
96-9	16318-16326	Montreal	_	
96-10	16327-16339	Neurological	_	
96-11	16340-16349	Institute	_	
96-12	16350-16351	(	_	
96-13	16351-16354	MNI	_	
96-14	16354-16355	)	_	
96-15	16356-16364	standard	_	
96-16	16365-16370	space	_	
96-17	16371-16376	using	_	
96-18	16377-16380	the	_	
96-19	16381-16389	template	_	
96-20	16390-16398	provided	_	
96-21	16399-16401	in	_	
96-22	16402-16405	SPM	_	
96-23	16405-16406	.	_	

#Text=The resultant time series was then smoothed using a 6 mm (FWHM) Gaussian kernel.
97-1	16407-16410	The	_	
97-2	16411-16420	resultant	_	
97-3	16421-16425	time	_	
97-4	16426-16432	series	_	
97-5	16433-16436	was	_	
97-6	16437-16441	then	_	
97-7	16442-16450	smoothed	_	
97-8	16451-16456	using	_	
97-9	16457-16458	a	_	
97-10	16459-16460	6	_	
97-11	16461-16463	mm	_	
97-12	16464-16465	(	_	
97-13	16465-16469	FWHM	_	
97-14	16469-16470	)	_	
97-15	16471-16479	Gaussian	_	
97-16	16480-16486	kernel	_	
97-17	16486-16487	.	_	

#Text=Also, for each dataset, the anatomical MPRAGE scan was co-registered to the BOLD first dynamic, normalized to MNI space, skull stripped and segmented to yield WM and CSF segments.
98-1	16488-16492	Also	_	
98-2	16492-16493	,	_	
98-3	16494-16497	for	_	
98-4	16498-16502	each	_	
98-5	16503-16510	dataset	_	
98-6	16510-16511	,	_	
98-7	16512-16515	the	_	
98-8	16516-16526	anatomical	_	
98-9	16527-16533	MPRAGE	_	
98-10	16534-16538	scan	_	
98-11	16539-16542	was	_	
98-12	16543-16556	co-registered	_	
98-13	16557-16559	to	_	
98-14	16560-16563	the	_	
98-15	16564-16568	BOLD	_	
98-16	16569-16574	first	_	
98-17	16575-16582	dynamic	_	
98-18	16582-16583	,	_	
98-19	16584-16594	normalized	_	
98-20	16595-16597	to	_	
98-21	16598-16601	MNI	_	
98-22	16602-16607	space	_	
98-23	16607-16608	,	_	
98-24	16609-16614	skull	_	
98-25	16615-16623	stripped	_	
98-26	16624-16627	and	_	
98-27	16628-16637	segmented	_	
98-28	16638-16640	to	_	
98-29	16641-16646	yield	_	
98-30	16647-16649	WM	_	
98-31	16650-16653	and	_	
98-32	16654-16657	CSF	_	
98-33	16658-16666	segments	_	
98-34	16666-16667	.	_	

#Text=The average BOLD time series within these segments were extracted using in-house Matlab scripts.
99-1	16668-16671	The	_	
99-2	16672-16679	average	_	
99-3	16680-16684	BOLD	_	
99-4	16685-16689	time	_	
99-5	16690-16696	series	_	
99-6	16697-16703	within	_	
99-7	16704-16709	these	_	
99-8	16710-16718	segments	_	
99-9	16719-16723	were	_	
99-10	16724-16733	extracted	_	
99-11	16734-16739	using	_	
99-12	16740-16748	in-house	_	
99-13	16749-16755	Matlab	_	
99-14	16756-16763	scripts	_	
99-15	16763-16764	.	_	

#Text=To determine the potential neural mechanisms of client in-session language, we modeled BOLD activation during client language (change talk and sustain talk) in the GLM analysis.
100-1	16765-16767	To	_	
100-2	16768-16777	determine	_	
100-3	16778-16781	the	_	
100-4	16782-16791	potential	_	
100-5	16792-16798	neural	_	
100-6	16799-16809	mechanisms	_	
100-7	16810-16812	of	_	
100-8	16813-16819	client	_	
100-9	16820-16830	in-session	_	
100-10	16831-16839	language	_	
100-11	16839-16840	,	_	
100-12	16841-16843	we	_	
100-13	16844-16851	modeled	_	
100-14	16852-16856	BOLD	_	
100-15	16857-16867	activation	_	
100-16	16868-16874	during	_	
100-17	16875-16881	client	_	
100-18	16882-16890	language	_	
100-19	16891-16892	(	_	
100-20	16892-16898	change	_	
100-21	16899-16903	talk	_	
100-22	16904-16907	and	_	
100-23	16908-16915	sustain	_	
100-24	16916-16920	talk	_	
100-25	16920-16921	)	_	
100-26	16922-16924	in	_	
100-27	16925-16928	the	_	
100-28	16929-16932	GLM	_	
100-29	16933-16941	analysis	_	
100-30	16941-16942	.	_	

#Text=All regressors were convolved with a canonical HRF included in SPM8.
101-1	16943-16946	All	_	
101-2	16947-16957	regressors	_	
101-3	16958-16962	were	_	
101-4	16963-16972	convolved	_	
101-5	16973-16977	with	_	
101-6	16978-16979	a	_	
101-7	16980-16989	canonical	_	
101-8	16990-16993	HRF	_	
101-9	16994-17002	included	_	
101-10	17003-17005	in	_	
101-11	17006-17010	SPM8	_	
101-12	17010-17011	.	_	

#Text=Ancillary non-target conditions of interest to this study (e.g., cue types and urge rating in the cannabis study, therapist language in the alcohol study) were modeled as nuisance regressors.
102-1	17012-17021	Ancillary	_	
102-2	17022-17032	non-target	_	
102-3	17033-17043	conditions	_	
102-4	17044-17046	of	_	
102-5	17047-17055	interest	_	
102-6	17056-17058	to	_	
102-7	17059-17063	this	_	
102-8	17064-17069	study	_	
102-9	17070-17071	(	_	
102-10	17071-17074	e.g	_	
102-11	17074-17075	.	_	
102-12	17075-17076	,	_	
102-13	17077-17080	cue	_	
102-14	17081-17086	types	_	
102-15	17087-17090	and	_	
102-16	17091-17095	urge	_	
102-17	17096-17102	rating	_	
102-18	17103-17105	in	_	
102-19	17106-17109	the	_	
102-20	17110-17118	cannabis	_	
102-21	17119-17124	study	_	
102-22	17124-17125	,	_	
102-23	17126-17135	therapist	_	
102-24	17136-17144	language	_	
102-25	17145-17147	in	_	
102-26	17148-17151	the	_	
102-27	17152-17159	alcohol	_	
102-28	17160-17165	study	_	
102-29	17165-17166	)	_	
102-30	17167-17171	were	_	
102-31	17172-17179	modeled	_	
102-32	17180-17182	as	_	
102-33	17183-17191	nuisance	_	
102-34	17192-17202	regressors	_	
102-35	17202-17203	.	_	

#Text=The mean WM and CSF signal were also included as regressors of no interest in the model.
103-1	17204-17207	The	_	
103-2	17208-17212	mean	_	
103-3	17213-17215	WM	_	
103-4	17216-17219	and	_	
103-5	17220-17223	CSF	_	
103-6	17224-17230	signal	_	
103-7	17231-17235	were	_	
103-8	17236-17240	also	_	
103-9	17241-17249	included	_	
103-10	17250-17252	as	_	
103-11	17253-17263	regressors	_	
103-12	17264-17266	of	_	
103-13	17267-17269	no	_	
103-14	17270-17278	interest	_	
103-15	17279-17281	in	_	
103-16	17282-17285	the	_	
103-17	17286-17291	model	_	
103-18	17291-17292	.	_	

#Text=Notably, these conditions did not contribute to baseline activation, and the resultant model fit was optimal.
#Text=2.5 fMRI Data Functional Connectivity Analysis
#Text=To determine functional connectivity, we performed whole brain psychophysiological interaction (PPI) analyses using the gPPI toolbox  for SPM8.
104-1	17293-17300	Notably	_	
104-2	17300-17301	,	_	
104-3	17302-17307	these	_	
104-4	17308-17318	conditions	_	
104-5	17319-17322	did	_	
104-6	17323-17326	not	_	
104-7	17327-17337	contribute	_	
104-8	17338-17340	to	_	
104-9	17341-17349	baseline	_	
104-10	17350-17360	activation	_	
104-11	17360-17361	,	_	
104-12	17362-17365	and	_	
104-13	17366-17369	the	_	
104-14	17370-17379	resultant	_	
104-15	17380-17385	model	_	
104-16	17386-17389	fit	_	
104-17	17390-17393	was	_	
104-18	17394-17401	optimal	_	
104-19	17401-17402	.	_	
104-20	17403-17406	2.5	_	
104-21	17407-17411	fMRI	_	
104-22	17412-17416	Data	_	
104-23	17417-17427	Functional	_	
104-24	17428-17440	Connectivity	_	
104-25	17441-17449	Analysis	_	
104-26	17450-17452	To	_	
104-27	17453-17462	determine	_	
104-28	17463-17473	functional	_	
104-29	17474-17486	connectivity	_	
104-30	17486-17487	,	_	
104-31	17488-17490	we	_	
104-32	17491-17500	performed	_	
104-33	17501-17506	whole	_	
104-34	17507-17512	brain	_	
104-35	17513-17532	psychophysiological	_	
104-36	17533-17544	interaction	_	
104-37	17545-17546	(	_	
104-38	17546-17549	PPI	_	
104-39	17549-17550	)	_	
104-40	17551-17559	analyses	_	
104-41	17560-17565	using	_	
104-42	17566-17569	the	_	
104-43	17570-17574	gPPI	_	
104-44	17575-17582	toolbox	_	
104-45	17584-17587	for	_	
104-46	17588-17592	SPM8	_	
104-47	17592-17593	.	_	

#Text=This approach shows how functional connectivity between brain regions is altered as a result of experimental or psychological context, such as following the receipt of psychotherapy or elements of psychotherapy (e.g., client language) .
105-1	17594-17598	This	_	
105-2	17599-17607	approach	_	
105-3	17608-17613	shows	_	
105-4	17614-17617	how	_	
105-5	17618-17628	functional	_	
105-6	17629-17641	connectivity	_	
105-7	17642-17649	between	_	
105-8	17650-17655	brain	_	
105-9	17656-17663	regions	_	
105-10	17664-17666	is	_	
105-11	17667-17674	altered	_	
105-12	17675-17677	as	_	
105-13	17678-17679	a	_	
105-14	17680-17686	result	_	
105-15	17687-17689	of	_	
105-16	17690-17702	experimental	_	
105-17	17703-17705	or	_	
105-18	17706-17719	psychological	_	
105-19	17720-17727	context	_	
105-20	17727-17728	,	_	
105-21	17729-17733	such	_	
105-22	17734-17736	as	_	
105-23	17737-17746	following	_	
105-24	17747-17750	the	_	
105-25	17751-17758	receipt	_	
105-26	17759-17761	of	_	
105-27	17762-17775	psychotherapy	_	
105-28	17776-17778	or	_	
105-29	17779-17787	elements	_	
105-30	17788-17790	of	_	
105-31	17791-17804	psychotherapy	_	
105-32	17805-17806	(	_	
105-33	17806-17809	e.g	_	
105-34	17809-17810	.	_	
105-35	17810-17811	,	_	
105-36	17812-17818	client	_	
105-37	17819-17827	language	_	
105-38	17827-17828	)	_	
105-39	17829-17830	.	_	

#Text=In order to maximize potential applicability across both types of in-session client language, we wanted to ensure that we selected a seed region that would be relevant not just for change talk, but also for sustain talk.
106-1	17831-17833	In	_	
106-2	17834-17839	order	_	
106-3	17840-17842	to	_	
106-4	17843-17851	maximize	_	
106-5	17852-17861	potential	_	
106-6	17862-17875	applicability	_	
106-7	17876-17882	across	_	
106-8	17883-17887	both	_	
106-9	17888-17893	types	_	
106-10	17894-17896	of	_	
106-11	17897-17907	in-session	_	
106-12	17908-17914	client	_	
106-13	17915-17923	language	_	
106-14	17923-17924	,	_	
106-15	17925-17927	we	_	
106-16	17928-17934	wanted	_	
106-17	17935-17937	to	_	
106-18	17938-17944	ensure	_	
106-19	17945-17949	that	_	
106-20	17950-17952	we	_	
106-21	17953-17961	selected	_	
106-22	17962-17963	a	_	
106-23	17964-17968	seed	_	
106-24	17969-17975	region	_	
106-25	17976-17980	that	_	
106-26	17981-17986	would	_	
106-27	17987-17989	be	_	
106-28	17990-17998	relevant	_	
106-29	17999-18002	not	_	
106-30	18003-18007	just	_	
106-31	18008-18011	for	_	
106-32	18012-18018	change	_	
106-33	18019-18023	talk	_	
106-34	18023-18024	,	_	
106-35	18025-18028	but	_	
106-36	18029-18033	also	_	
106-37	18034-18037	for	_	
106-38	18038-18045	sustain	_	
106-39	18046-18050	talk	_	
106-40	18050-18051	.	_	

#Text=Thus, to identify a seed region that was (a) significantly activated for both groups and both conditions of interest, and (b) within the same anatomic region across all subjects, we performed a conjunction analysis over the effects of interest (both client language conditions: change talk vs. baseline; sustain talk vs. baseline; FDR corrected p <0.05)  and in the pooled sample of user groups (cannabis users with alcohol users).
107-1	18052-18056	Thus	_	
107-2	18056-18057	,	_	
107-3	18058-18060	to	_	
107-4	18061-18069	identify	_	
107-5	18070-18071	a	_	
107-6	18072-18076	seed	_	
107-7	18077-18083	region	_	
107-8	18084-18088	that	_	
107-9	18089-18092	was	_	
107-10	18093-18094	(	_	
107-11	18094-18095	a	_	
107-12	18095-18096	)	_	
107-13	18097-18110	significantly	_	
107-14	18111-18120	activated	_	
107-15	18121-18124	for	_	
107-16	18125-18129	both	_	
107-17	18130-18136	groups	_	
107-18	18137-18140	and	_	
107-19	18141-18145	both	_	
107-20	18146-18156	conditions	_	
107-21	18157-18159	of	_	
107-22	18160-18168	interest	_	
107-23	18168-18169	,	_	
107-24	18170-18173	and	_	
107-25	18174-18175	(	_	
107-26	18175-18176	b	_	
107-27	18176-18177	)	_	
107-28	18178-18184	within	_	
107-29	18185-18188	the	_	
107-30	18189-18193	same	_	
107-31	18194-18202	anatomic	_	
107-32	18203-18209	region	_	
107-33	18210-18216	across	_	
107-34	18217-18220	all	_	
107-35	18221-18229	subjects	_	
107-36	18229-18230	,	_	
107-37	18231-18233	we	_	
107-38	18234-18243	performed	_	
107-39	18244-18245	a	_	
107-40	18246-18257	conjunction	_	
107-41	18258-18266	analysis	_	
107-42	18267-18271	over	_	
107-43	18272-18275	the	_	
107-44	18276-18283	effects	_	
107-45	18284-18286	of	_	
107-46	18287-18295	interest	_	
107-47	18296-18297	(	_	
107-48	18297-18301	both	_	
107-49	18302-18308	client	_	
107-50	18309-18317	language	_	
107-51	18318-18328	conditions	_	
107-52	18328-18329	:	_	
107-53	18330-18336	change	_	
107-54	18337-18341	talk	_	
107-55	18342-18344	vs	_	
107-56	18344-18345	.	_	
107-57	18346-18354	baseline	_	
107-58	18354-18355	;	_	
107-59	18356-18363	sustain	_	
107-60	18364-18368	talk	_	
107-61	18369-18371	vs	_	
107-62	18371-18372	.	_	
107-63	18373-18381	baseline	_	
107-64	18381-18382	;	_	
107-65	18383-18386	FDR	_	
107-66	18387-18396	corrected	_	
107-67	18397-18398	p	_	
107-68	18399-18400	<	_	
107-69	18400-18404	0.05	_	
107-70	18404-18405	)	_	
107-71	18407-18410	and	_	
107-72	18411-18413	in	_	
107-73	18414-18417	the	_	
107-74	18418-18424	pooled	_	
107-75	18425-18431	sample	_	
107-76	18432-18434	of	_	
107-77	18435-18439	user	_	
107-78	18440-18446	groups	_	
107-79	18447-18448	(	_	
107-80	18448-18456	cannabis	_	
107-81	18457-18462	users	_	
107-82	18463-18467	with	_	
107-83	18468-18475	alcohol	_	
107-84	18476-18481	users	_	
107-85	18481-18482	)	_	
107-86	18482-18483	.	_	

#Text=This approach generated a common region of activation within the orbitofrontal cortex (OFC) for all subjects across conditions; this functional mask for the OFC was then used as the seed region for all PPI analyses (see Supplementary Figures 4, 5, and 6).
108-1	18484-18488	This	_	
108-2	18489-18497	approach	_	
108-3	18498-18507	generated	_	
108-4	18508-18509	a	_	
108-5	18510-18516	common	_	
108-6	18517-18523	region	_	
108-7	18524-18526	of	_	
108-8	18527-18537	activation	_	
108-9	18538-18544	within	_	
108-10	18545-18548	the	_	
108-11	18549-18562	orbitofrontal	_	
108-12	18563-18569	cortex	_	
108-13	18570-18571	(	_	
108-14	18571-18574	OFC	_	
108-15	18574-18575	)	_	
108-16	18576-18579	for	_	
108-17	18580-18583	all	_	
108-18	18584-18592	subjects	_	
108-19	18593-18599	across	_	
108-20	18600-18610	conditions	_	
108-21	18610-18611	;	_	
108-22	18612-18616	this	_	
108-23	18617-18627	functional	_	
108-24	18628-18632	mask	_	
108-25	18633-18636	for	_	
108-26	18637-18640	the	_	
108-27	18641-18644	OFC	_	
108-28	18645-18648	was	_	
108-29	18649-18653	then	_	
108-30	18654-18658	used	_	
108-31	18659-18661	as	_	
108-32	18662-18665	the	_	
108-33	18666-18670	seed	_	
108-34	18671-18677	region	_	
108-35	18678-18681	for	_	
108-36	18682-18685	all	_	
108-37	18686-18689	PPI	_	
108-38	18690-18698	analyses	_	
108-39	18699-18700	(	_	
108-40	18700-18703	see	_	
108-41	18704-18717	Supplementary	_	
108-42	18718-18725	Figures	_	
108-43	18726-18727	4	_	
108-44	18727-18728	,	_	
108-45	18729-18730	5	_	
108-46	18730-18731	,	_	
108-47	18732-18735	and	_	
108-48	18736-18737	6	_	
108-49	18737-18738	)	_	
108-50	18738-18739	.	_	

#Text=For each subject, the first eigenvariate of fMRI signal was extracted from within the OFC seed, temporally filtered, and corrected for non-neuronal components of the design (such as session-specific mean).
109-1	18740-18743	For	_	
109-2	18744-18748	each	_	
109-3	18749-18756	subject	_	
109-4	18756-18757	,	_	
109-5	18758-18761	the	_	
109-6	18762-18767	first	_	
109-7	18768-18780	eigenvariate	_	
109-8	18781-18783	of	_	
109-9	18784-18788	fMRI	_	
109-10	18789-18795	signal	_	
109-11	18796-18799	was	_	
109-12	18800-18809	extracted	_	
109-13	18810-18814	from	_	
109-14	18815-18821	within	_	
109-15	18822-18825	the	_	
109-16	18826-18829	OFC	_	
109-17	18830-18834	seed	_	
109-18	18834-18835	,	_	
109-19	18836-18846	temporally	_	
109-20	18847-18855	filtered	_	
109-21	18855-18856	,	_	
109-22	18857-18860	and	_	
109-23	18861-18870	corrected	_	
109-24	18871-18874	for	_	
109-25	18875-18887	non-neuronal	_	
109-26	18888-18898	components	_	
109-27	18899-18901	of	_	
109-28	18902-18905	the	_	
109-29	18906-18912	design	_	
109-30	18913-18914	(	_	
109-31	18914-18918	such	_	
109-32	18919-18921	as	_	
109-33	18922-18938	session-specific	_	
109-34	18939-18943	mean	_	
109-35	18943-18944	)	_	
109-36	18944-18945	.	_	

#Text=This time series was deconvolved by the canonical HRF to estimate the time series for the neural activity (the physiological vector).
110-1	18946-18950	This	_	
110-2	18951-18955	time	_	
110-3	18956-18962	series	_	
110-4	18963-18966	was	_	
110-5	18967-18978	deconvolved	_	
110-6	18979-18981	by	_	
110-7	18982-18985	the	_	
110-8	18986-18995	canonical	_	
110-9	18996-18999	HRF	_	
110-10	19000-19002	to	_	
110-11	19003-19011	estimate	_	
110-12	19012-19015	the	_	
110-13	19016-19020	time	_	
110-14	19021-19027	series	_	
110-15	19028-19031	for	_	
110-16	19032-19035	the	_	
110-17	19036-19042	neural	_	
110-18	19043-19051	activity	_	
110-19	19052-19053	(	_	
110-20	19053-19056	the	_	
110-21	19057-19070	physiological	_	
110-22	19071-19077	vector	_	
110-23	19077-19078	)	_	
110-24	19078-19079	.	_	

#Text=The psychological vector was obtained by encoding the onset and duration of the client language blocks.
111-1	19080-19083	The	_	
111-2	19084-19097	psychological	_	
111-3	19098-19104	vector	_	
111-4	19105-19108	was	_	
111-5	19109-19117	obtained	_	
111-6	19118-19120	by	_	
111-7	19121-19129	encoding	_	
111-8	19130-19133	the	_	
111-9	19134-19139	onset	_	
111-10	19140-19143	and	_	
111-11	19144-19152	duration	_	
111-12	19153-19155	of	_	
111-13	19156-19159	the	_	
111-14	19160-19166	client	_	
111-15	19167-19175	language	_	
111-16	19176-19182	blocks	_	
111-17	19182-19183	.	_	

#Text=The physiological and psychological vectors were multiplied to obtain the corresponding PPI vector.
112-1	19184-19187	The	_	
112-2	19188-19201	physiological	_	
112-3	19202-19205	and	_	
112-4	19206-19219	psychological	_	
112-5	19220-19227	vectors	_	
112-6	19228-19232	were	_	
112-7	19233-19243	multiplied	_	
112-8	19244-19246	to	_	
112-9	19247-19253	obtain	_	
112-10	19254-19257	the	_	
112-11	19258-19271	corresponding	_	
112-12	19272-19275	PPI	_	
112-13	19276-19282	vector	_	
112-14	19282-19283	.	_	

#Text=Similar psychological and PPI vectors were also obtained for other conditions in the study to improve model fit.
113-1	19284-19291	Similar	_	
113-2	19292-19305	psychological	_	
113-3	19306-19309	and	_	
113-4	19310-19313	PPI	_	
113-5	19314-19321	vectors	_	
113-6	19322-19326	were	_	
113-7	19327-19331	also	_	
113-8	19332-19340	obtained	_	
113-9	19341-19344	for	_	
113-10	19345-19350	other	_	
113-11	19351-19361	conditions	_	
113-12	19362-19364	in	_	
113-13	19365-19368	the	_	
113-14	19369-19374	study	_	
113-15	19375-19377	to	_	
113-16	19378-19385	improve	_	
113-17	19386-19391	model	_	
113-18	19392-19395	fit	_	
113-19	19395-19396	.	_	

#Text=The averaged WM and CSF signals were also included in the model.
114-1	19397-19400	The	_	
114-2	19401-19409	averaged	_	
114-3	19410-19412	WM	_	
114-4	19413-19416	and	_	
114-5	19417-19420	CSF	_	
114-6	19421-19428	signals	_	
114-7	19429-19433	were	_	
114-8	19434-19438	also	_	
114-9	19439-19447	included	_	
114-10	19448-19450	in	_	
114-11	19451-19454	the	_	
114-12	19455-19460	model	_	
114-13	19460-19461	.	_	

#Text=The single subject PPI GLM thus comprised the PPI vectors, the corresponding psychological vectors, and physiological vector, each of which was convolved by the canonical HRF prior to GLM analysis.
#Text=2.6 Group-level analyses: Correlation between network connectivity strength and treatment response
#Text=To assess whether functional connectivity during change talk events differed as a function of post-treatment behavior change, we examined the associations between PPI estimates and treatment response in our adolescent cannabis-using sample (n = 30).
115-1	19462-19465	The	_	
115-2	19466-19472	single	_	
115-3	19473-19480	subject	_	
115-4	19481-19484	PPI	_	
115-5	19485-19488	GLM	_	
115-6	19489-19493	thus	_	
115-7	19494-19503	comprised	_	
115-8	19504-19507	the	_	
115-9	19508-19511	PPI	_	
115-10	19512-19519	vectors	_	
115-11	19519-19520	,	_	
115-12	19521-19524	the	_	
115-13	19525-19538	corresponding	_	
115-14	19539-19552	psychological	_	
115-15	19553-19560	vectors	_	
115-16	19560-19561	,	_	
115-17	19562-19565	and	_	
115-18	19566-19579	physiological	_	
115-19	19580-19586	vector	_	
115-20	19586-19587	,	_	
115-21	19588-19592	each	_	
115-22	19593-19595	of	_	
115-23	19596-19601	which	_	
115-24	19602-19605	was	_	
115-25	19606-19615	convolved	_	
115-26	19616-19618	by	_	
115-27	19619-19622	the	_	
115-28	19623-19632	canonical	_	
115-29	19633-19636	HRF	_	
115-30	19637-19642	prior	_	
115-31	19643-19645	to	_	
115-32	19646-19649	GLM	_	
115-33	19650-19658	analysis	_	
115-34	19658-19659	.	_	
115-35	19660-19663	2.6	_	
115-36	19664-19675	Group-level	_	
115-37	19676-19684	analyses	_	
115-38	19684-19685	:	_	
115-39	19686-19697	Correlation	_	
115-40	19698-19705	between	_	
115-41	19706-19713	network	_	
115-42	19714-19726	connectivity	_	
115-43	19727-19735	strength	_	
115-44	19736-19739	and	_	
115-45	19740-19749	treatment	_	
115-46	19750-19758	response	_	
115-47	19759-19761	To	_	
115-48	19762-19768	assess	_	
115-49	19769-19776	whether	_	
115-50	19777-19787	functional	_	
115-51	19788-19800	connectivity	_	
115-52	19801-19807	during	_	
115-53	19808-19814	change	_	
115-54	19815-19819	talk	_	
115-55	19820-19826	events	_	
115-56	19827-19835	differed	_	
115-57	19836-19838	as	_	
115-58	19839-19840	a	_	
115-59	19841-19849	function	_	
115-60	19850-19852	of	_	
115-61	19853-19867	post-treatment	_	
115-62	19868-19876	behavior	_	
115-63	19877-19883	change	_	
115-64	19883-19884	,	_	
115-65	19885-19887	we	_	
115-66	19888-19896	examined	_	
115-67	19897-19900	the	_	
115-68	19901-19913	associations	_	
115-69	19914-19921	between	_	
115-70	19922-19925	PPI	_	
115-71	19926-19935	estimates	_	
115-72	19936-19939	and	_	
115-73	19940-19949	treatment	_	
115-74	19950-19958	response	_	
115-75	19959-19961	in	_	
115-76	19962-19965	our	_	
115-77	19966-19976	adolescent	_	
115-78	19977-19991	cannabis-using	_	
115-79	19992-19998	sample	_	
115-80	19999-20000	(	_	
115-81	20000-20001	n	_	
115-82	20002-20003	=	_	
115-83	20004-20006	30	_	
115-84	20006-20007	)	_	
115-85	20007-20008	.	_	

#Text=Specifically, we correlated the change talk vs. baseline contrast map against the post-treatment measure of cannabis problems.
116-1	20009-20021	Specifically	_	
116-2	20021-20022	,	_	
116-3	20023-20025	we	_	
116-4	20026-20036	correlated	_	
116-5	20037-20040	the	_	
116-6	20041-20047	change	_	
116-7	20048-20052	talk	_	
116-8	20053-20055	vs	_	
116-9	20055-20056	.	_	
116-10	20057-20065	baseline	_	
116-11	20066-20074	contrast	_	
116-12	20075-20078	map	_	
116-13	20079-20086	against	_	
116-14	20087-20090	the	_	
116-15	20091-20105	post-treatment	_	
116-16	20106-20113	measure	_	
116-17	20114-20116	of	_	
116-18	20117-20125	cannabis	_	
116-19	20126-20134	problems	_	
116-20	20134-20135	.	_	

#Text=Analysis was restricted within a mask consisting of cortical and subcortical grey matter.
117-1	20136-20144	Analysis	_	
117-2	20145-20148	was	_	
117-3	20149-20159	restricted	_	
117-4	20160-20166	within	_	
117-5	20167-20168	a	_	
117-6	20169-20173	mask	_	
117-7	20174-20184	consisting	_	
117-8	20185-20187	of	_	
117-9	20188-20196	cortical	_	
117-10	20197-20200	and	_	
117-11	20201-20212	subcortical	_	
117-12	20213-20217	grey	_	
117-13	20218-20224	matter	_	
117-14	20224-20225	.	_	

#Text=In line with other neurodevelopmental and addiction connectivity studies , we corrected for multiple comparisons via SPM’s voxel-wise False Discovery Rate (FDR) correction for multiple comparisons at p<0.05  and utilized an extent threshold (k) of at least 50 voxels for all analyses.
118-1	20226-20228	In	_	
118-2	20229-20233	line	_	
118-3	20234-20238	with	_	
118-4	20239-20244	other	_	
118-5	20245-20263	neurodevelopmental	_	
118-6	20264-20267	and	_	
118-7	20268-20277	addiction	_	
118-8	20278-20290	connectivity	_	
118-9	20291-20298	studies	_	
118-10	20299-20300	,	_	
118-11	20301-20303	we	_	
118-12	20304-20313	corrected	_	
118-13	20314-20317	for	_	
118-14	20318-20326	multiple	_	
118-15	20327-20338	comparisons	_	
118-16	20339-20342	via	_	
118-17	20343-20346	SPM	_	
118-18	20346-20347	’	_	
118-19	20347-20348	s	_	
118-20	20349-20359	voxel-wise	_	
118-21	20360-20365	False	_	
118-22	20366-20375	Discovery	_	
118-23	20376-20380	Rate	_	
118-24	20381-20382	(	_	
118-25	20382-20385	FDR	_	
118-26	20385-20386	)	_	
118-27	20387-20397	correction	_	
118-28	20398-20401	for	_	
118-29	20402-20410	multiple	_	
118-30	20411-20422	comparisons	_	
118-31	20423-20425	at	_	
118-32	20426-20427	p	_	
118-33	20427-20428	<	_	
118-34	20428-20432	0.05	_	
118-35	20434-20437	and	_	
118-36	20438-20446	utilized	_	
118-37	20447-20449	an	_	
118-38	20450-20456	extent	_	
118-39	20457-20466	threshold	_	
118-40	20467-20468	(	_	
118-41	20468-20469	k	_	
118-42	20469-20470	)	_	
118-43	20471-20473	of	_	
118-44	20474-20476	at	_	
118-45	20477-20482	least	_	
118-46	20483-20485	50	_	
118-47	20486-20492	voxels	_	
118-48	20493-20496	for	_	
118-49	20497-20500	all	_	
118-50	20501-20509	analyses	_	
118-51	20509-20510	.	_	

#Text=The anatomical localization for all regions of activation was found using the xjview software (http://www.alivelearn.net/xjview).
119-1	20511-20514	The	_	
119-2	20515-20525	anatomical	_	
119-3	20526-20538	localization	_	
119-4	20539-20542	for	_	
119-5	20543-20546	all	_	
119-6	20547-20554	regions	_	
119-7	20555-20557	of	_	
119-8	20558-20568	activation	_	
119-9	20569-20572	was	_	
119-10	20573-20578	found	_	
119-11	20579-20584	using	_	
119-12	20585-20588	the	_	
119-13	20589-20595	xjview	_	
119-14	20596-20604	software	_	
119-15	20605-20606	(	_	
119-16	20606-20610	http	_	
119-17	20610-20611	:	_	
119-18	20611-20612	/	_	
119-19	20612-20613	/	_	
119-20	20613-20631	www.alivelearn.net	_	
119-21	20631-20632	/	_	
119-22	20632-20638	xjview	_	
119-23	20638-20639	)	_	
119-24	20639-20640	.	_	

#Text=For visualization and display of significant activation, the z-maps were overlaid on the MNI template provided within SPM.
120-1	20641-20644	For	_	
120-2	20645-20658	visualization	_	
120-3	20659-20662	and	_	
120-4	20663-20670	display	_	
120-5	20671-20673	of	_	
120-6	20674-20685	significant	_	
120-7	20686-20696	activation	_	
120-8	20696-20697	,	_	
120-9	20698-20701	the	_	
120-10	20702-20708	z-maps	_	
120-11	20709-20713	were	_	
120-12	20714-20722	overlaid	_	
120-13	20723-20725	on	_	
120-14	20726-20729	the	_	
120-15	20730-20733	MNI	_	
120-16	20734-20742	template	_	
120-17	20743-20751	provided	_	
120-18	20752-20758	within	_	
120-19	20759-20762	SPM	_	
120-20	20762-20763	.	_	

#Text=All results were examined with the addition of framewise displacement (FD) as a covariate.
121-1	20764-20767	All	_	
121-2	20768-20775	results	_	
121-3	20776-20780	were	_	
121-4	20781-20789	examined	_	
121-5	20790-20794	with	_	
121-6	20795-20798	the	_	
121-7	20799-20807	addition	_	
121-8	20808-20810	of	_	
121-9	20811-20820	framewise	_	
121-10	20821-20833	displacement	_	
121-11	20834-20835	(	_	
121-12	20835-20837	FD	_	
121-13	20837-20838	)	_	
121-14	20839-20841	as	_	
121-15	20842-20843	a	_	
121-16	20844-20853	covariate	_	
121-17	20853-20854	.	_	

#Text=Mean FD values were very low for both samples (M = 0.21 for each sample), as subjects with substantive head movement had already been omitted from analyses prior to the calculation of FD for each subject.
122-1	20855-20859	Mean	_	
122-2	20860-20862	FD	_	
122-3	20863-20869	values	_	
122-4	20870-20874	were	_	
122-5	20875-20879	very	_	
122-6	20880-20883	low	_	
122-7	20884-20887	for	_	
122-8	20888-20892	both	_	
122-9	20893-20900	samples	_	
122-10	20901-20902	(	_	
122-11	20902-20903	M	_	
122-12	20904-20905	=	_	
122-13	20906-20910	0.21	_	
122-14	20911-20914	for	_	
122-15	20915-20919	each	_	
122-16	20920-20926	sample	_	
122-17	20926-20927	)	_	
122-18	20927-20928	,	_	
122-19	20929-20931	as	_	
122-20	20932-20940	subjects	_	
122-21	20941-20945	with	_	
122-22	20946-20957	substantive	_	
122-23	20958-20962	head	_	
122-24	20963-20971	movement	_	
122-25	20972-20975	had	_	
122-26	20976-20983	already	_	
122-27	20984-20988	been	_	
122-28	20989-20996	omitted	_	
122-29	20997-21001	from	_	
122-30	21002-21010	analyses	_	
122-31	21011-21016	prior	_	
122-32	21017-21019	to	_	
122-33	21020-21023	the	_	
122-34	21024-21035	calculation	_	
122-35	21036-21038	of	_	
122-36	21039-21041	FD	_	
122-37	21042-21045	for	_	
122-38	21046-21050	each	_	
122-39	21051-21058	subject	_	
122-40	21058-21059	.	_	

#Text=In all cases, results with FD as a covariate did not differ from results without the inclusion this covariate.
123-1	21060-21062	In	_	
123-2	21063-21066	all	_	
123-3	21067-21072	cases	_	
123-4	21072-21073	,	_	
123-5	21074-21081	results	_	
123-6	21082-21086	with	_	
123-7	21087-21089	FD	_	
123-8	21090-21092	as	_	
123-9	21093-21094	a	_	
123-10	21095-21104	covariate	_	
123-11	21105-21108	did	_	
123-12	21109-21112	not	_	
123-13	21113-21119	differ	_	
123-14	21120-21124	from	_	
123-15	21125-21132	results	_	
123-16	21133-21140	without	_	
123-17	21141-21144	the	_	
123-18	21145-21154	inclusion	_	
123-19	21155-21159	this	_	
123-20	21160-21169	covariate	_	
123-21	21169-21170	.	_	

#Text=Thus, we retain original results and tables/figures without the inclusion of FD.
#Text=2.7 Exploratory conjunction analysis
#Text=To test the potentially cross-substance congruence of this network response across different adolescent substances of abuse , we performed a conjunction analysis to see whether a de novo sample of youth with alcohol abuse showed the same activation in the PPI network as the sample of cannabis users.
124-1	21171-21175	Thus	_	
124-2	21175-21176	,	_	
124-3	21177-21179	we	_	
124-4	21180-21186	retain	_	
124-5	21187-21195	original	_	
124-6	21196-21203	results	_	
124-7	21204-21207	and	_	
124-8	21208-21214	tables	_	
124-9	21214-21215	/	_	
124-10	21215-21222	figures	_	
124-11	21223-21230	without	_	
124-12	21231-21234	the	_	
124-13	21235-21244	inclusion	_	
124-14	21245-21247	of	_	
124-15	21248-21250	FD	_	
124-16	21250-21251	.	_	
124-17	21252-21255	2.7	_	
124-18	21256-21267	Exploratory	_	
124-19	21268-21279	conjunction	_	
124-20	21280-21288	analysis	_	
124-21	21289-21291	To	_	
124-22	21292-21296	test	_	
124-23	21297-21300	the	_	
124-24	21301-21312	potentially	_	
124-25	21313-21328	cross-substance	_	
124-26	21329-21339	congruence	_	
124-27	21340-21342	of	_	
124-28	21343-21347	this	_	
124-29	21348-21355	network	_	
124-30	21356-21364	response	_	
124-31	21365-21371	across	_	
124-32	21372-21381	different	_	
124-33	21382-21392	adolescent	_	
124-34	21393-21403	substances	_	
124-35	21404-21406	of	_	
124-36	21407-21412	abuse	_	
124-37	21413-21414	,	_	
124-38	21415-21417	we	_	
124-39	21418-21427	performed	_	
124-40	21428-21429	a	_	
124-41	21430-21441	conjunction	_	
124-42	21442-21450	analysis	_	
124-43	21451-21453	to	_	
124-44	21454-21457	see	_	
124-45	21458-21465	whether	_	
124-46	21466-21467	a	_	
124-47	21468-21470	de	_	
124-48	21471-21475	novo	_	
124-49	21476-21482	sample	_	
124-50	21483-21485	of	_	
124-51	21486-21491	youth	_	
124-52	21492-21496	with	_	
124-53	21497-21504	alcohol	_	
124-54	21505-21510	abuse	_	
124-55	21511-21517	showed	_	
124-56	21518-21521	the	_	
124-57	21522-21526	same	_	
124-58	21527-21537	activation	_	
124-59	21538-21540	in	_	
124-60	21541-21544	the	_	
124-61	21545-21548	PPI	_	
124-62	21549-21556	network	_	
124-63	21557-21559	as	_	
124-64	21560-21563	the	_	
124-65	21564-21570	sample	_	
124-66	21571-21573	of	_	
124-67	21574-21582	cannabis	_	
124-68	21583-21588	users	_	
124-69	21588-21589	.	_	

#Text=To evaluate the overlap in neural regions of activation, we utilized the same OFC seed region for both groups, and compared PPI maps from this cluster for both groups (see Supplement Figure 6).
125-1	21590-21592	To	_	
125-2	21593-21601	evaluate	_	
125-3	21602-21605	the	_	
125-4	21606-21613	overlap	_	
125-5	21614-21616	in	_	
125-6	21617-21623	neural	_	
125-7	21624-21631	regions	_	
125-8	21632-21634	of	_	
125-9	21635-21645	activation	_	
125-10	21645-21646	,	_	
125-11	21647-21649	we	_	
125-12	21650-21658	utilized	_	
125-13	21659-21662	the	_	
125-14	21663-21667	same	_	
125-15	21668-21671	OFC	_	
125-16	21672-21676	seed	_	
125-17	21677-21683	region	_	
125-18	21684-21687	for	_	
125-19	21688-21692	both	_	
125-20	21693-21699	groups	_	
125-21	21699-21700	,	_	
125-22	21701-21704	and	_	
125-23	21705-21713	compared	_	
125-24	21714-21717	PPI	_	
125-25	21718-21722	maps	_	
125-26	21723-21727	from	_	
125-27	21728-21732	this	_	
125-28	21733-21740	cluster	_	
125-29	21741-21744	for	_	
125-30	21745-21749	both	_	
125-31	21750-21756	groups	_	
125-32	21757-21758	(	_	
125-33	21758-21761	see	_	
125-34	21762-21772	Supplement	_	
125-35	21773-21779	Figure	_	
125-36	21780-21781	6	_	
125-37	21781-21782	)	_	
125-38	21782-21783	.	_	

#Text=The conjunction analysis included a total of 45 subjects (30 adolescent cannabis users, 15 adolescent alcohol users).
126-1	21784-21787	The	_	
126-2	21788-21799	conjunction	_	
126-3	21800-21808	analysis	_	
126-4	21809-21817	included	_	
126-5	21818-21819	a	_	
126-6	21820-21825	total	_	
126-7	21826-21828	of	_	
126-8	21829-21831	45	_	
126-9	21832-21840	subjects	_	
126-10	21841-21842	(	_	
126-11	21842-21844	30	_	
126-12	21845-21855	adolescent	_	
126-13	21856-21864	cannabis	_	
126-14	21865-21870	users	_	
126-15	21870-21871	,	_	
126-16	21872-21874	15	_	
126-17	21875-21885	adolescent	_	
126-18	21886-21893	alcohol	_	
126-19	21894-21899	users	_	
126-20	21899-21900	)	_	
126-21	21900-21901	.	_	

#Text=Due to original study questions, both the cannabis study and the alcohol study included several variables that were not the focus of the current study and were subsequently modeled as nuisance regressors (e.g., cannabis study = cannabis cues, rating period; alcohol study = therapist statements).
127-1	21902-21905	Due	_	
127-2	21906-21908	to	_	
127-3	21909-21917	original	_	
127-4	21918-21923	study	_	
127-5	21924-21933	questions	_	
127-6	21933-21934	,	_	
127-7	21935-21939	both	_	
127-8	21940-21943	the	_	
127-9	21944-21952	cannabis	_	
127-10	21953-21958	study	_	
127-11	21959-21962	and	_	
127-12	21963-21966	the	_	
127-13	21967-21974	alcohol	_	
127-14	21975-21980	study	_	
127-15	21981-21989	included	_	
127-16	21990-21997	several	_	
127-17	21998-22007	variables	_	
127-18	22008-22012	that	_	
127-19	22013-22017	were	_	
127-20	22018-22021	not	_	
127-21	22022-22025	the	_	
127-22	22026-22031	focus	_	
127-23	22032-22034	of	_	
127-24	22035-22038	the	_	
127-25	22039-22046	current	_	
127-26	22047-22052	study	_	
127-27	22053-22056	and	_	
127-28	22057-22061	were	_	
127-29	22062-22074	subsequently	_	
127-30	22075-22082	modeled	_	
127-31	22083-22085	as	_	
127-32	22086-22094	nuisance	_	
127-33	22095-22105	regressors	_	
127-34	22106-22107	(	_	
127-35	22107-22110	e.g	_	
127-36	22110-22111	.	_	
127-37	22111-22112	,	_	
127-38	22113-22121	cannabis	_	
127-39	22122-22127	study	_	
127-40	22128-22129	=	_	
127-41	22130-22138	cannabis	_	
127-42	22139-22143	cues	_	
127-43	22143-22144	,	_	
127-44	22145-22151	rating	_	
127-45	22152-22158	period	_	
127-46	22158-22159	;	_	
127-47	22160-22167	alcohol	_	
127-48	22168-22173	study	_	
127-49	22174-22175	=	_	
127-50	22176-22185	therapist	_	
127-51	22186-22196	statements	_	
127-52	22196-22197	)	_	
127-53	22197-22198	.	_	

#Text=PPI analyses in the alcohol study paralleled the cannabis study in explicitly modeling change talk (vs. baseline) and sustain talk (vs. baseline) seeded on the functional mask within OFC and regressing out all other vectors.
128-1	22199-22202	PPI	_	
128-2	22203-22211	analyses	_	
128-3	22212-22214	in	_	
128-4	22215-22218	the	_	
128-5	22219-22226	alcohol	_	
128-6	22227-22232	study	_	
128-7	22233-22243	paralleled	_	
128-8	22244-22247	the	_	
128-9	22248-22256	cannabis	_	
128-10	22257-22262	study	_	
128-11	22263-22265	in	_	
128-12	22266-22276	explicitly	_	
128-13	22277-22285	modeling	_	
128-14	22286-22292	change	_	
128-15	22293-22297	talk	_	
128-16	22298-22299	(	_	
128-17	22299-22301	vs	_	
128-18	22301-22302	.	_	
128-19	22303-22311	baseline	_	
128-20	22311-22312	)	_	
128-21	22313-22316	and	_	
128-22	22317-22324	sustain	_	
128-23	22325-22329	talk	_	
128-24	22330-22331	(	_	
128-25	22331-22333	vs	_	
128-26	22333-22334	.	_	
128-27	22335-22343	baseline	_	
128-28	22343-22344	)	_	
128-29	22345-22351	seeded	_	
128-30	22352-22354	on	_	
128-31	22355-22358	the	_	
128-32	22359-22369	functional	_	
128-33	22370-22374	mask	_	
128-34	22375-22381	within	_	
128-35	22382-22385	OFC	_	
128-36	22386-22389	and	_	
128-37	22390-22400	regressing	_	
128-38	22401-22404	out	_	
128-39	22405-22408	all	_	
128-40	22409-22414	other	_	
128-41	22415-22422	vectors	_	
128-42	22422-22423	.	_	

#Text=The single subject PPI GLM now comprised the PPI vectors, the corresponding psychological vectors and physiological vector, each of which was convolved by the canonical HRF prior to GLM analysis.
129-1	22424-22427	The	_	
129-2	22428-22434	single	_	
129-3	22435-22442	subject	_	
129-4	22443-22446	PPI	_	
129-5	22447-22450	GLM	_	
129-6	22451-22454	now	_	
129-7	22455-22464	comprised	_	
129-8	22465-22468	the	_	
129-9	22469-22472	PPI	_	
129-10	22473-22480	vectors	_	
129-11	22480-22481	,	_	
129-12	22482-22485	the	_	
129-13	22486-22499	corresponding	_	
129-14	22500-22513	psychological	_	
129-15	22514-22521	vectors	_	
129-16	22522-22525	and	_	
129-17	22526-22539	physiological	_	
129-18	22540-22546	vector	_	
129-19	22546-22547	,	_	
129-20	22548-22552	each	_	
129-21	22553-22555	of	_	
129-22	22556-22561	which	_	
129-23	22562-22565	was	_	
129-24	22566-22575	convolved	_	
129-25	22576-22578	by	_	
129-26	22579-22582	the	_	
129-27	22583-22592	canonical	_	
129-28	22593-22596	HRF	_	
129-29	22597-22602	prior	_	
129-30	22603-22605	to	_	
129-31	22606-22609	GLM	_	
129-32	22610-22618	analysis	_	
129-33	22618-22619	.	_	

#Text=Here as well, all results were similar with the inclusion of FD values as covariates.
130-1	22620-22624	Here	_	
130-2	22625-22627	as	_	
130-3	22628-22632	well	_	
130-4	22632-22633	,	_	
130-5	22634-22637	all	_	
130-6	22638-22645	results	_	
130-7	22646-22650	were	_	
130-8	22651-22658	similar	_	
130-9	22659-22663	with	_	
130-10	22664-22667	the	_	
130-11	22668-22677	inclusion	_	
130-12	22678-22680	of	_	
130-13	22681-22683	FD	_	
130-14	22684-22690	values	_	
130-15	22691-22693	as	_	
130-16	22694-22704	covariates	_	
130-17	22704-22705	.	_	

#Text=We also included time derivatives of the HRF in the model to account for any variations in response across subjects.
131-1	22706-22708	We	_	
131-2	22709-22713	also	_	
131-3	22714-22722	included	_	
131-4	22723-22727	time	_	
131-5	22728-22739	derivatives	_	
131-6	22740-22742	of	_	
131-7	22743-22746	the	_	
131-8	22747-22750	HRF	_	
131-9	22751-22753	in	_	
131-10	22754-22757	the	_	
131-11	22758-22763	model	_	
131-12	22764-22766	to	_	
131-13	22767-22774	account	_	
131-14	22775-22778	for	_	
131-15	22779-22782	any	_	
131-16	22783-22793	variations	_	
131-17	22794-22796	in	_	
131-18	22797-22805	response	_	
131-19	22806-22812	across	_	
131-20	22813-22821	subjects	_	
131-21	22821-22822	.	_	

#Text=Motion parameters along with averaged WM and CSF signals were also included in the model as regressors of no interest to improve model fit.
132-1	22823-22829	Motion	_	
132-2	22830-22840	parameters	_	
132-3	22841-22846	along	_	
132-4	22847-22851	with	_	
132-5	22852-22860	averaged	_	
132-6	22861-22863	WM	_	
132-7	22864-22867	and	_	
132-8	22868-22871	CSF	_	
132-9	22872-22879	signals	_	
132-10	22880-22884	were	_	
132-11	22885-22889	also	_	
132-12	22890-22898	included	_	
132-13	22899-22901	in	_	
132-14	22902-22905	the	_	
132-15	22906-22911	model	_	
132-16	22912-22914	as	_	
132-17	22915-22925	regressors	_	
132-18	22926-22928	of	_	
132-19	22929-22931	no	_	
132-20	22932-22940	interest	_	
132-21	22941-22943	to	_	
132-22	22944-22951	improve	_	
132-23	22952-22957	model	_	
132-24	22958-22961	fit	_	
132-25	22961-22962	.	_	

#Text=This approach is in line with recommendations by Power et al.
133-1	22963-22967	This	_	
133-2	22968-22976	approach	_	
133-3	22977-22979	is	_	
133-4	22980-22982	in	_	
133-5	22983-22987	line	_	
133-6	22988-22992	with	_	
133-7	22993-23008	recommendations	_	
133-8	23009-23011	by	_	
133-9	23012-23017	Power	_	
133-10	23018-23020	et	_	
133-11	23021-23023	al	_	
133-12	23023-23024	.	_	

#Text=that caution against decoupling covariates that may be related to the anticipated variables of interest.
134-1	23026-23030	that	_	
134-2	23031-23038	caution	_	
134-3	23039-23046	against	_	
134-4	23047-23057	decoupling	_	
134-5	23058-23068	covariates	_	
134-6	23069-23073	that	_	
134-7	23074-23077	may	_	
134-8	23078-23080	be	_	
134-9	23081-23088	related	_	
134-10	23089-23091	to	_	
134-11	23092-23095	the	_	
134-12	23096-23107	anticipated	_	
134-13	23108-23117	variables	_	
134-14	23118-23120	of	_	
134-15	23121-23129	interest	_	
134-16	23129-23130	.	_	

#Text=This is an especially important consideration in young, clinical populations where motion tends to be high.
135-1	23131-23135	This	_	
135-2	23136-23138	is	_	
135-3	23139-23141	an	_	
135-4	23142-23152	especially	_	
135-5	23153-23162	important	_	
135-6	23163-23176	consideration	_	
135-7	23177-23179	in	_	
135-8	23180-23185	young	_	
135-9	23185-23186	,	_	
135-10	23187-23195	clinical	_	
135-11	23196-23207	populations	_	
135-12	23208-23213	where	_	
135-13	23214-23220	motion	_	
135-14	23221-23226	tends	_	
135-15	23227-23229	to	_	
135-16	23230-23232	be	_	
135-17	23233-23237	high	_	
135-18	23237-23238	.	_	

#Text=The connectivity maps from both groups of cannabis and alcohol users were entered into a random effects ANOVA model to look at the degree of conjunction, or overlapping regions of consistent connectivity increases or decreases, with the OFC for both substance abuse populations.
136-1	23239-23242	The	_	
136-2	23243-23255	connectivity	_	
136-3	23256-23260	maps	_	
136-4	23261-23265	from	_	
136-5	23266-23270	both	_	
136-6	23271-23277	groups	_	
136-7	23278-23280	of	_	
136-8	23281-23289	cannabis	_	
136-9	23290-23293	and	_	
136-10	23294-23301	alcohol	_	
136-11	23302-23307	users	_	
136-12	23308-23312	were	_	
136-13	23313-23320	entered	_	
136-14	23321-23325	into	_	
136-15	23326-23327	a	_	
136-16	23328-23334	random	_	
136-17	23335-23342	effects	_	
136-18	23343-23348	ANOVA	_	
136-19	23349-23354	model	_	
136-20	23355-23357	to	_	
136-21	23358-23362	look	_	
136-22	23363-23365	at	_	
136-23	23366-23369	the	_	
136-24	23370-23376	degree	_	
136-25	23377-23379	of	_	
136-26	23380-23391	conjunction	_	
136-27	23391-23392	,	_	
136-28	23393-23395	or	_	
136-29	23396-23407	overlapping	_	
136-30	23408-23415	regions	_	
136-31	23416-23418	of	_	
136-32	23419-23429	consistent	_	
136-33	23430-23442	connectivity	_	
136-34	23443-23452	increases	_	
136-35	23453-23455	or	_	
136-36	23456-23465	decreases	_	
136-37	23465-23466	,	_	
136-38	23467-23471	with	_	
136-39	23472-23475	the	_	
136-40	23476-23479	OFC	_	
136-41	23480-23483	for	_	
136-42	23484-23488	both	_	
136-43	23489-23498	substance	_	
136-44	23499-23504	abuse	_	
136-45	23505-23516	populations	_	
136-46	23516-23517	.	_	

#Text=As described above, analyses were restricted within a mask consisting of cortical and subcortical grey matter.
137-1	23518-23520	As	_	
137-2	23521-23530	described	_	
137-3	23531-23536	above	_	
137-4	23536-23537	,	_	
137-5	23538-23546	analyses	_	
137-6	23547-23551	were	_	
137-7	23552-23562	restricted	_	
137-8	23563-23569	within	_	
137-9	23570-23571	a	_	
137-10	23572-23576	mask	_	
137-11	23577-23587	consisting	_	
137-12	23588-23590	of	_	
137-13	23591-23599	cortical	_	
137-14	23600-23603	and	_	
137-15	23604-23615	subcortical	_	
137-16	23616-23620	grey	_	
137-17	23621-23627	matter	_	
137-18	23627-23628	.	_	

#Text=Significant activations were identified within the mask using SPM’s voxel-based FDR corrected p<0.05, k>50 voxels.
138-1	23629-23640	Significant	_	
138-2	23641-23652	activations	_	
138-3	23653-23657	were	_	
138-4	23658-23668	identified	_	
138-5	23669-23675	within	_	
138-6	23676-23679	the	_	
138-7	23680-23684	mask	_	
138-8	23685-23690	using	_	
138-9	23691-23694	SPM	_	
138-10	23694-23695	’	_	
138-11	23695-23696	s	_	
138-12	23697-23708	voxel-based	_	
138-13	23709-23712	FDR	_	
138-14	23713-23722	corrected	_	
138-15	23723-23724	p	_	
138-16	23724-23725	<	_	
138-17	23725-23729	0.05	_	
138-18	23729-23730	,	_	
138-19	23731-23732	k	_	
138-20	23732-23733	>	_	
138-21	23733-23735	50	_	
138-22	23736-23742	voxels	_	
138-23	23742-23743	.	_	

#Text=Results
#Text=3.1 Treatment Response
#Text=As observed in Table 1, both groups of adolescents reported heavy use at baseline, as supported by their weekly cannabis use and/or binge drinking.
139-1	23744-23751	Results	_	
139-2	23752-23755	3.1	_	
139-3	23756-23765	Treatment	_	
139-4	23766-23774	Response	_	
139-5	23775-23777	As	_	
139-6	23778-23786	observed	_	
139-7	23787-23789	in	_	
139-8	23790-23795	Table	_	
139-9	23796-23797	1	_	
139-10	23797-23798	,	_	
139-11	23799-23803	both	_	
139-12	23804-23810	groups	_	
139-13	23811-23813	of	_	
139-14	23814-23825	adolescents	_	
139-15	23826-23834	reported	_	
139-16	23835-23840	heavy	_	
139-17	23841-23844	use	_	
139-18	23845-23847	at	_	
139-19	23848-23856	baseline	_	
139-20	23856-23857	,	_	
139-21	23858-23860	as	_	
139-22	23861-23870	supported	_	
139-23	23871-23873	by	_	
139-24	23874-23879	their	_	
139-25	23880-23886	weekly	_	
139-26	23887-23895	cannabis	_	
139-27	23896-23899	use	_	
139-28	23900-23903	and	_	
139-29	23903-23904	/	_	
139-30	23904-23906	or	_	
139-31	23907-23912	binge	_	
139-32	23913-23921	drinking	_	
139-33	23921-23922	.	_	

#Text=Across both studies, we had excellent retention at 1-month follow-up (97.67% for cannabis sample; 82% for alcohol sample).
140-1	23923-23929	Across	_	
140-2	23930-23934	both	_	
140-3	23935-23942	studies	_	
140-4	23942-23943	,	_	
140-5	23944-23946	we	_	
140-6	23947-23950	had	_	
140-7	23951-23960	excellent	_	
140-8	23961-23970	retention	_	
140-9	23971-23973	at	_	
140-10	23974-23975	1	_	
140-11	23975-23976	-	_	
140-12	23976-23981	month	_	
140-13	23982-23991	follow-up	_	
140-14	23992-23993	(	_	
140-15	23993-23999	97.67%	_	
140-16	24000-24003	for	_	
140-17	24004-24012	cannabis	_	
140-18	24013-24019	sample	_	
140-19	24019-24020	;	_	
140-20	24021-24024	82%	_	
140-21	24025-24028	for	_	
140-22	24029-24036	alcohol	_	
140-23	24037-24043	sample	_	
140-24	24043-24044	)	_	
140-25	24044-24045	.	_	

#Text=Consistent with similar studies that have highlighted the challenges in retaining substance using youth , missing youth were unreachable despite repeated staff efforts.
141-1	24046-24056	Consistent	_	
141-2	24057-24061	with	_	
141-3	24062-24069	similar	_	
141-4	24070-24077	studies	_	
141-5	24078-24082	that	_	
141-6	24083-24087	have	_	
141-7	24088-24099	highlighted	_	
141-8	24100-24103	the	_	
141-9	24104-24114	challenges	_	
141-10	24115-24117	in	_	
141-11	24118-24127	retaining	_	
141-12	24128-24137	substance	_	
141-13	24138-24143	using	_	
141-14	24144-24149	youth	_	
141-15	24150-24151	,	_	
141-16	24152-24159	missing	_	
141-17	24160-24165	youth	_	
141-18	24166-24170	were	_	
141-19	24171-24182	unreachable	_	
141-20	24183-24190	despite	_	
141-21	24191-24199	repeated	_	
141-22	24200-24205	staff	_	
141-23	24206-24213	efforts	_	
141-24	24213-24214	.	_	

#Text=Importantly, adolescents in both samples evidenced clinically-significant behavior change for their target substance of abuse from baseline to follow-up, as measured by statistically significant reductions in frequency of use (substance use days for only the target substance of abuse) and a halving of substance-related problems (p’s<.001; see Table 1).
142-1	24215-24226	Importantly	_	
142-2	24226-24227	,	_	
142-3	24228-24239	adolescents	_	
142-4	24240-24242	in	_	
142-5	24243-24247	both	_	
142-6	24248-24255	samples	_	
142-7	24256-24265	evidenced	_	
142-8	24266-24288	clinically-significant	_	
142-9	24289-24297	behavior	_	
142-10	24298-24304	change	_	
142-11	24305-24308	for	_	
142-12	24309-24314	their	_	
142-13	24315-24321	target	_	
142-14	24322-24331	substance	_	
142-15	24332-24334	of	_	
142-16	24335-24340	abuse	_	
142-17	24341-24345	from	_	
142-18	24346-24354	baseline	_	
142-19	24355-24357	to	_	
142-20	24358-24367	follow-up	_	
142-21	24367-24368	,	_	
142-22	24369-24371	as	_	
142-23	24372-24380	measured	_	
142-24	24381-24383	by	_	
142-25	24384-24397	statistically	_	
142-26	24398-24409	significant	_	
142-27	24410-24420	reductions	_	
142-28	24421-24423	in	_	
142-29	24424-24433	frequency	_	
142-30	24434-24436	of	_	
142-31	24437-24440	use	_	
142-32	24441-24442	(	_	
142-33	24442-24451	substance	_	
142-34	24452-24455	use	_	
142-35	24456-24460	days	_	
142-36	24461-24464	for	_	
142-37	24465-24469	only	_	
142-38	24470-24473	the	_	
142-39	24474-24480	target	_	
142-40	24481-24490	substance	_	
142-41	24491-24493	of	_	
142-42	24494-24499	abuse	_	
142-43	24499-24500	)	_	
142-44	24501-24504	and	_	
142-45	24505-24506	a	_	
142-46	24507-24514	halving	_	
142-47	24515-24517	of	_	
142-48	24518-24535	substance-related	_	
142-49	24536-24544	problems	_	
142-50	24545-24546	(	_	
142-51	24546-24547	p	_	
142-52	24547-24548	’	_	
142-53	24548-24549	s	_	
142-54	24549-24550	<	_	
142-55	24550-24554	.001	_	
142-56	24554-24555	;	_	
142-57	24556-24559	see	_	
142-58	24560-24565	Table	_	
142-59	24566-24567	1	_	
142-60	24567-24568	)	_	
142-61	24568-24569	.	_	

#Text=Notably, the non-target substances of abuse did not show clinically or statistically significant change from pre-to-post treatment in these studies (e.g., alcohol use did not decrease in the cannabis study; cannabis use did not decrease in the alcohol study), indicating the specificity of the treatment effects to the target substance.
#Text=3.2 Functional connectivity and treatment mechanisms: PPI results
#Text=In line with recent neurodevelopmental studies in the field of adolescent cannabis use and connectivity , all adolescents in this sample had movement within standard neurodevelopmental limits (<2 mm translation and <2 degrees rotation).
143-1	24570-24577	Notably	_	
143-2	24577-24578	,	_	
143-3	24579-24582	the	_	
143-4	24583-24593	non-target	_	
143-5	24594-24604	substances	_	
143-6	24605-24607	of	_	
143-7	24608-24613	abuse	_	
143-8	24614-24617	did	_	
143-9	24618-24621	not	_	
143-10	24622-24626	show	_	
143-11	24627-24637	clinically	_	
143-12	24638-24640	or	_	
143-13	24641-24654	statistically	_	
143-14	24655-24666	significant	_	
143-15	24667-24673	change	_	
143-16	24674-24678	from	_	
143-17	24679-24690	pre-to-post	_	
143-18	24691-24700	treatment	_	
143-19	24701-24703	in	_	
143-20	24704-24709	these	_	
143-21	24710-24717	studies	_	
143-22	24718-24719	(	_	
143-23	24719-24722	e.g	_	
143-24	24722-24723	.	_	
143-25	24723-24724	,	_	
143-26	24725-24732	alcohol	_	
143-27	24733-24736	use	_	
143-28	24737-24740	did	_	
143-29	24741-24744	not	_	
143-30	24745-24753	decrease	_	
143-31	24754-24756	in	_	
143-32	24757-24760	the	_	
143-33	24761-24769	cannabis	_	
143-34	24770-24775	study	_	
143-35	24775-24776	;	_	
143-36	24777-24785	cannabis	_	
143-37	24786-24789	use	_	
143-38	24790-24793	did	_	
143-39	24794-24797	not	_	
143-40	24798-24806	decrease	_	
143-41	24807-24809	in	_	
143-42	24810-24813	the	_	
143-43	24814-24821	alcohol	_	
143-44	24822-24827	study	_	
143-45	24827-24828	)	_	
143-46	24828-24829	,	_	
143-47	24830-24840	indicating	_	
143-48	24841-24844	the	_	
143-49	24845-24856	specificity	_	
143-50	24857-24859	of	_	
143-51	24860-24863	the	_	
143-52	24864-24873	treatment	_	
143-53	24874-24881	effects	_	
143-54	24882-24884	to	_	
143-55	24885-24888	the	_	
143-56	24889-24895	target	_	
143-57	24896-24905	substance	_	
143-58	24905-24906	.	_	
143-59	24907-24910	3.2	_	
143-60	24911-24921	Functional	_	
143-61	24922-24934	connectivity	_	
143-62	24935-24938	and	_	
143-63	24939-24948	treatment	_	
143-64	24949-24959	mechanisms	_	
143-65	24959-24960	:	_	
143-66	24961-24964	PPI	_	
143-67	24965-24972	results	_	
143-68	24973-24975	In	_	
143-69	24976-24980	line	_	
143-70	24981-24985	with	_	
143-71	24986-24992	recent	_	
143-72	24993-25011	neurodevelopmental	_	
143-73	25012-25019	studies	_	
143-74	25020-25022	in	_	
143-75	25023-25026	the	_	
143-76	25027-25032	field	_	
143-77	25033-25035	of	_	
143-78	25036-25046	adolescent	_	
143-79	25047-25055	cannabis	_	
143-80	25056-25059	use	_	
143-81	25060-25063	and	_	
143-82	25064-25076	connectivity	_	
143-83	25077-25078	,	_	
143-84	25079-25082	all	_	
143-85	25083-25094	adolescents	_	
143-86	25095-25097	in	_	
143-87	25098-25102	this	_	
143-88	25103-25109	sample	_	
143-89	25110-25113	had	_	
143-90	25114-25122	movement	_	
143-91	25123-25129	within	_	
143-92	25130-25138	standard	_	
143-93	25139-25157	neurodevelopmental	_	
143-94	25158-25164	limits	_	
143-95	25165-25166	(	_	
143-96	25166-25167	<	_	
143-97	25167-25168	2	_	
143-98	25169-25171	mm	_	
143-99	25172-25183	translation	_	
143-100	25184-25187	and	_	
143-101	25188-25189	<	_	
143-102	25189-25190	2	_	
143-103	25191-25198	degrees	_	
143-104	25199-25207	rotation	_	
143-105	25207-25208	)	_	
143-106	25208-25209	.	_	

#Text=Additionally, motion parameters were included as nuisance regressors in the GLM for both activation and PPI analysis.
144-1	25210-25222	Additionally	_	
144-2	25222-25223	,	_	
144-3	25224-25230	motion	_	
144-4	25231-25241	parameters	_	
144-5	25242-25246	were	_	
144-6	25247-25255	included	_	
144-7	25256-25258	as	_	
144-8	25259-25267	nuisance	_	
144-9	25268-25278	regressors	_	
144-10	25279-25281	in	_	
144-11	25282-25285	the	_	
144-12	25286-25289	GLM	_	
144-13	25290-25293	for	_	
144-14	25294-25298	both	_	
144-15	25299-25309	activation	_	
144-16	25310-25313	and	_	
144-17	25314-25317	PPI	_	
144-18	25318-25326	analysis	_	
144-19	25326-25327	.	_	

#Text=The averaged WM and CSF signal were included as nuisance regressors in the GLM.
145-1	25328-25331	The	_	
145-2	25332-25340	averaged	_	
145-3	25341-25343	WM	_	
145-4	25344-25347	and	_	
145-5	25348-25351	CSF	_	
145-6	25352-25358	signal	_	
145-7	25359-25363	were	_	
145-8	25364-25372	included	_	
145-9	25373-25375	as	_	
145-10	25376-25384	nuisance	_	
145-11	25385-25395	regressors	_	
145-12	25396-25398	in	_	
145-13	25399-25402	the	_	
145-14	25403-25406	GLM	_	
145-15	25406-25407	.	_	

#Text=For this analysis, we examined OFC network connectivity as a mechanism of behavior change.
146-1	25408-25411	For	_	
146-2	25412-25416	this	_	
146-3	25417-25425	analysis	_	
146-4	25425-25426	,	_	
146-5	25427-25429	we	_	
146-6	25430-25438	examined	_	
146-7	25439-25442	OFC	_	
146-8	25443-25450	network	_	
146-9	25451-25463	connectivity	_	
146-10	25464-25466	as	_	
146-11	25467-25468	a	_	
146-12	25469-25478	mechanism	_	
146-13	25479-25481	of	_	
146-14	25482-25490	behavior	_	
146-15	25491-25497	change	_	
146-16	25497-25498	.	_	

#Text=When examining functional connectivity during change talk vs. baseline, we observed significant increases in functional connectivity between the OFC seed and areas including the IFG, precentral gyrus, anterior and posterior cingulate gyrus, SMA, superior frontal gyrus, pallidus, caudate, and parahippocampal gyrus.
147-1	25499-25503	When	_	
147-2	25504-25513	examining	_	
147-3	25514-25524	functional	_	
147-4	25525-25537	connectivity	_	
147-5	25538-25544	during	_	
147-6	25545-25551	change	_	
147-7	25552-25556	talk	_	
147-8	25557-25559	vs	_	
147-9	25559-25560	.	_	
147-10	25561-25569	baseline	_	
147-11	25569-25570	,	_	
147-12	25571-25573	we	_	
147-13	25574-25582	observed	_	
147-14	25583-25594	significant	_	
147-15	25595-25604	increases	_	
147-16	25605-25607	in	_	
147-17	25608-25618	functional	_	
147-18	25619-25631	connectivity	_	
147-19	25632-25639	between	_	
147-20	25640-25643	the	_	
147-21	25644-25647	OFC	_	
147-22	25648-25652	seed	_	
147-23	25653-25656	and	_	
147-24	25657-25662	areas	_	
147-25	25663-25672	including	_	
147-26	25673-25676	the	_	
147-27	25677-25680	IFG	_	
147-28	25680-25681	,	_	
147-29	25682-25692	precentral	_	
147-30	25693-25698	gyrus	_	
147-31	25698-25699	,	_	
147-32	25700-25708	anterior	_	
147-33	25709-25712	and	_	
147-34	25713-25722	posterior	_	
147-35	25723-25732	cingulate	_	
147-36	25733-25738	gyrus	_	
147-37	25738-25739	,	_	
147-38	25740-25743	SMA	_	
147-39	25743-25744	,	_	
147-40	25745-25753	superior	_	
147-41	25754-25761	frontal	_	
147-42	25762-25767	gyrus	_	
147-43	25767-25768	,	_	
147-44	25769-25777	pallidus	_	
147-45	25777-25778	,	_	
147-46	25779-25786	caudate	_	
147-47	25786-25787	,	_	
147-48	25788-25791	and	_	
147-49	25792-25807	parahippocampal	_	
147-50	25808-25813	gyrus	_	
147-51	25813-25814	.	_	

#Text=We also observed significant decreases in functional connectivity between the OFC seed and several areas including the precuneus, superior/middle frontal gyrus, parahippocampal gyrus, thalamus, inferior parietal lobule, cingulate gyrus.
148-1	25815-25817	We	_	
148-2	25818-25822	also	_	
148-3	25823-25831	observed	_	
148-4	25832-25843	significant	_	
148-5	25844-25853	decreases	_	
148-6	25854-25856	in	_	
148-7	25857-25867	functional	_	
148-8	25868-25880	connectivity	_	
148-9	25881-25888	between	_	
148-10	25889-25892	the	_	
148-11	25893-25896	OFC	_	
148-12	25897-25901	seed	_	
148-13	25902-25905	and	_	
148-14	25906-25913	several	_	
148-15	25914-25919	areas	_	
148-16	25920-25929	including	_	
148-17	25930-25933	the	_	
148-18	25934-25943	precuneus	_	
148-19	25943-25944	,	_	
148-20	25945-25953	superior	_	
148-21	25953-25954	/	_	
148-22	25954-25960	middle	_	
148-23	25961-25968	frontal	_	
148-24	25969-25974	gyrus	_	
148-25	25974-25975	,	_	
148-26	25976-25991	parahippocampal	_	
148-27	25992-25997	gyrus	_	
148-28	25997-25998	,	_	
148-29	25999-26007	thalamus	_	
148-30	26007-26008	,	_	
148-31	26009-26017	inferior	_	
148-32	26018-26026	parietal	_	
148-33	26027-26033	lobule	_	
148-34	26033-26034	,	_	
148-35	26035-26044	cingulate	_	
148-36	26045-26050	gyrus	_	
148-37	26050-26051	.	_	

#Text=All analyses were FDR corrected p<0.05, k>50.
149-1	26052-26055	All	_	
149-2	26056-26064	analyses	_	
149-3	26065-26069	were	_	
149-4	26070-26073	FDR	_	
149-5	26074-26083	corrected	_	
149-6	26084-26085	p	_	
149-7	26085-26086	<	_	
149-8	26086-26090	0.05	_	
149-9	26090-26091	,	_	
149-10	26092-26093	k	_	
149-11	26093-26094	>	_	
149-12	26094-26096	50	_	
149-13	26096-26097	.	_	

#Text=(Table 2a and 2b; Figure 2).
#Text=3.3 Functional connectivity and treatment response
#Text=To examine how functional connectivity may serve as a mechanism of adolescent behavior change, we examined the correlation between OFC connectivity and post-treatment cannabis problems.
150-1	26098-26099	(	_	
150-2	26099-26104	Table	_	
150-3	26105-26107	2a	_	
150-4	26108-26111	and	_	
150-5	26112-26114	2b	_	
150-6	26114-26115	;	_	
150-7	26116-26122	Figure	_	
150-8	26123-26124	2	_	
150-9	26124-26125	)	_	
150-10	26125-26126	.	_	
150-11	26127-26130	3.3	_	
150-12	26131-26141	Functional	_	
150-13	26142-26154	connectivity	_	
150-14	26155-26158	and	_	
150-15	26159-26168	treatment	_	
150-16	26169-26177	response	_	
150-17	26178-26180	To	_	
150-18	26181-26188	examine	_	
150-19	26189-26192	how	_	
150-20	26193-26203	functional	_	
150-21	26204-26216	connectivity	_	
150-22	26217-26220	may	_	
150-23	26221-26226	serve	_	
150-24	26227-26229	as	_	
150-25	26230-26231	a	_	
150-26	26232-26241	mechanism	_	
150-27	26242-26244	of	_	
150-28	26245-26255	adolescent	_	
150-29	26256-26264	behavior	_	
150-30	26265-26271	change	_	
150-31	26271-26272	,	_	
150-32	26273-26275	we	_	
150-33	26276-26284	examined	_	
150-34	26285-26288	the	_	
150-35	26289-26300	correlation	_	
150-36	26301-26308	between	_	
150-37	26309-26312	OFC	_	
150-38	26313-26325	connectivity	_	
150-39	26326-26329	and	_	
150-40	26330-26344	post-treatment	_	
150-41	26345-26353	cannabis	_	
150-42	26354-26362	problems	_	
150-43	26362-26363	.	_	

#Text=We found a significant positive correlation, such that greater connectivity between the OFC and anterior cingulate/medial frontal gyrus was associated with more post-treatment cannabis problems (FDR corrected p<0.05, k>50).
151-1	26364-26366	We	_	
151-2	26367-26372	found	_	
151-3	26373-26374	a	_	
151-4	26375-26386	significant	_	
151-5	26387-26395	positive	_	
151-6	26396-26407	correlation	_	
151-7	26407-26408	,	_	
151-8	26409-26413	such	_	
151-9	26414-26418	that	_	
151-10	26419-26426	greater	_	
151-11	26427-26439	connectivity	_	
151-12	26440-26447	between	_	
151-13	26448-26451	the	_	
151-14	26452-26455	OFC	_	
151-15	26456-26459	and	_	
151-16	26460-26468	anterior	_	
151-17	26469-26478	cingulate	_	
151-18	26478-26479	/	_	
151-19	26479-26485	medial	_	
151-20	26486-26493	frontal	_	
151-21	26494-26499	gyrus	_	
151-22	26500-26503	was	_	
151-23	26504-26514	associated	_	
151-24	26515-26519	with	_	
151-25	26520-26524	more	_	
151-26	26525-26539	post-treatment	_	
151-27	26540-26548	cannabis	_	
151-28	26549-26557	problems	_	
151-29	26558-26559	(	_	
151-30	26559-26562	FDR	_	
151-31	26563-26572	corrected	_	
151-32	26573-26574	p	_	
151-33	26574-26575	<	_	
151-34	26575-26579	0.05	_	
151-35	26579-26580	,	_	
151-36	26581-26582	k	_	
151-37	26582-26583	>	_	
151-38	26583-26585	50	_	
151-39	26585-26586	)	_	
151-40	26586-26587	.	_	

#Text=There were no negative correlations, or correlations with the regions of decreased connectivity (Table 2c; Figure 3).
#Text=3.4 Exploratory conjunction analysis between adolescent cannabis and alcohol users
#Text=We also explored how congruent these networks were across youth receiving treatment targeting two different substances of abuse: cannabis vs. alcohol.
152-1	26588-26593	There	_	
152-2	26594-26598	were	_	
152-3	26599-26601	no	_	
152-4	26602-26610	negative	_	
152-5	26611-26623	correlations	_	
152-6	26623-26624	,	_	
152-7	26625-26627	or	_	
152-8	26628-26640	correlations	_	
152-9	26641-26645	with	_	
152-10	26646-26649	the	_	
152-11	26650-26657	regions	_	
152-12	26658-26660	of	_	
152-13	26661-26670	decreased	_	
152-14	26671-26683	connectivity	_	
152-15	26684-26685	(	_	
152-16	26685-26690	Table	_	
152-17	26691-26693	2c	_	
152-18	26693-26694	;	_	
152-19	26695-26701	Figure	_	
152-20	26702-26703	3	_	
152-21	26703-26704	)	_	
152-22	26704-26705	.	_	
152-23	26706-26709	3.4	_	
152-24	26710-26721	Exploratory	_	
152-25	26722-26733	conjunction	_	
152-26	26734-26742	analysis	_	
152-27	26743-26750	between	_	
152-28	26751-26761	adolescent	_	
152-29	26762-26770	cannabis	_	
152-30	26771-26774	and	_	
152-31	26775-26782	alcohol	_	
152-32	26783-26788	users	_	
152-33	26789-26791	We	_	
152-34	26792-26796	also	_	
152-35	26797-26805	explored	_	
152-36	26806-26809	how	_	
152-37	26810-26819	congruent	_	
152-38	26820-26825	these	_	
152-39	26826-26834	networks	_	
152-40	26835-26839	were	_	
152-41	26840-26846	across	_	
152-42	26847-26852	youth	_	
152-43	26853-26862	receiving	_	
152-44	26863-26872	treatment	_	
152-45	26873-26882	targeting	_	
152-46	26883-26886	two	_	
152-47	26887-26896	different	_	
152-48	26897-26907	substances	_	
152-49	26908-26910	of	_	
152-50	26911-26916	abuse	_	
152-51	26916-26917	:	_	
152-52	26918-26926	cannabis	_	
152-53	26927-26929	vs	_	
152-54	26929-26930	.	_	
152-55	26931-26938	alcohol	_	
152-56	26938-26939	.	_	

#Text=Networks of functional connectivity were specific to the target substance of abuse discussed during the treatment sessions (cannabis for the cannabis sample; alcohol for the alcohol sample).
153-1	26940-26948	Networks	_	
153-2	26949-26951	of	_	
153-3	26952-26962	functional	_	
153-4	26963-26975	connectivity	_	
153-5	26976-26980	were	_	
153-6	26981-26989	specific	_	
153-7	26990-26992	to	_	
153-8	26993-26996	the	_	
153-9	26997-27003	target	_	
153-10	27004-27013	substance	_	
153-11	27014-27016	of	_	
153-12	27017-27022	abuse	_	
153-13	27023-27032	discussed	_	
153-14	27033-27039	during	_	
153-15	27040-27043	the	_	
153-16	27044-27053	treatment	_	
153-17	27054-27062	sessions	_	
153-18	27063-27064	(	_	
153-19	27064-27072	cannabis	_	
153-20	27073-27076	for	_	
153-21	27077-27080	the	_	
153-22	27081-27089	cannabis	_	
153-23	27090-27096	sample	_	
153-24	27096-27097	;	_	
153-25	27098-27105	alcohol	_	
153-26	27106-27109	for	_	
153-27	27110-27113	the	_	
153-28	27114-27121	alcohol	_	
153-29	27122-27128	sample	_	
153-30	27128-27129	)	_	
153-31	27129-27130	.	_	

#Text=For substance-specific conversations about changing the target substance of abuse (e.g., change talk), we observed no areas of overlapping connectivity increases or decreases at the chosen threshold (FDR corrected p<0.05; k>50).
#Text=3.5 Post hoc examination of the sustain talk condition
#Text=Post hoc analyses of the sustain talk condition are detailed in the Supplement.
154-1	27131-27134	For	_	
154-2	27135-27153	substance-specific	_	
154-3	27154-27167	conversations	_	
154-4	27168-27173	about	_	
154-5	27174-27182	changing	_	
154-6	27183-27186	the	_	
154-7	27187-27193	target	_	
154-8	27194-27203	substance	_	
154-9	27204-27206	of	_	
154-10	27207-27212	abuse	_	
154-11	27213-27214	(	_	
154-12	27214-27217	e.g	_	
154-13	27217-27218	.	_	
154-14	27218-27219	,	_	
154-15	27220-27226	change	_	
154-16	27227-27231	talk	_	
154-17	27231-27232	)	_	
154-18	27232-27233	,	_	
154-19	27234-27236	we	_	
154-20	27237-27245	observed	_	
154-21	27246-27248	no	_	
154-22	27249-27254	areas	_	
154-23	27255-27257	of	_	
154-24	27258-27269	overlapping	_	
154-25	27270-27282	connectivity	_	
154-26	27283-27292	increases	_	
154-27	27293-27295	or	_	
154-28	27296-27305	decreases	_	
154-29	27306-27308	at	_	
154-30	27309-27312	the	_	
154-31	27313-27319	chosen	_	
154-32	27320-27329	threshold	_	
154-33	27330-27331	(	_	
154-34	27331-27334	FDR	_	
154-35	27335-27344	corrected	_	
154-36	27345-27346	p	_	
154-37	27346-27347	<	_	
154-38	27347-27351	0.05	_	
154-39	27351-27352	;	_	
154-40	27353-27354	k	_	
154-41	27354-27355	>	_	
154-42	27355-27357	50	_	
154-43	27357-27358	)	_	
154-44	27358-27359	.	_	
154-45	27360-27363	3.5	_	
154-46	27364-27368	Post	_	
154-47	27369-27372	hoc	_	
154-48	27373-27384	examination	_	
154-49	27385-27387	of	_	
154-50	27388-27391	the	_	
154-51	27392-27399	sustain	_	
154-52	27400-27404	talk	_	
154-53	27405-27414	condition	_	
154-54	27415-27419	Post	_	
154-55	27420-27423	hoc	_	
154-56	27424-27432	analyses	_	
154-57	27433-27435	of	_	
154-58	27436-27439	the	_	
154-59	27440-27447	sustain	_	
154-60	27448-27452	talk	_	
154-61	27453-27462	condition	_	
154-62	27463-27466	are	_	
154-63	27467-27475	detailed	_	
154-64	27476-27478	in	_	
154-65	27479-27482	the	_	
154-66	27483-27493	Supplement	_	
154-67	27493-27494	.	_	

#Text=We examined the contrast between change talk and sustain talk for the PPI analysis; no significant regions emerged at our pre-determined level of statistical correction.
155-1	27495-27497	We	_	
155-2	27498-27506	examined	_	
155-3	27507-27510	the	_	
155-4	27511-27519	contrast	_	
155-5	27520-27527	between	_	
155-6	27528-27534	change	_	
155-7	27535-27539	talk	_	
155-8	27540-27543	and	_	
155-9	27544-27551	sustain	_	
155-10	27552-27556	talk	_	
155-11	27557-27560	for	_	
155-12	27561-27564	the	_	
155-13	27565-27568	PPI	_	
155-14	27569-27577	analysis	_	
155-15	27577-27578	;	_	
155-16	27579-27581	no	_	
155-17	27582-27593	significant	_	
155-18	27594-27601	regions	_	
155-19	27602-27609	emerged	_	
155-20	27610-27612	at	_	
155-21	27613-27616	our	_	
155-22	27617-27631	pre-determined	_	
155-23	27632-27637	level	_	
155-24	27638-27640	of	_	
155-25	27641-27652	statistical	_	
155-26	27653-27663	correction	_	
155-27	27663-27664	.	_	

#Text=However, within the conjunction analysis, we did observe significant overlap in functional connectivity between the adolescent cannabis and alcohol using samples during the sustain talk condition (OFC seed with IFG, SMA, superior frontal gyrus, middle temporal gyrus; see Supplement, Table 4).
156-1	27665-27672	However	_	
156-2	27672-27673	,	_	
156-3	27674-27680	within	_	
156-4	27681-27684	the	_	
156-5	27685-27696	conjunction	_	
156-6	27697-27705	analysis	_	
156-7	27705-27706	,	_	
156-8	27707-27709	we	_	
156-9	27710-27713	did	_	
156-10	27714-27721	observe	_	
156-11	27722-27733	significant	_	
156-12	27734-27741	overlap	_	
156-13	27742-27744	in	_	
156-14	27745-27755	functional	_	
156-15	27756-27768	connectivity	_	
156-16	27769-27776	between	_	
156-17	27777-27780	the	_	
156-18	27781-27791	adolescent	_	
156-19	27792-27800	cannabis	_	
156-20	27801-27804	and	_	
156-21	27805-27812	alcohol	_	
156-22	27813-27818	using	_	
156-23	27819-27826	samples	_	
156-24	27827-27833	during	_	
156-25	27834-27837	the	_	
156-26	27838-27845	sustain	_	
156-27	27846-27850	talk	_	
156-28	27851-27860	condition	_	
156-29	27861-27862	(	_	
156-30	27862-27865	OFC	_	
156-31	27866-27870	seed	_	
156-32	27871-27875	with	_	
156-33	27876-27879	IFG	_	
156-34	27879-27880	,	_	
156-35	27881-27884	SMA	_	
156-36	27884-27885	,	_	
156-37	27886-27894	superior	_	
156-38	27895-27902	frontal	_	
156-39	27903-27908	gyrus	_	
156-40	27908-27909	,	_	
156-41	27910-27916	middle	_	
156-42	27917-27925	temporal	_	
156-43	27926-27931	gyrus	_	
156-44	27931-27932	;	_	
156-45	27933-27936	see	_	
156-46	27937-27947	Supplement	_	
156-47	27947-27948	,	_	
156-48	27949-27954	Table	_	
156-49	27955-27956	4	_	
156-50	27956-27957	)	_	
156-51	27957-27958	.	_	

#Text=Discussion
#Text=While studies are increasingly using PPI to evaluate functional connectivity in the brain and its correspondence to addiction , this represents the first published study, to our knowledge, to examine functional connectivity as a mechanism of change in adolescent addiction treatment.
157-1	27959-27969	Discussion	_	
157-2	27970-27975	While	_	
157-3	27976-27983	studies	_	
157-4	27984-27987	are	_	
157-5	27988-28000	increasingly	_	
157-6	28001-28006	using	_	
157-7	28007-28010	PPI	_	
157-8	28011-28013	to	_	
157-9	28014-28022	evaluate	_	
157-10	28023-28033	functional	_	
157-11	28034-28046	connectivity	_	
157-12	28047-28049	in	_	
157-13	28050-28053	the	_	
157-14	28054-28059	brain	_	
157-15	28060-28063	and	_	
157-16	28064-28067	its	_	
157-17	28068-28082	correspondence	_	
157-18	28083-28085	to	_	
157-19	28086-28095	addiction	_	
157-20	28096-28097	,	_	
157-21	28098-28102	this	_	
157-22	28103-28113	represents	_	
157-23	28114-28117	the	_	
157-24	28118-28123	first	_	
157-25	28124-28133	published	_	
157-26	28134-28139	study	_	
157-27	28139-28140	,	_	
157-28	28141-28143	to	_	
157-29	28144-28147	our	_	
157-30	28148-28157	knowledge	_	
157-31	28157-28158	,	_	
157-32	28159-28161	to	_	
157-33	28162-28169	examine	_	
157-34	28170-28180	functional	_	
157-35	28181-28193	connectivity	_	
157-36	28194-28196	as	_	
157-37	28197-28198	a	_	
157-38	28199-28208	mechanism	_	
157-39	28209-28211	of	_	
157-40	28212-28218	change	_	
157-41	28219-28221	in	_	
157-42	28222-28232	adolescent	_	
157-43	28233-28242	addiction	_	
157-44	28243-28252	treatment	_	
157-45	28252-28253	.	_	

#Text=Based on foundational behavioral and neuroimaging work, which has identified the importance of client language in adolescents’ MI treatment response , we took a three-step approach to identify the extent and location of network connectivity during a key aspect of treatment response (client language in favor of change; change talk), the link between that connectivity and adolescent behavior change, and an exploratory look at the generalizability of those networks across two different adolescent substances of abuse (cannabis and alcohol).
158-1	28254-28259	Based	_	
158-2	28260-28262	on	_	
158-3	28263-28275	foundational	_	
158-4	28276-28286	behavioral	_	
158-5	28287-28290	and	_	
158-6	28291-28303	neuroimaging	_	
158-7	28304-28308	work	_	
158-8	28308-28309	,	_	
158-9	28310-28315	which	_	
158-10	28316-28319	has	_	
158-11	28320-28330	identified	_	
158-12	28331-28334	the	_	
158-13	28335-28345	importance	_	
158-14	28346-28348	of	_	
158-15	28349-28355	client	_	
158-16	28356-28364	language	_	
158-17	28365-28367	in	_	
158-18	28368-28379	adolescents	_	
158-19	28379-28380	’	_	
158-20	28381-28383	MI	_	
158-21	28384-28393	treatment	_	
158-22	28394-28402	response	_	
158-23	28403-28404	,	_	
158-24	28405-28407	we	_	
158-25	28408-28412	took	_	
158-26	28413-28414	a	_	
158-27	28415-28425	three-step	_	
158-28	28426-28434	approach	_	
158-29	28435-28437	to	_	
158-30	28438-28446	identify	_	
158-31	28447-28450	the	_	
158-32	28451-28457	extent	_	
158-33	28458-28461	and	_	
158-34	28462-28470	location	_	
158-35	28471-28473	of	_	
158-36	28474-28481	network	_	
158-37	28482-28494	connectivity	_	
158-38	28495-28501	during	_	
158-39	28502-28503	a	_	
158-40	28504-28507	key	_	
158-41	28508-28514	aspect	_	
158-42	28515-28517	of	_	
158-43	28518-28527	treatment	_	
158-44	28528-28536	response	_	
158-45	28537-28538	(	_	
158-46	28538-28544	client	_	
158-47	28545-28553	language	_	
158-48	28554-28556	in	_	
158-49	28557-28562	favor	_	
158-50	28563-28565	of	_	
158-51	28566-28572	change	_	
158-52	28572-28573	;	_	
158-53	28574-28580	change	_	
158-54	28581-28585	talk	_	
158-55	28585-28586	)	_	
158-56	28586-28587	,	_	
158-57	28588-28591	the	_	
158-58	28592-28596	link	_	
158-59	28597-28604	between	_	
158-60	28605-28609	that	_	
158-61	28610-28622	connectivity	_	
158-62	28623-28626	and	_	
158-63	28627-28637	adolescent	_	
158-64	28638-28646	behavior	_	
158-65	28647-28653	change	_	
158-66	28653-28654	,	_	
158-67	28655-28658	and	_	
158-68	28659-28661	an	_	
158-69	28662-28673	exploratory	_	
158-70	28674-28678	look	_	
158-71	28679-28681	at	_	
158-72	28682-28685	the	_	
158-73	28686-28702	generalizability	_	
158-74	28703-28705	of	_	
158-75	28706-28711	those	_	
158-76	28712-28720	networks	_	
158-77	28721-28727	across	_	
158-78	28728-28731	two	_	
158-79	28732-28741	different	_	
158-80	28742-28752	adolescent	_	
158-81	28753-28763	substances	_	
158-82	28764-28766	of	_	
158-83	28767-28772	abuse	_	
158-84	28773-28774	(	_	
158-85	28774-28782	cannabis	_	
158-86	28783-28786	and	_	
158-87	28787-28794	alcohol	_	
158-88	28794-28795	)	_	
158-89	28795-28796	.	_	

#Text=The OFC is a highly relevant region, both within addiction, and across the broader field of psychopathology.
159-1	28797-28800	The	_	
159-2	28801-28804	OFC	_	
159-3	28805-28807	is	_	
159-4	28808-28809	a	_	
159-5	28810-28816	highly	_	
159-6	28817-28825	relevant	_	
159-7	28826-28832	region	_	
159-8	28832-28833	,	_	
159-9	28834-28838	both	_	
159-10	28839-28845	within	_	
159-11	28846-28855	addiction	_	
159-12	28855-28856	,	_	
159-13	28857-28860	and	_	
159-14	28861-28867	across	_	
159-15	28868-28871	the	_	
159-16	28872-28879	broader	_	
159-17	28880-28885	field	_	
159-18	28886-28888	of	_	
159-19	28889-28904	psychopathology	_	
159-20	28904-28905	.	_	

#Text=For example, recent studies reflect that the OFC may underlie neural sensitivity to cannabis cues and place individuals at greater risk for a more protracted trajectory of use, particularly when youth begin using at an earlier age .
160-1	28906-28909	For	_	
160-2	28910-28917	example	_	
160-3	28917-28918	,	_	
160-4	28919-28925	recent	_	
160-5	28926-28933	studies	_	
160-6	28934-28941	reflect	_	
160-7	28942-28946	that	_	
160-8	28947-28950	the	_	
160-9	28951-28954	OFC	_	
160-10	28955-28958	may	_	
160-11	28959-28967	underlie	_	
160-12	28968-28974	neural	_	
160-13	28975-28986	sensitivity	_	
160-14	28987-28989	to	_	
160-15	28990-28998	cannabis	_	
160-16	28999-29003	cues	_	
160-17	29004-29007	and	_	
160-18	29008-29013	place	_	
160-19	29014-29025	individuals	_	
160-20	29026-29028	at	_	
160-21	29029-29036	greater	_	
160-22	29037-29041	risk	_	
160-23	29042-29045	for	_	
160-24	29046-29047	a	_	
160-25	29048-29052	more	_	
160-26	29053-29063	protracted	_	
160-27	29064-29074	trajectory	_	
160-28	29075-29077	of	_	
160-29	29078-29081	use	_	
160-30	29081-29082	,	_	
160-31	29083-29095	particularly	_	
160-32	29096-29100	when	_	
160-33	29101-29106	youth	_	
160-34	29107-29112	begin	_	
160-35	29113-29118	using	_	
160-36	29119-29121	at	_	
160-37	29122-29124	an	_	
160-38	29125-29132	earlier	_	
160-39	29133-29136	age	_	
160-40	29137-29138	.	_	

#Text=Further, OFC dysregulation appears to be a signature feature across anxiety, OCD, and anorexia nervosa , subsequently indicating its relevance as a marker of neural health, and potentially, a region that may be disrupted during the transition into emergent or more long-standing psychiatric conditions.
161-1	29139-29146	Further	_	
161-2	29146-29147	,	_	
161-3	29148-29151	OFC	_	
161-4	29152-29165	dysregulation	_	
161-5	29166-29173	appears	_	
161-6	29174-29176	to	_	
161-7	29177-29179	be	_	
161-8	29180-29181	a	_	
161-9	29182-29191	signature	_	
161-10	29192-29199	feature	_	
161-11	29200-29206	across	_	
161-12	29207-29214	anxiety	_	
161-13	29214-29215	,	_	
161-14	29216-29219	OCD	_	
161-15	29219-29220	,	_	
161-16	29221-29224	and	_	
161-17	29225-29233	anorexia	_	
161-18	29234-29241	nervosa	_	
161-19	29242-29243	,	_	
161-20	29244-29256	subsequently	_	
161-21	29257-29267	indicating	_	
161-22	29268-29271	its	_	
161-23	29272-29281	relevance	_	
161-24	29282-29284	as	_	
161-25	29285-29286	a	_	
161-26	29287-29293	marker	_	
161-27	29294-29296	of	_	
161-28	29297-29303	neural	_	
161-29	29304-29310	health	_	
161-30	29310-29311	,	_	
161-31	29312-29315	and	_	
161-32	29316-29327	potentially	_	
161-33	29327-29328	,	_	
161-34	29329-29330	a	_	
161-35	29331-29337	region	_	
161-36	29338-29342	that	_	
161-37	29343-29346	may	_	
161-38	29347-29349	be	_	
161-39	29350-29359	disrupted	_	
161-40	29360-29366	during	_	
161-41	29367-29370	the	_	
161-42	29371-29381	transition	_	
161-43	29382-29386	into	_	
161-44	29387-29395	emergent	_	
161-45	29396-29398	or	_	
161-46	29399-29403	more	_	
161-47	29404-29417	long-standing	_	
161-48	29418-29429	psychiatric	_	
161-49	29430-29440	conditions	_	
161-50	29440-29441	.	_	

#Text=In this study, during client statements in favor of change (change talk), we found increased neural cohesion between the OFC seed and a number of regions including the IFG, precentral gyrus, anterior and posterior cingulate gyrus, SMA, superior frontal gyrus, pallidus, caudate, parahippocampal gyrus.
162-1	29442-29444	In	_	
162-2	29445-29449	this	_	
162-3	29450-29455	study	_	
162-4	29455-29456	,	_	
162-5	29457-29463	during	_	
162-6	29464-29470	client	_	
162-7	29471-29481	statements	_	
162-8	29482-29484	in	_	
162-9	29485-29490	favor	_	
162-10	29491-29493	of	_	
162-11	29494-29500	change	_	
162-12	29501-29502	(	_	
162-13	29502-29508	change	_	
162-14	29509-29513	talk	_	
162-15	29513-29514	)	_	
162-16	29514-29515	,	_	
162-17	29516-29518	we	_	
162-18	29519-29524	found	_	
162-19	29525-29534	increased	_	
162-20	29535-29541	neural	_	
162-21	29542-29550	cohesion	_	
162-22	29551-29558	between	_	
162-23	29559-29562	the	_	
162-24	29563-29566	OFC	_	
162-25	29567-29571	seed	_	
162-26	29572-29575	and	_	
162-27	29576-29577	a	_	
162-28	29578-29584	number	_	
162-29	29585-29587	of	_	
162-30	29588-29595	regions	_	
162-31	29596-29605	including	_	
162-32	29606-29609	the	_	
162-33	29610-29613	IFG	_	
162-34	29613-29614	,	_	
162-35	29615-29625	precentral	_	
162-36	29626-29631	gyrus	_	
162-37	29631-29632	,	_	
162-38	29633-29641	anterior	_	
162-39	29642-29645	and	_	
162-40	29646-29655	posterior	_	
162-41	29656-29665	cingulate	_	
162-42	29666-29671	gyrus	_	
162-43	29671-29672	,	_	
162-44	29673-29676	SMA	_	
162-45	29676-29677	,	_	
162-46	29678-29686	superior	_	
162-47	29687-29694	frontal	_	
162-48	29695-29700	gyrus	_	
162-49	29700-29701	,	_	
162-50	29702-29710	pallidus	_	
162-51	29710-29711	,	_	
162-52	29712-29719	caudate	_	
162-53	29719-29720	,	_	
162-54	29721-29736	parahippocampal	_	
162-55	29737-29742	gyrus	_	
162-56	29742-29743	.	_	

#Text=We also observed several areas of decreased functional connectivity between the OFC seed and a number of areas, including the precuneus, superior/middle frontal gyrus, parahippocampal gyrus, thalamus, inferior parietal lobule, and cingulate gyrus.
163-1	29744-29746	We	_	
163-2	29747-29751	also	_	
163-3	29752-29760	observed	_	
163-4	29761-29768	several	_	
163-5	29769-29774	areas	_	
163-6	29775-29777	of	_	
163-7	29778-29787	decreased	_	
163-8	29788-29798	functional	_	
163-9	29799-29811	connectivity	_	
163-10	29812-29819	between	_	
163-11	29820-29823	the	_	
163-12	29824-29827	OFC	_	
163-13	29828-29832	seed	_	
163-14	29833-29836	and	_	
163-15	29837-29838	a	_	
163-16	29839-29845	number	_	
163-17	29846-29848	of	_	
163-18	29849-29854	areas	_	
163-19	29854-29855	,	_	
163-20	29856-29865	including	_	
163-21	29866-29869	the	_	
163-22	29870-29879	precuneus	_	
163-23	29879-29880	,	_	
163-24	29881-29889	superior	_	
163-25	29889-29890	/	_	
163-26	29890-29896	middle	_	
163-27	29897-29904	frontal	_	
163-28	29905-29910	gyrus	_	
163-29	29910-29911	,	_	
163-30	29912-29927	parahippocampal	_	
163-31	29928-29933	gyrus	_	
163-32	29933-29934	,	_	
163-33	29935-29943	thalamus	_	
163-34	29943-29944	,	_	
163-35	29945-29953	inferior	_	
163-36	29954-29962	parietal	_	
163-37	29963-29969	lobule	_	
163-38	29969-29970	,	_	
163-39	29971-29974	and	_	
163-40	29975-29984	cingulate	_	
163-41	29985-29990	gyrus	_	
163-42	29990-29991	.	_	

#Text=We believe that these findings are of high clinical relevance, as they take a substantial step beyond regional activation studies, to support the existence of a cohesive network of neural communication during client language in favor of change.
164-1	29992-29994	We	_	
164-2	29995-30002	believe	_	
164-3	30003-30007	that	_	
164-4	30008-30013	these	_	
164-5	30014-30022	findings	_	
164-6	30023-30026	are	_	
164-7	30027-30029	of	_	
164-8	30030-30034	high	_	
164-9	30035-30043	clinical	_	
164-10	30044-30053	relevance	_	
164-11	30053-30054	,	_	
164-12	30055-30057	as	_	
164-13	30058-30062	they	_	
164-14	30063-30067	take	_	
164-15	30068-30069	a	_	
164-16	30070-30081	substantial	_	
164-17	30082-30086	step	_	
164-18	30087-30093	beyond	_	
164-19	30094-30102	regional	_	
164-20	30103-30113	activation	_	
164-21	30114-30121	studies	_	
164-22	30121-30122	,	_	
164-23	30123-30125	to	_	
164-24	30126-30133	support	_	
164-25	30134-30137	the	_	
164-26	30138-30147	existence	_	
164-27	30148-30150	of	_	
164-28	30151-30152	a	_	
164-29	30153-30161	cohesive	_	
164-30	30162-30169	network	_	
164-31	30170-30172	of	_	
164-32	30173-30179	neural	_	
164-33	30180-30193	communication	_	
164-34	30194-30200	during	_	
164-35	30201-30207	client	_	
164-36	30208-30216	language	_	
164-37	30217-30219	in	_	
164-38	30220-30225	favor	_	
164-39	30226-30228	of	_	
164-40	30229-30235	change	_	
164-41	30235-30236	.	_	

#Text=Compellingly, this study offers the first study to actually accrue empirical support for networks that our team had previously hypothesized might be relevant in treatment response in 2011 .
165-1	30237-30249	Compellingly	_	
165-2	30249-30250	,	_	
165-3	30251-30255	this	_	
165-4	30256-30261	study	_	
165-5	30262-30268	offers	_	
165-6	30269-30272	the	_	
165-7	30273-30278	first	_	
165-8	30279-30284	study	_	
165-9	30285-30287	to	_	
165-10	30288-30296	actually	_	
165-11	30297-30303	accrue	_	
165-12	30304-30313	empirical	_	
165-13	30314-30321	support	_	
165-14	30322-30325	for	_	
165-15	30326-30334	networks	_	
165-16	30335-30339	that	_	
165-17	30340-30343	our	_	
165-18	30344-30348	team	_	
165-19	30349-30352	had	_	
165-20	30353-30363	previously	_	
165-21	30364-30376	hypothesized	_	
165-22	30377-30382	might	_	
165-23	30383-30385	be	_	
165-24	30386-30394	relevant	_	
165-25	30395-30397	in	_	
165-26	30398-30407	treatment	_	
165-27	30408-30416	response	_	
165-28	30417-30419	in	_	
165-29	30420-30424	2011	_	
165-30	30425-30426	.	_	

#Text=More specifically, we proposed that the OFC might co-activate with the IFG, in what we had titled the “executive control network”, to clinically facilitate an individual’s movement toward behavior change.
166-1	30427-30431	More	_	
166-2	30432-30444	specifically	_	
166-3	30444-30445	,	_	
166-4	30446-30448	we	_	
166-5	30449-30457	proposed	_	
166-6	30458-30462	that	_	
166-7	30463-30466	the	_	
166-8	30467-30470	OFC	_	
166-9	30471-30476	might	_	
166-10	30477-30488	co-activate	_	
166-11	30489-30493	with	_	
166-12	30494-30497	the	_	
166-13	30498-30501	IFG	_	
166-14	30501-30502	,	_	
166-15	30503-30505	in	_	
166-16	30506-30510	what	_	
166-17	30511-30513	we	_	
166-18	30514-30517	had	_	
166-19	30518-30524	titled	_	
166-20	30525-30528	the	_	
166-21	30529-30530	“	_	
166-22	30530-30539	executive	_	
166-23	30540-30547	control	_	
166-24	30548-30555	network	_	
166-25	30555-30556	”	_	
166-26	30556-30557	,	_	
166-27	30558-30560	to	_	
166-28	30561-30571	clinically	_	
166-29	30572-30582	facilitate	_	
166-30	30583-30585	an	_	
166-31	30586-30596	individual	_	
166-32	30596-30597	’	_	
166-33	30597-30598	s	_	
166-34	30599-30607	movement	_	
166-35	30608-30614	toward	_	
166-36	30615-30623	behavior	_	
166-37	30624-30630	change	_	
166-38	30630-30631	.	_	

#Text=In this capacity, we believed that this OFC-based network might underlie an individual’s capacity to continue to actually implement ideas generated during the treatment session to real-world reduction in use.
167-1	30632-30634	In	_	
167-2	30635-30639	this	_	
167-3	30640-30648	capacity	_	
167-4	30648-30649	,	_	
167-5	30650-30652	we	_	
167-6	30653-30661	believed	_	
167-7	30662-30666	that	_	
167-8	30667-30671	this	_	
167-9	30672-30681	OFC-based	_	
167-10	30682-30689	network	_	
167-11	30690-30695	might	_	
167-12	30696-30704	underlie	_	
167-13	30705-30707	an	_	
167-14	30708-30718	individual	_	
167-15	30718-30719	’	_	
167-16	30719-30720	s	_	
167-17	30721-30729	capacity	_	
167-18	30730-30732	to	_	
167-19	30733-30741	continue	_	
167-20	30742-30744	to	_	
167-21	30745-30753	actually	_	
167-22	30754-30763	implement	_	
167-23	30764-30769	ideas	_	
167-24	30770-30779	generated	_	
167-25	30780-30786	during	_	
167-26	30787-30790	the	_	
167-27	30791-30800	treatment	_	
167-28	30801-30808	session	_	
167-29	30809-30811	to	_	
167-30	30812-30822	real-world	_	
167-31	30823-30832	reduction	_	
167-32	30833-30835	in	_	
167-33	30836-30839	use	_	
167-34	30839-30840	.	_	

#Text=Interestingly, while sustain talk was not the original focus of this investigation, we also examined areas of regional connectivity for this comparison condition (see Supplement).
168-1	30841-30854	Interestingly	_	
168-2	30854-30855	,	_	
168-3	30856-30861	while	_	
168-4	30862-30869	sustain	_	
168-5	30870-30874	talk	_	
168-6	30875-30878	was	_	
168-7	30879-30882	not	_	
168-8	30883-30886	the	_	
168-9	30887-30895	original	_	
168-10	30896-30901	focus	_	
168-11	30902-30904	of	_	
168-12	30905-30909	this	_	
168-13	30910-30923	investigation	_	
168-14	30923-30924	,	_	
168-15	30925-30927	we	_	
168-16	30928-30932	also	_	
168-17	30933-30941	examined	_	
168-18	30942-30947	areas	_	
168-19	30948-30950	of	_	
168-20	30951-30959	regional	_	
168-21	30960-30972	connectivity	_	
168-22	30973-30976	for	_	
168-23	30977-30981	this	_	
168-24	30982-30992	comparison	_	
168-25	30993-31002	condition	_	
168-26	31003-31004	(	_	
168-27	31004-31007	see	_	
168-28	31008-31018	Supplement	_	
168-29	31018-31019	)	_	
168-30	31019-31020	.	_	

#Text=Here we found that sustain talk was associated with a large area of increased connectivity between the OFC with regions including the IFG, SMA, superior frontal gyrus, posterior cingulate, pallidus, and caudate.
169-1	31021-31025	Here	_	
169-2	31026-31028	we	_	
169-3	31029-31034	found	_	
169-4	31035-31039	that	_	
169-5	31040-31047	sustain	_	
169-6	31048-31052	talk	_	
169-7	31053-31056	was	_	
169-8	31057-31067	associated	_	
169-9	31068-31072	with	_	
169-10	31073-31074	a	_	
169-11	31075-31080	large	_	
169-12	31081-31085	area	_	
169-13	31086-31088	of	_	
169-14	31089-31098	increased	_	
169-15	31099-31111	connectivity	_	
169-16	31112-31119	between	_	
169-17	31120-31123	the	_	
169-18	31124-31127	OFC	_	
169-19	31128-31132	with	_	
169-20	31133-31140	regions	_	
169-21	31141-31150	including	_	
169-22	31151-31154	the	_	
169-23	31155-31158	IFG	_	
169-24	31158-31159	,	_	
169-25	31160-31163	SMA	_	
169-26	31163-31164	,	_	
169-27	31165-31173	superior	_	
169-28	31174-31181	frontal	_	
169-29	31182-31187	gyrus	_	
169-30	31187-31188	,	_	
169-31	31189-31198	posterior	_	
169-32	31199-31208	cingulate	_	
169-33	31208-31209	,	_	
169-34	31210-31218	pallidus	_	
169-35	31218-31219	,	_	
169-36	31220-31223	and	_	
169-37	31224-31231	caudate	_	
169-38	31231-31232	.	_	

#Text=As with change talk, connectivity during sustain talk was also showed a large area of decreased connectivity between the OFC seed and regions including the precuneus, caudate, middle/superior frontal gyrus, thalamus, insula, and SMA.
170-1	31233-31235	As	_	
170-2	31236-31240	with	_	
170-3	31241-31247	change	_	
170-4	31248-31252	talk	_	
170-5	31252-31253	,	_	
170-6	31254-31266	connectivity	_	
170-7	31267-31273	during	_	
170-8	31274-31281	sustain	_	
170-9	31282-31286	talk	_	
170-10	31287-31290	was	_	
170-11	31291-31295	also	_	
170-12	31296-31302	showed	_	
170-13	31303-31304	a	_	
170-14	31305-31310	large	_	
170-15	31311-31315	area	_	
170-16	31316-31318	of	_	
170-17	31319-31328	decreased	_	
170-18	31329-31341	connectivity	_	
170-19	31342-31349	between	_	
170-20	31350-31353	the	_	
170-21	31354-31357	OFC	_	
170-22	31358-31362	seed	_	
170-23	31363-31366	and	_	
170-24	31367-31374	regions	_	
170-25	31375-31384	including	_	
170-26	31385-31388	the	_	
170-27	31389-31398	precuneus	_	
170-28	31398-31399	,	_	
170-29	31400-31407	caudate	_	
170-30	31407-31408	,	_	
170-31	31409-31415	middle	_	
170-32	31415-31416	/	_	
170-33	31416-31424	superior	_	
170-34	31425-31432	frontal	_	
170-35	31433-31438	gyrus	_	
170-36	31438-31439	,	_	
170-37	31440-31448	thalamus	_	
170-38	31448-31449	,	_	
170-39	31450-31456	insula	_	
170-40	31456-31457	,	_	
170-41	31458-31461	and	_	
170-42	31462-31465	SMA	_	
170-43	31465-31466	.	_	

#Text=Most simply, these data reflect the substantive OFC network communication during adolescents’ processing of both types of clinical, in-session language.
171-1	31467-31471	Most	_	
171-2	31472-31478	simply	_	
171-3	31478-31479	,	_	
171-4	31480-31485	these	_	
171-5	31486-31490	data	_	
171-6	31491-31498	reflect	_	
171-7	31499-31502	the	_	
171-8	31503-31514	substantive	_	
171-9	31515-31518	OFC	_	
171-10	31519-31526	network	_	
171-11	31527-31540	communication	_	
171-12	31541-31547	during	_	
171-13	31548-31559	adolescents	_	
171-14	31559-31560	’	_	
171-15	31561-31571	processing	_	
171-16	31572-31574	of	_	
171-17	31575-31579	both	_	
171-18	31580-31585	types	_	
171-19	31586-31588	of	_	
171-20	31589-31597	clinical	_	
171-21	31597-31598	,	_	
171-22	31599-31609	in-session	_	
171-23	31610-31618	language	_	
171-24	31618-31619	.	_	

#Text=Interestingly, when contrasted directly, we found a parallel level of response across both types of client response; in other words, network connectivity was not greater for one type of client statement relative to the other (CT vs.
172-1	31620-31633	Interestingly	_	
172-2	31633-31634	,	_	
172-3	31635-31639	when	_	
172-4	31640-31650	contrasted	_	
172-5	31651-31659	directly	_	
172-6	31659-31660	,	_	
172-7	31661-31663	we	_	
172-8	31664-31669	found	_	
172-9	31670-31671	a	_	
172-10	31672-31680	parallel	_	
172-11	31681-31686	level	_	
172-12	31687-31689	of	_	
172-13	31690-31698	response	_	
172-14	31699-31705	across	_	
172-15	31706-31710	both	_	
172-16	31711-31716	types	_	
172-17	31717-31719	of	_	
172-18	31720-31726	client	_	
172-19	31727-31735	response	_	
172-20	31735-31736	;	_	
172-21	31737-31739	in	_	
172-22	31740-31745	other	_	
172-23	31746-31751	words	_	
172-24	31751-31752	,	_	
172-25	31753-31760	network	_	
172-26	31761-31773	connectivity	_	
172-27	31774-31777	was	_	
172-28	31778-31781	not	_	
172-29	31782-31789	greater	_	
172-30	31790-31793	for	_	
172-31	31794-31797	one	_	
172-32	31798-31802	type	_	
172-33	31803-31805	of	_	
172-34	31806-31812	client	_	
172-35	31813-31822	statement	_	
172-36	31823-31831	relative	_	
172-37	31832-31834	to	_	
172-38	31835-31838	the	_	
172-39	31839-31844	other	_	
172-40	31845-31846	(	_	
172-41	31846-31848	CT	_	
172-42	31849-31851	vs	_	
172-43	31851-31852	.	_	

#Text=ST).
173-1	31853-31855	ST	_	
173-2	31855-31856	)	_	
173-3	31856-31857	.	_	

#Text=We posit that, for adolescents, comparable, and similarly powered, neural network systems are activated during language in favor of changing, along with language in favor of staying the same.
174-1	31858-31860	We	_	
174-2	31861-31866	posit	_	
174-3	31867-31871	that	_	
174-4	31871-31872	,	_	
174-5	31873-31876	for	_	
174-6	31877-31888	adolescents	_	
174-7	31888-31889	,	_	
174-8	31890-31900	comparable	_	
174-9	31900-31901	,	_	
174-10	31902-31905	and	_	
174-11	31906-31915	similarly	_	
174-12	31916-31923	powered	_	
174-13	31923-31924	,	_	
174-14	31925-31931	neural	_	
174-15	31932-31939	network	_	
174-16	31940-31947	systems	_	
174-17	31948-31951	are	_	
174-18	31952-31961	activated	_	
174-19	31962-31968	during	_	
174-20	31969-31977	language	_	
174-21	31978-31980	in	_	
174-22	31981-31986	favor	_	
174-23	31987-31989	of	_	
174-24	31990-31998	changing	_	
174-25	31998-31999	,	_	
174-26	32000-32005	along	_	
174-27	32006-32010	with	_	
174-28	32011-32019	language	_	
174-29	32020-32022	in	_	
174-30	32023-32028	favor	_	
174-31	32029-32031	of	_	
174-32	32032-32039	staying	_	
174-33	32040-32043	the	_	
174-34	32044-32048	same	_	
174-35	32048-32049	.	_	

#Text=Notably, these two types of client language that have been associated with very different behavioral response within the adult treatment literature; more specifically, client change talk has been associated with positive treatment response (lower substance use post-treatment), whereas client sustain talk has been associated with much poorer treatment outcomes (greater substance use post-treatment) .
175-1	32050-32057	Notably	_	
175-2	32057-32058	,	_	
175-3	32059-32064	these	_	
175-4	32065-32068	two	_	
175-5	32069-32074	types	_	
175-6	32075-32077	of	_	
175-7	32078-32084	client	_	
175-8	32085-32093	language	_	
175-9	32094-32098	that	_	
175-10	32099-32103	have	_	
175-11	32104-32108	been	_	
175-12	32109-32119	associated	_	
175-13	32120-32124	with	_	
175-14	32125-32129	very	_	
175-15	32130-32139	different	_	
175-16	32140-32150	behavioral	_	
175-17	32151-32159	response	_	
175-18	32160-32166	within	_	
175-19	32167-32170	the	_	
175-20	32171-32176	adult	_	
175-21	32177-32186	treatment	_	
175-22	32187-32197	literature	_	
175-23	32197-32198	;	_	
175-24	32199-32203	more	_	
175-25	32204-32216	specifically	_	
175-26	32216-32217	,	_	
175-27	32218-32224	client	_	
175-28	32225-32231	change	_	
175-29	32232-32236	talk	_	
175-30	32237-32240	has	_	
175-31	32241-32245	been	_	
175-32	32246-32256	associated	_	
175-33	32257-32261	with	_	
175-34	32262-32270	positive	_	
175-35	32271-32280	treatment	_	
175-36	32281-32289	response	_	
175-37	32290-32291	(	_	
175-38	32291-32296	lower	_	
175-39	32297-32306	substance	_	
175-40	32307-32310	use	_	
175-41	32311-32325	post-treatment	_	
175-42	32325-32326	)	_	
175-43	32326-32327	,	_	
175-44	32328-32335	whereas	_	
175-45	32336-32342	client	_	
175-46	32343-32350	sustain	_	
175-47	32351-32355	talk	_	
175-48	32356-32359	has	_	
175-49	32360-32364	been	_	
175-50	32365-32375	associated	_	
175-51	32376-32380	with	_	
175-52	32381-32385	much	_	
175-53	32386-32392	poorer	_	
175-54	32393-32402	treatment	_	
175-55	32403-32411	outcomes	_	
175-56	32412-32413	(	_	
175-57	32413-32420	greater	_	
175-58	32421-32430	substance	_	
175-59	32431-32434	use	_	
175-60	32435-32449	post-treatment	_	
175-61	32449-32450	)	_	
175-62	32451-32452	.	_	

#Text=We believe that future work must continue to disentangle the nature of neural response during both types of client language in order to understand the strength and pattern of brain response in adolescent addiction treatment, with a particular eye to how network response and post-treatment change may be unique within this developmental period, as compared with other age groups who are more often examined in treatment contexts (e.g., treatment-seeking adults) .
176-1	32453-32455	We	_	
176-2	32456-32463	believe	_	
176-3	32464-32468	that	_	
176-4	32469-32475	future	_	
176-5	32476-32480	work	_	
176-6	32481-32485	must	_	
176-7	32486-32494	continue	_	
176-8	32495-32497	to	_	
176-9	32498-32509	disentangle	_	
176-10	32510-32513	the	_	
176-11	32514-32520	nature	_	
176-12	32521-32523	of	_	
176-13	32524-32530	neural	_	
176-14	32531-32539	response	_	
176-15	32540-32546	during	_	
176-16	32547-32551	both	_	
176-17	32552-32557	types	_	
176-18	32558-32560	of	_	
176-19	32561-32567	client	_	
176-20	32568-32576	language	_	
176-21	32577-32579	in	_	
176-22	32580-32585	order	_	
176-23	32586-32588	to	_	
176-24	32589-32599	understand	_	
176-25	32600-32603	the	_	
176-26	32604-32612	strength	_	
176-27	32613-32616	and	_	
176-28	32617-32624	pattern	_	
176-29	32625-32627	of	_	
176-30	32628-32633	brain	_	
176-31	32634-32642	response	_	
176-32	32643-32645	in	_	
176-33	32646-32656	adolescent	_	
176-34	32657-32666	addiction	_	
176-35	32667-32676	treatment	_	
176-36	32676-32677	,	_	
176-37	32678-32682	with	_	
176-38	32683-32684	a	_	
176-39	32685-32695	particular	_	
176-40	32696-32699	eye	_	
176-41	32700-32702	to	_	
176-42	32703-32706	how	_	
176-43	32707-32714	network	_	
176-44	32715-32723	response	_	
176-45	32724-32727	and	_	
176-46	32728-32742	post-treatment	_	
176-47	32743-32749	change	_	
176-48	32750-32753	may	_	
176-49	32754-32756	be	_	
176-50	32757-32763	unique	_	
176-51	32764-32770	within	_	
176-52	32771-32775	this	_	
176-53	32776-32789	developmental	_	
176-54	32790-32796	period	_	
176-55	32796-32797	,	_	
176-56	32798-32800	as	_	
176-57	32801-32809	compared	_	
176-58	32810-32814	with	_	
176-59	32815-32820	other	_	
176-60	32821-32824	age	_	
176-61	32825-32831	groups	_	
176-62	32832-32835	who	_	
176-63	32836-32839	are	_	
176-64	32840-32844	more	_	
176-65	32845-32850	often	_	
176-66	32851-32859	examined	_	
176-67	32860-32862	in	_	
176-68	32863-32872	treatment	_	
176-69	32873-32881	contexts	_	
176-70	32882-32883	(	_	
176-71	32883-32886	e.g	_	
176-72	32886-32887	.	_	
176-73	32887-32888	,	_	
176-74	32889-32906	treatment-seeking	_	
176-75	32907-32913	adults	_	
176-76	32913-32914	)	_	
176-77	32915-32916	.	_	

#Text=In terms of treatment response, OFC connectivity with the anterior cingulate/medial frontal gyrus - during change talk (only) - was significantly correlated with adolescents’ behavior change in this study.
177-1	32917-32919	In	_	
177-2	32920-32925	terms	_	
177-3	32926-32928	of	_	
177-4	32929-32938	treatment	_	
177-5	32939-32947	response	_	
177-6	32947-32948	,	_	
177-7	32949-32952	OFC	_	
177-8	32953-32965	connectivity	_	
177-9	32966-32970	with	_	
177-10	32971-32974	the	_	
177-11	32975-32983	anterior	_	
177-12	32984-32993	cingulate	_	
177-13	32993-32994	/	_	
177-14	32994-33000	medial	_	
177-15	33001-33008	frontal	_	
177-16	33009-33014	gyrus	_	
177-17	33015-33016	-	_	
177-18	33017-33023	during	_	
177-19	33024-33030	change	_	
177-20	33031-33035	talk	_	
177-21	33036-33037	(	_	
177-22	33037-33041	only	_	
177-23	33041-33042	)	_	
177-24	33043-33044	-	_	
177-25	33045-33048	was	_	
177-26	33049-33062	significantly	_	
177-27	33063-33073	correlated	_	
177-28	33074-33078	with	_	
177-29	33079-33090	adolescents	_	
177-30	33090-33091	’	_	
177-31	33092-33100	behavior	_	
177-32	33101-33107	change	_	
177-33	33108-33110	in	_	
177-34	33111-33115	this	_	
177-35	33116-33121	study	_	
177-36	33121-33122	.	_	

#Text=These results reflect that greater OFC connectivity may be a flag, or indicator, of more post-treatment cannabis problems.
178-1	33123-33128	These	_	
178-2	33129-33136	results	_	
178-3	33137-33144	reflect	_	
178-4	33145-33149	that	_	
178-5	33150-33157	greater	_	
178-6	33158-33161	OFC	_	
178-7	33162-33174	connectivity	_	
178-8	33175-33178	may	_	
178-9	33179-33181	be	_	
178-10	33182-33183	a	_	
178-11	33184-33188	flag	_	
178-12	33188-33189	,	_	
178-13	33190-33192	or	_	
178-14	33193-33202	indicator	_	
178-15	33202-33203	,	_	
178-16	33204-33206	of	_	
178-17	33207-33211	more	_	
178-18	33212-33226	post-treatment	_	
178-19	33227-33235	cannabis	_	
178-20	33236-33244	problems	_	
178-21	33244-33245	.	_	

#Text=This is interesting, as it maps onto larger scale studies of cannabis use, where greater OFC connectivity, specifically, has been a distinguishing marker of a much greater risk profile, in terms of protracted use and associated problems .
179-1	33246-33250	This	_	
179-2	33251-33253	is	_	
179-3	33254-33265	interesting	_	
179-4	33265-33266	,	_	
179-5	33267-33269	as	_	
179-6	33270-33272	it	_	
179-7	33273-33277	maps	_	
179-8	33278-33282	onto	_	
179-9	33283-33289	larger	_	
179-10	33290-33295	scale	_	
179-11	33296-33303	studies	_	
179-12	33304-33306	of	_	
179-13	33307-33315	cannabis	_	
179-14	33316-33319	use	_	
179-15	33319-33320	,	_	
179-16	33321-33326	where	_	
179-17	33327-33334	greater	_	
179-18	33335-33338	OFC	_	
179-19	33339-33351	connectivity	_	
179-20	33351-33352	,	_	
179-21	33353-33365	specifically	_	
179-22	33365-33366	,	_	
179-23	33367-33370	has	_	
179-24	33371-33375	been	_	
179-25	33376-33377	a	_	
179-26	33378-33392	distinguishing	_	
179-27	33393-33399	marker	_	
179-28	33400-33402	of	_	
179-29	33403-33404	a	_	
179-30	33405-33409	much	_	
179-31	33410-33417	greater	_	
179-32	33418-33422	risk	_	
179-33	33423-33430	profile	_	
179-34	33430-33431	,	_	
179-35	33432-33434	in	_	
179-36	33435-33440	terms	_	
179-37	33441-33443	of	_	
179-38	33444-33454	protracted	_	
179-39	33455-33458	use	_	
179-40	33459-33462	and	_	
179-41	33463-33473	associated	_	
179-42	33474-33482	problems	_	
179-43	33483-33484	.	_	

#Text=Further, these data are also in line with a recent meta-analysis in the field of depression, which supported the impact of psychotherapy on similar neural circuits .
180-1	33485-33492	Further	_	
180-2	33492-33493	,	_	
180-3	33494-33499	these	_	
180-4	33500-33504	data	_	
180-5	33505-33508	are	_	
180-6	33509-33513	also	_	
180-7	33514-33516	in	_	
180-8	33517-33521	line	_	
180-9	33522-33526	with	_	
180-10	33527-33528	a	_	
180-11	33529-33535	recent	_	
180-12	33536-33549	meta-analysis	_	
180-13	33550-33552	in	_	
180-14	33553-33556	the	_	
180-15	33557-33562	field	_	
180-16	33563-33565	of	_	
180-17	33566-33576	depression	_	
180-18	33576-33577	,	_	
180-19	33578-33583	which	_	
180-20	33584-33593	supported	_	
180-21	33594-33597	the	_	
180-22	33598-33604	impact	_	
180-23	33605-33607	of	_	
180-24	33608-33621	psychotherapy	_	
180-25	33622-33624	on	_	
180-26	33625-33632	similar	_	
180-27	33633-33639	neural	_	
180-28	33640-33648	circuits	_	
180-29	33649-33650	.	_	

#Text=Moreover, OFC network systems may not only be responsive to therapy, but potentially modifiable through therapy directly, and/or potentially through an adjunctive venue to enhance brain response to psychotherapy (e.g., neurostimulation) .
181-1	33651-33659	Moreover	_	
181-2	33659-33660	,	_	
181-3	33661-33664	OFC	_	
181-4	33665-33672	network	_	
181-5	33673-33680	systems	_	
181-6	33681-33684	may	_	
181-7	33685-33688	not	_	
181-8	33689-33693	only	_	
181-9	33694-33696	be	_	
181-10	33697-33707	responsive	_	
181-11	33708-33710	to	_	
181-12	33711-33718	therapy	_	
181-13	33718-33719	,	_	
181-14	33720-33723	but	_	
181-15	33724-33735	potentially	_	
181-16	33736-33746	modifiable	_	
181-17	33747-33754	through	_	
181-18	33755-33762	therapy	_	
181-19	33763-33771	directly	_	
181-20	33771-33772	,	_	
181-21	33773-33776	and	_	
181-22	33776-33777	/	_	
181-23	33777-33779	or	_	
181-24	33780-33791	potentially	_	
181-25	33792-33799	through	_	
181-26	33800-33802	an	_	
181-27	33803-33813	adjunctive	_	
181-28	33814-33819	venue	_	
181-29	33820-33822	to	_	
181-30	33823-33830	enhance	_	
181-31	33831-33836	brain	_	
181-32	33837-33845	response	_	
181-33	33846-33848	to	_	
181-34	33849-33862	psychotherapy	_	
181-35	33863-33864	(	_	
181-36	33864-33867	e.g	_	
181-37	33867-33868	.	_	
181-38	33868-33869	,	_	
181-39	33870-33886	neurostimulation	_	
181-40	33886-33887	)	_	
181-41	33888-33889	.	_	

#Text=For instance, others have found that not only is ACC response particularly responsive to social reward, with neurofeedback, it can be refined and modulated .
182-1	33890-33893	For	_	
182-2	33894-33902	instance	_	
182-3	33902-33903	,	_	
182-4	33904-33910	others	_	
182-5	33911-33915	have	_	
182-6	33916-33921	found	_	
182-7	33922-33926	that	_	
182-8	33927-33930	not	_	
182-9	33931-33935	only	_	
182-10	33936-33938	is	_	
182-11	33939-33942	ACC	_	
182-12	33943-33951	response	_	
182-13	33952-33964	particularly	_	
182-14	33965-33975	responsive	_	
182-15	33976-33978	to	_	
182-16	33979-33985	social	_	
182-17	33986-33992	reward	_	
182-18	33992-33993	,	_	
182-19	33994-33998	with	_	
182-20	33999-34012	neurofeedback	_	
182-21	34012-34013	,	_	
182-22	34014-34016	it	_	
182-23	34017-34020	can	_	
182-24	34021-34023	be	_	
182-25	34024-34031	refined	_	
182-26	34032-34035	and	_	
182-27	34036-34045	modulated	_	
182-28	34046-34047	.	_	

#Text=Interestingly, while we observed a relationship between network connectivity and treatment response for change talk, our supplementary analyses did not reflect the same relationship for client language in favor of staying the same (sustain talk).
183-1	34048-34061	Interestingly	_	
183-2	34061-34062	,	_	
183-3	34063-34068	while	_	
183-4	34069-34071	we	_	
183-5	34072-34080	observed	_	
183-6	34081-34082	a	_	
183-7	34083-34095	relationship	_	
183-8	34096-34103	between	_	
183-9	34104-34111	network	_	
183-10	34112-34124	connectivity	_	
183-11	34125-34128	and	_	
183-12	34129-34138	treatment	_	
183-13	34139-34147	response	_	
183-14	34148-34151	for	_	
183-15	34152-34158	change	_	
183-16	34159-34163	talk	_	
183-17	34163-34164	,	_	
183-18	34165-34168	our	_	
183-19	34169-34182	supplementary	_	
183-20	34183-34191	analyses	_	
183-21	34192-34195	did	_	
183-22	34196-34199	not	_	
183-23	34200-34207	reflect	_	
183-24	34208-34211	the	_	
183-25	34212-34216	same	_	
183-26	34217-34229	relationship	_	
183-27	34230-34233	for	_	
183-28	34234-34240	client	_	
183-29	34241-34249	language	_	
183-30	34250-34252	in	_	
183-31	34253-34258	favor	_	
183-32	34259-34261	of	_	
183-33	34262-34269	staying	_	
183-34	34270-34273	the	_	
183-35	34274-34278	same	_	
183-36	34279-34280	(	_	
183-37	34280-34287	sustain	_	
183-38	34288-34292	talk	_	
183-39	34292-34293	)	_	
183-40	34293-34294	.	_	

#Text=In other words, while the functional connectivity maps for change talk and sustain talk looked similar in terms of strength, direction, and location, only one type of client language was significantly associated with post-treatment behavior change: change talk.
184-1	34295-34297	In	_	
184-2	34298-34303	other	_	
184-3	34304-34309	words	_	
184-4	34309-34310	,	_	
184-5	34311-34316	while	_	
184-6	34317-34320	the	_	
184-7	34321-34331	functional	_	
184-8	34332-34344	connectivity	_	
184-9	34345-34349	maps	_	
184-10	34350-34353	for	_	
184-11	34354-34360	change	_	
184-12	34361-34365	talk	_	
184-13	34366-34369	and	_	
184-14	34370-34377	sustain	_	
184-15	34378-34382	talk	_	
184-16	34383-34389	looked	_	
184-17	34390-34397	similar	_	
184-18	34398-34400	in	_	
184-19	34401-34406	terms	_	
184-20	34407-34409	of	_	
184-21	34410-34418	strength	_	
184-22	34418-34419	,	_	
184-23	34420-34429	direction	_	
184-24	34429-34430	,	_	
184-25	34431-34434	and	_	
184-26	34435-34443	location	_	
184-27	34443-34444	,	_	
184-28	34445-34449	only	_	
184-29	34450-34453	one	_	
184-30	34454-34458	type	_	
184-31	34459-34461	of	_	
184-32	34462-34468	client	_	
184-33	34469-34477	language	_	
184-34	34478-34481	was	_	
184-35	34482-34495	significantly	_	
184-36	34496-34506	associated	_	
184-37	34507-34511	with	_	
184-38	34512-34526	post-treatment	_	
184-39	34527-34535	behavior	_	
184-40	34536-34542	change	_	
184-41	34542-34543	:	_	
184-42	34544-34550	change	_	
184-43	34551-34555	talk	_	
184-44	34555-34556	.	_	

#Text=Clinically – this is a very interesting finding, and one that is highly informative in terms of guiding in-session clinician efforts.
185-1	34557-34567	Clinically	_	
185-2	34568-34569	–	_	
185-3	34570-34574	this	_	
185-4	34575-34577	is	_	
185-5	34578-34579	a	_	
185-6	34580-34584	very	_	
185-7	34585-34596	interesting	_	
185-8	34597-34604	finding	_	
185-9	34604-34605	,	_	
185-10	34606-34609	and	_	
185-11	34610-34613	one	_	
185-12	34614-34618	that	_	
185-13	34619-34621	is	_	
185-14	34622-34628	highly	_	
185-15	34629-34640	informative	_	
185-16	34641-34643	in	_	
185-17	34644-34649	terms	_	
185-18	34650-34652	of	_	
185-19	34653-34660	guiding	_	
185-20	34661-34671	in-session	_	
185-21	34672-34681	clinician	_	
185-22	34682-34689	efforts	_	
185-23	34689-34690	.	_	

#Text=In other words, even though these types of language (sustain talk and change talk) may be processed in the adolescent brain similarly, they are highly different in terms of clinical predictive validity; only change talk was associated with reductions in substance use .
186-1	34691-34693	In	_	
186-2	34694-34699	other	_	
186-3	34700-34705	words	_	
186-4	34705-34706	,	_	
186-5	34707-34711	even	_	
186-6	34712-34718	though	_	
186-7	34719-34724	these	_	
186-8	34725-34730	types	_	
186-9	34731-34733	of	_	
186-10	34734-34742	language	_	
186-11	34743-34744	(	_	
186-12	34744-34751	sustain	_	
186-13	34752-34756	talk	_	
186-14	34757-34760	and	_	
186-15	34761-34767	change	_	
186-16	34768-34772	talk	_	
186-17	34772-34773	)	_	
186-18	34774-34777	may	_	
186-19	34778-34780	be	_	
186-20	34781-34790	processed	_	
186-21	34791-34793	in	_	
186-22	34794-34797	the	_	
186-23	34798-34808	adolescent	_	
186-24	34809-34814	brain	_	
186-25	34815-34824	similarly	_	
186-26	34824-34825	,	_	
186-27	34826-34830	they	_	
186-28	34831-34834	are	_	
186-29	34835-34841	highly	_	
186-30	34842-34851	different	_	
186-31	34852-34854	in	_	
186-32	34855-34860	terms	_	
186-33	34861-34863	of	_	
186-34	34864-34872	clinical	_	
186-35	34873-34883	predictive	_	
186-36	34884-34892	validity	_	
186-37	34892-34893	;	_	
186-38	34894-34898	only	_	
186-39	34899-34905	change	_	
186-40	34906-34910	talk	_	
186-41	34911-34914	was	_	
186-42	34915-34925	associated	_	
186-43	34926-34930	with	_	
186-44	34931-34941	reductions	_	
186-45	34942-34944	in	_	
186-46	34945-34954	substance	_	
186-47	34955-34958	use	_	
186-48	34959-34960	.	_	

#Text=This is a real-world tangible difference that is relevant for clinicians, as it continues to indicate the importance of eliciting and bolstering client statements in favor of change during in-session clinical exchanges; these exchanges may be predictive of true, real-world, behavior change.
187-1	34961-34965	This	_	
187-2	34966-34968	is	_	
187-3	34969-34970	a	_	
187-4	34971-34981	real-world	_	
187-5	34982-34990	tangible	_	
187-6	34991-35001	difference	_	
187-7	35002-35006	that	_	
187-8	35007-35009	is	_	
187-9	35010-35018	relevant	_	
187-10	35019-35022	for	_	
187-11	35023-35033	clinicians	_	
187-12	35033-35034	,	_	
187-13	35035-35037	as	_	
187-14	35038-35040	it	_	
187-15	35041-35050	continues	_	
187-16	35051-35053	to	_	
187-17	35054-35062	indicate	_	
187-18	35063-35066	the	_	
187-19	35067-35077	importance	_	
187-20	35078-35080	of	_	
187-21	35081-35090	eliciting	_	
187-22	35091-35094	and	_	
187-23	35095-35105	bolstering	_	
187-24	35106-35112	client	_	
187-25	35113-35123	statements	_	
187-26	35124-35126	in	_	
187-27	35127-35132	favor	_	
187-28	35133-35135	of	_	
187-29	35136-35142	change	_	
187-30	35143-35149	during	_	
187-31	35150-35160	in-session	_	
187-32	35161-35169	clinical	_	
187-33	35170-35179	exchanges	_	
187-34	35179-35180	;	_	
187-35	35181-35186	these	_	
187-36	35187-35196	exchanges	_	
187-37	35197-35200	may	_	
187-38	35201-35203	be	_	
187-39	35204-35214	predictive	_	
187-40	35215-35217	of	_	
187-41	35218-35222	true	_	
187-42	35222-35223	,	_	
187-43	35224-35234	real-world	_	
187-44	35234-35235	,	_	
187-45	35236-35244	behavior	_	
187-46	35245-35251	change	_	
187-47	35251-35252	.	_	

#Text=One additional element that is compelling to consider in this equation is the dyadic and social role of the therapeutic exchange.
188-1	35253-35256	One	_	
188-2	35257-35267	additional	_	
188-3	35268-35275	element	_	
188-4	35276-35280	that	_	
188-5	35281-35283	is	_	
188-6	35284-35294	compelling	_	
188-7	35295-35297	to	_	
188-8	35298-35306	consider	_	
188-9	35307-35309	in	_	
188-10	35310-35314	this	_	
188-11	35315-35323	equation	_	
188-12	35324-35326	is	_	
188-13	35327-35330	the	_	
188-14	35331-35337	dyadic	_	
188-15	35338-35341	and	_	
188-16	35342-35348	social	_	
188-17	35349-35353	role	_	
188-18	35354-35356	of	_	
188-19	35357-35360	the	_	
188-20	35361-35372	therapeutic	_	
188-21	35373-35381	exchange	_	
188-22	35381-35382	.	_	

#Text=Emerging studies have suggested that functional coupling between ACC and frontal cortex corresponds with less efficient inhibitory processing .
189-1	35383-35391	Emerging	_	
189-2	35392-35399	studies	_	
189-3	35400-35404	have	_	
189-4	35405-35414	suggested	_	
189-5	35415-35419	that	_	
189-6	35420-35430	functional	_	
189-7	35431-35439	coupling	_	
189-8	35440-35447	between	_	
189-9	35448-35451	ACC	_	
189-10	35452-35455	and	_	
189-11	35456-35463	frontal	_	
189-12	35464-35470	cortex	_	
189-13	35471-35482	corresponds	_	
189-14	35483-35487	with	_	
189-15	35488-35492	less	_	
189-16	35493-35502	efficient	_	
189-17	35503-35513	inhibitory	_	
189-18	35514-35524	processing	_	
189-19	35525-35526	.	_	

#Text=This is relevant because the anterior cingulate has been implicated in social processing, including for cannabis users .
190-1	35527-35531	This	_	
190-2	35532-35534	is	_	
190-3	35535-35543	relevant	_	
190-4	35544-35551	because	_	
190-5	35552-35555	the	_	
190-6	35556-35564	anterior	_	
190-7	35565-35574	cingulate	_	
190-8	35575-35578	has	_	
190-9	35579-35583	been	_	
190-10	35584-35594	implicated	_	
190-11	35595-35597	in	_	
190-12	35598-35604	social	_	
190-13	35605-35615	processing	_	
190-14	35615-35616	,	_	
190-15	35617-35626	including	_	
190-16	35627-35630	for	_	
190-17	35631-35639	cannabis	_	
190-18	35640-35645	users	_	
190-19	35646-35647	.	_	

#Text=Further, the connection between frontal and cingulate cortical regions has also been involved in children’s neural processing of feedback from their parents ; similar substrates are likely to be involved in clinical, dyadic exchanges with a therapist.
191-1	35648-35655	Further	_	
191-2	35655-35656	,	_	
191-3	35657-35660	the	_	
191-4	35661-35671	connection	_	
191-5	35672-35679	between	_	
191-6	35680-35687	frontal	_	
191-7	35688-35691	and	_	
191-8	35692-35701	cingulate	_	
191-9	35702-35710	cortical	_	
191-10	35711-35718	regions	_	
191-11	35719-35722	has	_	
191-12	35723-35727	also	_	
191-13	35728-35732	been	_	
191-14	35733-35741	involved	_	
191-15	35742-35744	in	_	
191-16	35745-35753	children	_	
191-17	35753-35754	’	_	
191-18	35754-35755	s	_	
191-19	35756-35762	neural	_	
191-20	35763-35773	processing	_	
191-21	35774-35776	of	_	
191-22	35777-35785	feedback	_	
191-23	35786-35790	from	_	
191-24	35791-35796	their	_	
191-25	35797-35804	parents	_	
191-26	35805-35806	;	_	
191-27	35807-35814	similar	_	
191-28	35815-35825	substrates	_	
191-29	35826-35829	are	_	
191-30	35830-35836	likely	_	
191-31	35837-35839	to	_	
191-32	35840-35842	be	_	
191-33	35843-35851	involved	_	
191-34	35852-35854	in	_	
191-35	35855-35863	clinical	_	
191-36	35863-35864	,	_	
191-37	35865-35871	dyadic	_	
191-38	35872-35881	exchanges	_	
191-39	35882-35886	with	_	
191-40	35887-35888	a	_	
191-41	35889-35898	therapist	_	
191-42	35898-35899	.	_	

#Text=Our final exploratory examination was on the degree of neural overlap with a small, de novo sample of adolescent alcohol users.
192-1	35900-35903	Our	_	
192-2	35904-35909	final	_	
192-3	35910-35921	exploratory	_	
192-4	35922-35933	examination	_	
192-5	35934-35937	was	_	
192-6	35938-35940	on	_	
192-7	35941-35944	the	_	
192-8	35945-35951	degree	_	
192-9	35952-35954	of	_	
192-10	35955-35961	neural	_	
192-11	35962-35969	overlap	_	
192-12	35970-35974	with	_	
192-13	35975-35976	a	_	
192-14	35977-35982	small	_	
192-15	35982-35983	,	_	
192-16	35984-35986	de	_	
192-17	35987-35991	novo	_	
192-18	35992-35998	sample	_	
192-19	35999-36001	of	_	
192-20	36002-36012	adolescent	_	
192-21	36013-36020	alcohol	_	
192-22	36021-36026	users	_	
192-23	36026-36027	.	_	

#Text=Importantly, while this comparison was limited by a small sample size, we did not observe any regions of overlapping connectivity for client language about change (change talk).
193-1	36028-36039	Importantly	_	
193-2	36039-36040	,	_	
193-3	36041-36046	while	_	
193-4	36047-36051	this	_	
193-5	36052-36062	comparison	_	
193-6	36063-36066	was	_	
193-7	36067-36074	limited	_	
193-8	36075-36077	by	_	
193-9	36078-36079	a	_	
193-10	36080-36085	small	_	
193-11	36086-36092	sample	_	
193-12	36093-36097	size	_	
193-13	36097-36098	,	_	
193-14	36099-36101	we	_	
193-15	36102-36105	did	_	
193-16	36106-36109	not	_	
193-17	36110-36117	observe	_	
193-18	36118-36121	any	_	
193-19	36122-36129	regions	_	
193-20	36130-36132	of	_	
193-21	36133-36144	overlapping	_	
193-22	36145-36157	connectivity	_	
193-23	36158-36161	for	_	
193-24	36162-36168	client	_	
193-25	36169-36177	language	_	
193-26	36178-36183	about	_	
193-27	36184-36190	change	_	
193-28	36191-36192	(	_	
193-29	36192-36198	change	_	
193-30	36199-36203	talk	_	
193-31	36203-36204	)	_	
193-32	36204-36205	.	_	

#Text=In contrast, in our supplemental exploration, we did observe areas of conjunction during client language about continuing their substance use (sustain talk) across the IFG, SMA, and superior frontal gyrus.
194-1	36206-36208	In	_	
194-2	36209-36217	contrast	_	
194-3	36217-36218	,	_	
194-4	36219-36221	in	_	
194-5	36222-36225	our	_	
194-6	36226-36238	supplemental	_	
194-7	36239-36250	exploration	_	
194-8	36250-36251	,	_	
194-9	36252-36254	we	_	
194-10	36255-36258	did	_	
194-11	36259-36266	observe	_	
194-12	36267-36272	areas	_	
194-13	36273-36275	of	_	
194-14	36276-36287	conjunction	_	
194-15	36288-36294	during	_	
194-16	36295-36301	client	_	
194-17	36302-36310	language	_	
194-18	36311-36316	about	_	
194-19	36317-36327	continuing	_	
194-20	36328-36333	their	_	
194-21	36334-36343	substance	_	
194-22	36344-36347	use	_	
194-23	36348-36349	(	_	
194-24	36349-36356	sustain	_	
194-25	36357-36361	talk	_	
194-26	36361-36362	)	_	
194-27	36363-36369	across	_	
194-28	36370-36373	the	_	
194-29	36374-36377	IFG	_	
194-30	36377-36378	,	_	
194-31	36379-36382	SMA	_	
194-32	36382-36383	,	_	
194-33	36384-36387	and	_	
194-34	36388-36396	superior	_	
194-35	36397-36404	frontal	_	
194-36	36405-36410	gyrus	_	
194-37	36410-36411	.	_	

#Text=While interpretation of these findings must be made with caution due to the very small sample size, these data serve as preliminary indication that within the adolescent brain, processes underlying or driving addiction (such as reasons for using) may be more common across substances of abuse, than potential reasons for changing.
195-1	36412-36417	While	_	
195-2	36418-36432	interpretation	_	
195-3	36433-36435	of	_	
195-4	36436-36441	these	_	
195-5	36442-36450	findings	_	
195-6	36451-36455	must	_	
195-7	36456-36458	be	_	
195-8	36459-36463	made	_	
195-9	36464-36468	with	_	
195-10	36469-36476	caution	_	
195-11	36477-36480	due	_	
195-12	36481-36483	to	_	
195-13	36484-36487	the	_	
195-14	36488-36492	very	_	
195-15	36493-36498	small	_	
195-16	36499-36505	sample	_	
195-17	36506-36510	size	_	
195-18	36510-36511	,	_	
195-19	36512-36517	these	_	
195-20	36518-36522	data	_	
195-21	36523-36528	serve	_	
195-22	36529-36531	as	_	
195-23	36532-36543	preliminary	_	
195-24	36544-36554	indication	_	
195-25	36555-36559	that	_	
195-26	36560-36566	within	_	
195-27	36567-36570	the	_	
195-28	36571-36581	adolescent	_	
195-29	36582-36587	brain	_	
195-30	36587-36588	,	_	
195-31	36589-36598	processes	_	
195-32	36599-36609	underlying	_	
195-33	36610-36612	or	_	
195-34	36613-36620	driving	_	
195-35	36621-36630	addiction	_	
195-36	36631-36632	(	_	
195-37	36632-36636	such	_	
195-38	36637-36639	as	_	
195-39	36640-36647	reasons	_	
195-40	36648-36651	for	_	
195-41	36652-36657	using	_	
195-42	36657-36658	)	_	
195-43	36659-36662	may	_	
195-44	36663-36665	be	_	
195-45	36666-36670	more	_	
195-46	36671-36677	common	_	
195-47	36678-36684	across	_	
195-48	36685-36695	substances	_	
195-49	36696-36698	of	_	
195-50	36699-36704	abuse	_	
195-51	36704-36705	,	_	
195-52	36706-36710	than	_	
195-53	36711-36720	potential	_	
195-54	36721-36728	reasons	_	
195-55	36729-36732	for	_	
195-56	36733-36741	changing	_	
195-57	36741-36742	.	_	

#Text=In contrast, it is possible that cognition and related connectivity around processing whether/how/why to change substance use, may be substance specific.
196-1	36743-36745	In	_	
196-2	36746-36754	contrast	_	
196-3	36754-36755	,	_	
196-4	36756-36758	it	_	
196-5	36759-36761	is	_	
196-6	36762-36770	possible	_	
196-7	36771-36775	that	_	
196-8	36776-36785	cognition	_	
196-9	36786-36789	and	_	
196-10	36790-36797	related	_	
196-11	36798-36810	connectivity	_	
196-12	36811-36817	around	_	
196-13	36818-36828	processing	_	
196-14	36829-36836	whether	_	
196-15	36836-36837	/	_	
196-16	36837-36840	how	_	
196-17	36840-36841	/	_	
196-18	36841-36844	why	_	
196-19	36845-36847	to	_	
196-20	36848-36854	change	_	
196-21	36855-36864	substance	_	
196-22	36865-36868	use	_	
196-23	36868-36869	,	_	
196-24	36870-36873	may	_	
196-25	36874-36876	be	_	
196-26	36877-36886	substance	_	
196-27	36887-36895	specific	_	
196-28	36895-36896	.	_	

#Text=We will continue to examine these relationships in larger, more fully powered samples to get more definitive answers regarding these thought-provoking possibilities.
197-1	36897-36899	We	_	
197-2	36900-36904	will	_	
197-3	36905-36913	continue	_	
197-4	36914-36916	to	_	
197-5	36917-36924	examine	_	
197-6	36925-36930	these	_	
197-7	36931-36944	relationships	_	
197-8	36945-36947	in	_	
197-9	36948-36954	larger	_	
197-10	36954-36955	,	_	
197-11	36956-36960	more	_	
197-12	36961-36966	fully	_	
197-13	36967-36974	powered	_	
197-14	36975-36982	samples	_	
197-15	36983-36985	to	_	
197-16	36986-36989	get	_	
197-17	36990-36994	more	_	
197-18	36995-37005	definitive	_	
197-19	37006-37013	answers	_	
197-20	37014-37023	regarding	_	
197-21	37024-37029	these	_	
197-22	37030-37047	thought-provoking	_	
197-23	37048-37061	possibilities	_	
197-24	37061-37062	.	_	

#Text=In terms of clinical relevance, the next question is how these data may translate to the treatment context.
198-1	37063-37065	In	_	
198-2	37066-37071	terms	_	
198-3	37072-37074	of	_	
198-4	37075-37083	clinical	_	
198-5	37084-37093	relevance	_	
198-6	37093-37094	,	_	
198-7	37095-37098	the	_	
198-8	37099-37103	next	_	
198-9	37104-37112	question	_	
198-10	37113-37115	is	_	
198-11	37116-37119	how	_	
198-12	37120-37125	these	_	
198-13	37126-37130	data	_	
198-14	37131-37134	may	_	
198-15	37135-37144	translate	_	
198-16	37145-37147	to	_	
198-17	37148-37151	the	_	
198-18	37152-37161	treatment	_	
198-19	37162-37169	context	_	
198-20	37169-37170	.	_	

#Text=Based on advances in the field of translational “bench-to-bedside” science , there are two different avenues through which these data could inform direct care.
199-1	37171-37176	Based	_	
199-2	37177-37179	on	_	
199-3	37180-37188	advances	_	
199-4	37189-37191	in	_	
199-5	37192-37195	the	_	
199-6	37196-37201	field	_	
199-7	37202-37204	of	_	
199-8	37205-37218	translational	_	
199-9	37219-37220	“	_	
199-10	37220-37236	bench-to-bedside	_	
199-11	37236-37237	”	_	
199-12	37238-37245	science	_	
199-13	37246-37247	,	_	
199-14	37248-37253	there	_	
199-15	37254-37257	are	_	
199-16	37258-37261	two	_	
199-17	37262-37271	different	_	
199-18	37272-37279	avenues	_	
199-19	37280-37287	through	_	
199-20	37288-37293	which	_	
199-21	37294-37299	these	_	
199-22	37300-37304	data	_	
199-23	37305-37310	could	_	
199-24	37311-37317	inform	_	
199-25	37318-37324	direct	_	
199-26	37325-37329	care	_	
199-27	37329-37330	.	_	

#Text=One is by evaluating the strength of the role of the OFC network as a predictor of treatment response.
200-1	37331-37334	One	_	
200-2	37335-37337	is	_	
200-3	37338-37340	by	_	
200-4	37341-37351	evaluating	_	
200-5	37352-37355	the	_	
200-6	37356-37364	strength	_	
200-7	37365-37367	of	_	
200-8	37368-37371	the	_	
200-9	37372-37376	role	_	
200-10	37377-37379	of	_	
200-11	37380-37383	the	_	
200-12	37384-37387	OFC	_	
200-13	37388-37395	network	_	
200-14	37396-37398	as	_	
200-15	37399-37400	a	_	
200-16	37401-37410	predictor	_	
200-17	37411-37413	of	_	
200-18	37414-37423	treatment	_	
200-19	37424-37432	response	_	
200-20	37432-37433	.	_	

#Text=Emerging studies with adults and adolescents suggest that brain markers may represent more sensitive and powerful metrics of clinical symptoms and behavior change .
201-1	37434-37442	Emerging	_	
201-2	37443-37450	studies	_	
201-3	37451-37455	with	_	
201-4	37456-37462	adults	_	
201-5	37463-37466	and	_	
201-6	37467-37478	adolescents	_	
201-7	37479-37486	suggest	_	
201-8	37487-37491	that	_	
201-9	37492-37497	brain	_	
201-10	37498-37505	markers	_	
201-11	37506-37509	may	_	
201-12	37510-37519	represent	_	
201-13	37520-37524	more	_	
201-14	37525-37534	sensitive	_	
201-15	37535-37538	and	_	
201-16	37539-37547	powerful	_	
201-17	37548-37555	metrics	_	
201-18	37556-37558	of	_	
201-19	37559-37567	clinical	_	
201-20	37568-37576	symptoms	_	
201-21	37577-37580	and	_	
201-22	37581-37589	behavior	_	
201-23	37590-37596	change	_	
201-24	37597-37598	.	_	

#Text=A second role for the use of neural metrics is to continue to examine different facets of behavior change .
202-1	37599-37600	A	_	
202-2	37601-37607	second	_	
202-3	37608-37612	role	_	
202-4	37613-37616	for	_	
202-5	37617-37620	the	_	
202-6	37621-37624	use	_	
202-7	37625-37627	of	_	
202-8	37628-37634	neural	_	
202-9	37635-37642	metrics	_	
202-10	37643-37645	is	_	
202-11	37646-37648	to	_	
202-12	37649-37657	continue	_	
202-13	37658-37660	to	_	
202-14	37661-37668	examine	_	
202-15	37669-37678	different	_	
202-16	37679-37685	facets	_	
202-17	37686-37688	of	_	
202-18	37689-37697	behavior	_	
202-19	37698-37704	change	_	
202-20	37705-37706	.	_	

#Text=This is still very much at the cutting edge, with an increasing number of studies examining how to integrate neural parameters into clinical trials.
203-1	37707-37711	This	_	
203-2	37712-37714	is	_	
203-3	37715-37720	still	_	
203-4	37721-37725	very	_	
203-5	37726-37730	much	_	
203-6	37731-37733	at	_	
203-7	37734-37737	the	_	
203-8	37738-37745	cutting	_	
203-9	37746-37750	edge	_	
203-10	37750-37751	,	_	
203-11	37752-37756	with	_	
203-12	37757-37759	an	_	
203-13	37760-37770	increasing	_	
203-14	37771-37777	number	_	
203-15	37778-37780	of	_	
203-16	37781-37788	studies	_	
203-17	37789-37798	examining	_	
203-18	37799-37802	how	_	
203-19	37803-37805	to	_	
203-20	37806-37815	integrate	_	
203-21	37816-37822	neural	_	
203-22	37823-37833	parameters	_	
203-23	37834-37838	into	_	
203-24	37839-37847	clinical	_	
203-25	37848-37854	trials	_	
203-26	37854-37855	.	_	

#Text=However, it is our position that this approach is scientifically savvy; if we can continue to identify which neural mechanisms underlie positive behavior change, we can then take steps to strengthen those treatment elements in our clinical approaches .
204-1	37856-37863	However	_	
204-2	37863-37864	,	_	
204-3	37865-37867	it	_	
204-4	37868-37870	is	_	
204-5	37871-37874	our	_	
204-6	37875-37883	position	_	
204-7	37884-37888	that	_	
204-8	37889-37893	this	_	
204-9	37894-37902	approach	_	
204-10	37903-37905	is	_	
204-11	37906-37920	scientifically	_	
204-12	37921-37926	savvy	_	
204-13	37926-37927	;	_	
204-14	37928-37930	if	_	
204-15	37931-37933	we	_	
204-16	37934-37937	can	_	
204-17	37938-37946	continue	_	
204-18	37947-37949	to	_	
204-19	37950-37958	identify	_	
204-20	37959-37964	which	_	
204-21	37965-37971	neural	_	
204-22	37972-37982	mechanisms	_	
204-23	37983-37991	underlie	_	
204-24	37992-38000	positive	_	
204-25	38001-38009	behavior	_	
204-26	38010-38016	change	_	
204-27	38016-38017	,	_	
204-28	38018-38020	we	_	
204-29	38021-38024	can	_	
204-30	38025-38029	then	_	
204-31	38030-38034	take	_	
204-32	38035-38040	steps	_	
204-33	38041-38043	to	_	
204-34	38044-38054	strengthen	_	
204-35	38055-38060	those	_	
204-36	38061-38070	treatment	_	
204-37	38071-38079	elements	_	
204-38	38080-38082	in	_	
204-39	38083-38086	our	_	
204-40	38087-38095	clinical	_	
204-41	38096-38106	approaches	_	
204-42	38107-38108	.	_	

#Text=Limitations and Conclusions
#Text=While there are notable strengths to the current study, including the novel use of in-session client language to better understand brain networks during the psychotherapeutic exchange and their relation to behavior change, the following limitations warrant consideration.
205-1	38109-38120	Limitations	_	
205-2	38121-38124	and	_	
205-3	38125-38136	Conclusions	_	
205-4	38137-38142	While	_	
205-5	38143-38148	there	_	
205-6	38149-38152	are	_	
205-7	38153-38160	notable	_	
205-8	38161-38170	strengths	_	
205-9	38171-38173	to	_	
205-10	38174-38177	the	_	
205-11	38178-38185	current	_	
205-12	38186-38191	study	_	
205-13	38191-38192	,	_	
205-14	38193-38202	including	_	
205-15	38203-38206	the	_	
205-16	38207-38212	novel	_	
205-17	38213-38216	use	_	
205-18	38217-38219	of	_	
205-19	38220-38230	in-session	_	
205-20	38231-38237	client	_	
205-21	38238-38246	language	_	
205-22	38247-38249	to	_	
205-23	38250-38256	better	_	
205-24	38257-38267	understand	_	
205-25	38268-38273	brain	_	
205-26	38274-38282	networks	_	
205-27	38283-38289	during	_	
205-28	38290-38293	the	_	
205-29	38294-38311	psychotherapeutic	_	
205-30	38312-38320	exchange	_	
205-31	38321-38324	and	_	
205-32	38325-38330	their	_	
205-33	38331-38339	relation	_	
205-34	38340-38342	to	_	
205-35	38343-38351	behavior	_	
205-36	38352-38358	change	_	
205-37	38358-38359	,	_	
205-38	38360-38363	the	_	
205-39	38364-38373	following	_	
205-40	38374-38385	limitations	_	
205-41	38386-38393	warrant	_	
205-42	38394-38407	consideration	_	
205-43	38407-38408	.	_	

#Text=First, and most importantly, while advances are being made in this direction, it is still not possible to conduct behavioral interventions in the MRI; an in vivo, temporal evaluation of these relationships represents an important next step in understanding these data.
206-1	38409-38414	First	_	
206-2	38414-38415	,	_	
206-3	38416-38419	and	_	
206-4	38420-38424	most	_	
206-5	38425-38436	importantly	_	
206-6	38436-38437	,	_	
206-7	38438-38443	while	_	
206-8	38444-38452	advances	_	
206-9	38453-38456	are	_	
206-10	38457-38462	being	_	
206-11	38463-38467	made	_	
206-12	38468-38470	in	_	
206-13	38471-38475	this	_	
206-14	38476-38485	direction	_	
206-15	38485-38486	,	_	
206-16	38487-38489	it	_	
206-17	38490-38492	is	_	
206-18	38493-38498	still	_	
206-19	38499-38502	not	_	
206-20	38503-38511	possible	_	
206-21	38512-38514	to	_	
206-22	38515-38522	conduct	_	
206-23	38523-38533	behavioral	_	
206-24	38534-38547	interventions	_	
206-25	38548-38550	in	_	
206-26	38551-38554	the	_	
206-27	38555-38558	MRI	_	
206-28	38558-38559	;	_	
206-29	38560-38562	an	_	
206-30	38563-38565	in	_	
206-31	38566-38570	vivo	_	
206-32	38570-38571	,	_	
206-33	38572-38580	temporal	_	
206-34	38581-38591	evaluation	_	
206-35	38592-38594	of	_	
206-36	38595-38600	these	_	
206-37	38601-38614	relationships	_	
206-38	38615-38625	represents	_	
206-39	38626-38628	an	_	
206-40	38629-38638	important	_	
206-41	38639-38643	next	_	
206-42	38644-38648	step	_	
206-43	38649-38651	in	_	
206-44	38652-38665	understanding	_	
206-45	38666-38671	these	_	
206-46	38672-38676	data	_	
206-47	38676-38677	.	_	

#Text=Second, the binge drinking sample was a pilot study with a small sample size; we are currently conducting a larger study which will allow us to better parse out auditory and narrative components of the task for added specificity of findings.
207-1	38678-38684	Second	_	
207-2	38684-38685	,	_	
207-3	38686-38689	the	_	
207-4	38690-38695	binge	_	
207-5	38696-38704	drinking	_	
207-6	38705-38711	sample	_	
207-7	38712-38715	was	_	
207-8	38716-38717	a	_	
207-9	38718-38723	pilot	_	
207-10	38724-38729	study	_	
207-11	38730-38734	with	_	
207-12	38735-38736	a	_	
207-13	38737-38742	small	_	
207-14	38743-38749	sample	_	
207-15	38750-38754	size	_	
207-16	38754-38755	;	_	
207-17	38756-38758	we	_	
207-18	38759-38762	are	_	
207-19	38763-38772	currently	_	
207-20	38773-38783	conducting	_	
207-21	38784-38785	a	_	
207-22	38786-38792	larger	_	
207-23	38793-38798	study	_	
207-24	38799-38804	which	_	
207-25	38805-38809	will	_	
207-26	38810-38815	allow	_	
207-27	38816-38818	us	_	
207-28	38819-38821	to	_	
207-29	38822-38828	better	_	
207-30	38829-38834	parse	_	
207-31	38835-38838	out	_	
207-32	38839-38847	auditory	_	
207-33	38848-38851	and	_	
207-34	38852-38861	narrative	_	
207-35	38862-38872	components	_	
207-36	38873-38875	of	_	
207-37	38876-38879	the	_	
207-38	38880-38884	task	_	
207-39	38885-38888	for	_	
207-40	38889-38894	added	_	
207-41	38895-38906	specificity	_	
207-42	38907-38909	of	_	
207-43	38910-38918	findings	_	
207-44	38918-38919	.	_	

#Text=Replication of the conjunction analysis with this larger sample will help strengthen study findings, and allow for additional exploration into potential age and gender differences in neural networks and treatment response.
208-1	38920-38931	Replication	_	
208-2	38932-38934	of	_	
208-3	38935-38938	the	_	
208-4	38939-38950	conjunction	_	
208-5	38951-38959	analysis	_	
208-6	38960-38964	with	_	
208-7	38965-38969	this	_	
208-8	38970-38976	larger	_	
208-9	38977-38983	sample	_	
208-10	38984-38988	will	_	
208-11	38989-38993	help	_	
208-12	38994-39004	strengthen	_	
208-13	39005-39010	study	_	
208-14	39011-39019	findings	_	
208-15	39019-39020	,	_	
208-16	39021-39024	and	_	
208-17	39025-39030	allow	_	
208-18	39031-39034	for	_	
208-19	39035-39045	additional	_	
208-20	39046-39057	exploration	_	
208-21	39058-39062	into	_	
208-22	39063-39072	potential	_	
208-23	39073-39076	age	_	
208-24	39077-39080	and	_	
208-25	39081-39087	gender	_	
208-26	39088-39099	differences	_	
208-27	39100-39102	in	_	
208-28	39103-39109	neural	_	
208-29	39110-39118	networks	_	
208-30	39119-39122	and	_	
208-31	39123-39132	treatment	_	
208-32	39133-39141	response	_	
208-33	39141-39142	.	_	

#Text=Third, in line with standard protocols in adolescent addiction treatment studies , there was no healthy control group in this study; this is because the sample needed to have adequate levels of substance abuse in order to be able to potentially detect behavior change in post-treatment substance use patterns.
209-1	39143-39148	Third	_	
209-2	39148-39149	,	_	
209-3	39150-39152	in	_	
209-4	39153-39157	line	_	
209-5	39158-39162	with	_	
209-6	39163-39171	standard	_	
209-7	39172-39181	protocols	_	
209-8	39182-39184	in	_	
209-9	39185-39195	adolescent	_	
209-10	39196-39205	addiction	_	
209-11	39206-39215	treatment	_	
209-12	39216-39223	studies	_	
209-13	39224-39225	,	_	
209-14	39226-39231	there	_	
209-15	39232-39235	was	_	
209-16	39236-39238	no	_	
209-17	39239-39246	healthy	_	
209-18	39247-39254	control	_	
209-19	39255-39260	group	_	
209-20	39261-39263	in	_	
209-21	39264-39268	this	_	
209-22	39269-39274	study	_	
209-23	39274-39275	;	_	
209-24	39276-39280	this	_	
209-25	39281-39283	is	_	
209-26	39284-39291	because	_	
209-27	39292-39295	the	_	
209-28	39296-39302	sample	_	
209-29	39303-39309	needed	_	
209-30	39310-39312	to	_	
209-31	39313-39317	have	_	
209-32	39318-39326	adequate	_	
209-33	39327-39333	levels	_	
209-34	39334-39336	of	_	
209-35	39337-39346	substance	_	
209-36	39347-39352	abuse	_	
209-37	39353-39355	in	_	
209-38	39356-39361	order	_	
209-39	39362-39364	to	_	
209-40	39365-39367	be	_	
209-41	39368-39372	able	_	
209-42	39373-39375	to	_	
209-43	39376-39387	potentially	_	
209-44	39388-39394	detect	_	
209-45	39395-39403	behavior	_	
209-46	39404-39410	change	_	
209-47	39411-39413	in	_	
209-48	39414-39428	post-treatment	_	
209-49	39429-39438	substance	_	
209-50	39439-39442	use	_	
209-51	39443-39451	patterns	_	
209-52	39451-39452	.	_	

#Text=In other words, it would not be possible for participants to show behavior change (e.g., reduction in potential substance use) if they began as a non-user.
210-1	39453-39455	In	_	
210-2	39456-39461	other	_	
210-3	39462-39467	words	_	
210-4	39467-39468	,	_	
210-5	39469-39471	it	_	
210-6	39472-39477	would	_	
210-7	39478-39481	not	_	
210-8	39482-39484	be	_	
210-9	39485-39493	possible	_	
210-10	39494-39497	for	_	
210-11	39498-39510	participants	_	
210-12	39511-39513	to	_	
210-13	39514-39518	show	_	
210-14	39519-39527	behavior	_	
210-15	39528-39534	change	_	
210-16	39535-39536	(	_	
210-17	39536-39539	e.g	_	
210-18	39539-39540	.	_	
210-19	39540-39541	,	_	
210-20	39542-39551	reduction	_	
210-21	39552-39554	in	_	
210-22	39555-39564	potential	_	
210-23	39565-39574	substance	_	
210-24	39575-39578	use	_	
210-25	39578-39579	)	_	
210-26	39580-39582	if	_	
210-27	39583-39587	they	_	
210-28	39588-39593	began	_	
210-29	39594-39596	as	_	
210-30	39597-39598	a	_	
210-31	39599-39607	non-user	_	
210-32	39607-39608	.	_	

#Text=Fourth, while client change talk was the focus of this investigation, we included the results for the sustain talk condition in the supplemental analyses; compellingly, these data support that the relationship between OFC network response for client language and treatment outcomes was specific to change talk only.
211-1	39609-39615	Fourth	_	
211-2	39615-39616	,	_	
211-3	39617-39622	while	_	
211-4	39623-39629	client	_	
211-5	39630-39636	change	_	
211-6	39637-39641	talk	_	
211-7	39642-39645	was	_	
211-8	39646-39649	the	_	
211-9	39650-39655	focus	_	
211-10	39656-39658	of	_	
211-11	39659-39663	this	_	
211-12	39664-39677	investigation	_	
211-13	39677-39678	,	_	
211-14	39679-39681	we	_	
211-15	39682-39690	included	_	
211-16	39691-39694	the	_	
211-17	39695-39702	results	_	
211-18	39703-39706	for	_	
211-19	39707-39710	the	_	
211-20	39711-39718	sustain	_	
211-21	39719-39723	talk	_	
211-22	39724-39733	condition	_	
211-23	39734-39736	in	_	
211-24	39737-39740	the	_	
211-25	39741-39753	supplemental	_	
211-26	39754-39762	analyses	_	
211-27	39762-39763	;	_	
211-28	39764-39776	compellingly	_	
211-29	39776-39777	,	_	
211-30	39778-39783	these	_	
211-31	39784-39788	data	_	
211-32	39789-39796	support	_	
211-33	39797-39801	that	_	
211-34	39802-39805	the	_	
211-35	39806-39818	relationship	_	
211-36	39819-39826	between	_	
211-37	39827-39830	OFC	_	
211-38	39831-39838	network	_	
211-39	39839-39847	response	_	
211-40	39848-39851	for	_	
211-41	39852-39858	client	_	
211-42	39859-39867	language	_	
211-43	39868-39871	and	_	
211-44	39872-39881	treatment	_	
211-45	39882-39890	outcomes	_	
211-46	39891-39894	was	_	
211-47	39895-39903	specific	_	
211-48	39904-39906	to	_	
211-49	39907-39913	change	_	
211-50	39914-39918	talk	_	
211-51	39919-39923	only	_	
211-52	39923-39924	.	_	

#Text=No relationship was observed between sustain talk and client treatment outcomes.
212-1	39925-39927	No	_	
212-2	39928-39940	relationship	_	
212-3	39941-39944	was	_	
212-4	39945-39953	observed	_	
212-5	39954-39961	between	_	
212-6	39962-39969	sustain	_	
212-7	39970-39974	talk	_	
212-8	39975-39978	and	_	
212-9	39979-39985	client	_	
212-10	39986-39995	treatment	_	
212-11	39996-40004	outcomes	_	
212-12	40004-40005	.	_	

#Text=However, future work will examine in greater depth the relationship between change talk vs. sustain talk, in order to disentangle the relationship between treatment elements, neural network response, and treatment outcomes for adolescents.
213-1	40006-40013	However	_	
213-2	40013-40014	,	_	
213-3	40015-40021	future	_	
213-4	40022-40026	work	_	
213-5	40027-40031	will	_	
213-6	40032-40039	examine	_	
213-7	40040-40042	in	_	
213-8	40043-40050	greater	_	
213-9	40051-40056	depth	_	
213-10	40057-40060	the	_	
213-11	40061-40073	relationship	_	
213-12	40074-40081	between	_	
213-13	40082-40088	change	_	
213-14	40089-40093	talk	_	
213-15	40094-40096	vs	_	
213-16	40096-40097	.	_	
213-17	40098-40105	sustain	_	
213-18	40106-40110	talk	_	
213-19	40110-40111	,	_	
213-20	40112-40114	in	_	
213-21	40115-40120	order	_	
213-22	40121-40123	to	_	
213-23	40124-40135	disentangle	_	
213-24	40136-40139	the	_	
213-25	40140-40152	relationship	_	
213-26	40153-40160	between	_	
213-27	40161-40170	treatment	_	
213-28	40171-40179	elements	_	
213-29	40179-40180	,	_	
213-30	40181-40187	neural	_	
213-31	40188-40195	network	_	
213-32	40196-40204	response	_	
213-33	40204-40205	,	_	
213-34	40206-40209	and	_	
213-35	40210-40219	treatment	_	
213-36	40220-40228	outcomes	_	
213-37	40229-40232	for	_	
213-38	40233-40244	adolescents	_	
213-39	40244-40245	.	_	

#Text=Fifth, we acknowledge that head movement in the scanner during fMRI data acquisition can cause artifacts.
214-1	40246-40251	Fifth	_	
214-2	40251-40252	,	_	
214-3	40253-40255	we	_	
214-4	40256-40267	acknowledge	_	
214-5	40268-40272	that	_	
214-6	40273-40277	head	_	
214-7	40278-40286	movement	_	
214-8	40287-40289	in	_	
214-9	40290-40293	the	_	
214-10	40294-40301	scanner	_	
214-11	40302-40308	during	_	
214-12	40309-40313	fMRI	_	
214-13	40314-40318	data	_	
214-14	40319-40330	acquisition	_	
214-15	40331-40334	can	_	
214-16	40335-40340	cause	_	
214-17	40341-40350	artifacts	_	
214-18	40350-40351	.	_	

#Text=Although task-based fMRI data is less systematically affected by very low amplitude head movements, we utilized several strategies to minimize head movement during data collection (e.g., mock scanner motion training, foam padding) as well as approaches to assess data quality and account for motion during processing and analysis (regressing motion estimates and other nuisance regressors).
215-1	40352-40360	Although	_	
215-2	40361-40371	task-based	_	
215-3	40372-40376	fMRI	_	
215-4	40377-40381	data	_	
215-5	40382-40384	is	_	
215-6	40385-40389	less	_	
215-7	40390-40404	systematically	_	
215-8	40405-40413	affected	_	
215-9	40414-40416	by	_	
215-10	40417-40421	very	_	
215-11	40422-40425	low	_	
215-12	40426-40435	amplitude	_	
215-13	40436-40440	head	_	
215-14	40441-40450	movements	_	
215-15	40450-40451	,	_	
215-16	40452-40454	we	_	
215-17	40455-40463	utilized	_	
215-18	40464-40471	several	_	
215-19	40472-40482	strategies	_	
215-20	40483-40485	to	_	
215-21	40486-40494	minimize	_	
215-22	40495-40499	head	_	
215-23	40500-40508	movement	_	
215-24	40509-40515	during	_	
215-25	40516-40520	data	_	
215-26	40521-40531	collection	_	
215-27	40532-40533	(	_	
215-28	40533-40536	e.g	_	
215-29	40536-40537	.	_	
215-30	40537-40538	,	_	
215-31	40539-40543	mock	_	
215-32	40544-40551	scanner	_	
215-33	40552-40558	motion	_	
215-34	40559-40567	training	_	
215-35	40567-40568	,	_	
215-36	40569-40573	foam	_	
215-37	40574-40581	padding	_	
215-38	40581-40582	)	_	
215-39	40583-40585	as	_	
215-40	40586-40590	well	_	
215-41	40591-40593	as	_	
215-42	40594-40604	approaches	_	
215-43	40605-40607	to	_	
215-44	40608-40614	assess	_	
215-45	40615-40619	data	_	
215-46	40620-40627	quality	_	
215-47	40628-40631	and	_	
215-48	40632-40639	account	_	
215-49	40640-40643	for	_	
215-50	40644-40650	motion	_	
215-51	40651-40657	during	_	
215-52	40658-40668	processing	_	
215-53	40669-40672	and	_	
215-54	40673-40681	analysis	_	
215-55	40682-40683	(	_	
215-56	40683-40693	regressing	_	
215-57	40694-40700	motion	_	
215-58	40701-40710	estimates	_	
215-59	40711-40714	and	_	
215-60	40715-40720	other	_	
215-61	40721-40729	nuisance	_	
215-62	40730-40740	regressors	_	
215-63	40740-40741	)	_	
215-64	40741-40742	.	_	

#Text=Further, tests of motion correlates did not indicate greater motion during change talk relative to sustain talk; together, our observed effects in the presence of sub-millimeter motion suggests that these significant findings are robust.
216-1	40743-40750	Further	_	
216-2	40750-40751	,	_	
216-3	40752-40757	tests	_	
216-4	40758-40760	of	_	
216-5	40761-40767	motion	_	
216-6	40768-40778	correlates	_	
216-7	40779-40782	did	_	
216-8	40783-40786	not	_	
216-9	40787-40795	indicate	_	
216-10	40796-40803	greater	_	
216-11	40804-40810	motion	_	
216-12	40811-40817	during	_	
216-13	40818-40824	change	_	
216-14	40825-40829	talk	_	
216-15	40830-40838	relative	_	
216-16	40839-40841	to	_	
216-17	40842-40849	sustain	_	
216-18	40850-40854	talk	_	
216-19	40854-40855	;	_	
216-20	40856-40864	together	_	
216-21	40864-40865	,	_	
216-22	40866-40869	our	_	
216-23	40870-40878	observed	_	
216-24	40879-40886	effects	_	
216-25	40887-40889	in	_	
216-26	40890-40893	the	_	
216-27	40894-40902	presence	_	
216-28	40903-40905	of	_	
216-29	40906-40920	sub-millimeter	_	
216-30	40921-40927	motion	_	
216-31	40928-40936	suggests	_	
216-32	40937-40941	that	_	
216-33	40942-40947	these	_	
216-34	40948-40959	significant	_	
216-35	40960-40968	findings	_	
216-36	40969-40972	are	_	
216-37	40973-40979	robust	_	
216-38	40979-40980	.	_	

#Text=Finally, we suggest understanding networks of neural response is useful in that it offers a creative and innovative approach to accelerate discovery of critical neural mechanisms.
217-1	40981-40988	Finally	_	
217-2	40988-40989	,	_	
217-3	40990-40992	we	_	
217-4	40993-41000	suggest	_	
217-5	41001-41014	understanding	_	
217-6	41015-41023	networks	_	
217-7	41024-41026	of	_	
217-8	41027-41033	neural	_	
217-9	41034-41042	response	_	
217-10	41043-41045	is	_	
217-11	41046-41052	useful	_	
217-12	41053-41055	in	_	
217-13	41056-41060	that	_	
217-14	41061-41063	it	_	
217-15	41064-41070	offers	_	
217-16	41071-41072	a	_	
217-17	41073-41081	creative	_	
217-18	41082-41085	and	_	
217-19	41086-41096	innovative	_	
217-20	41097-41105	approach	_	
217-21	41106-41108	to	_	
217-22	41109-41119	accelerate	_	
217-23	41120-41129	discovery	_	
217-24	41130-41132	of	_	
217-25	41133-41141	critical	_	
217-26	41142-41148	neural	_	
217-27	41149-41159	mechanisms	_	
217-28	41159-41160	.	_	

#Text=In other words, it is important to consider that one of the critical contributions of this manuscript is that it sets the foundation for those who want to pursue this type of translational research.
218-1	41161-41163	In	_	
218-2	41164-41169	other	_	
218-3	41170-41175	words	_	
218-4	41175-41176	,	_	
218-5	41177-41179	it	_	
218-6	41180-41182	is	_	
218-7	41183-41192	important	_	
218-8	41193-41195	to	_	
218-9	41196-41204	consider	_	
218-10	41205-41209	that	_	
218-11	41210-41213	one	_	
218-12	41214-41216	of	_	
218-13	41217-41220	the	_	
218-14	41221-41229	critical	_	
218-15	41230-41243	contributions	_	
218-16	41244-41246	of	_	
218-17	41247-41251	this	_	
218-18	41252-41262	manuscript	_	
218-19	41263-41265	is	_	
218-20	41266-41270	that	_	
218-21	41271-41273	it	_	
218-22	41274-41278	sets	_	
218-23	41279-41282	the	_	
218-24	41283-41293	foundation	_	
218-25	41294-41297	for	_	
218-26	41298-41303	those	_	
218-27	41304-41307	who	_	
218-28	41308-41312	want	_	
218-29	41313-41315	to	_	
218-30	41316-41322	pursue	_	
218-31	41323-41327	this	_	
218-32	41328-41332	type	_	
218-33	41333-41335	of	_	
218-34	41336-41349	translational	_	
218-35	41350-41358	research	_	
218-36	41358-41359	.	_	

#Text=This is a multi-step approach, which we hope will culminate in generating practical, clinical data to inform and drive behavioral strategies to facilitate positive behavior change for adolescents.
219-1	41360-41364	This	_	
219-2	41365-41367	is	_	
219-3	41368-41369	a	_	
219-4	41370-41380	multi-step	_	
219-5	41381-41389	approach	_	
219-6	41389-41390	,	_	
219-7	41391-41396	which	_	
219-8	41397-41399	we	_	
219-9	41400-41404	hope	_	
219-10	41405-41409	will	_	
219-11	41410-41419	culminate	_	
219-12	41420-41422	in	_	
219-13	41423-41433	generating	_	
219-14	41434-41443	practical	_	
219-15	41443-41444	,	_	
219-16	41445-41453	clinical	_	
219-17	41454-41458	data	_	
219-18	41459-41461	to	_	
219-19	41462-41468	inform	_	
219-20	41469-41472	and	_	
219-21	41473-41478	drive	_	
219-22	41479-41489	behavioral	_	
219-23	41490-41500	strategies	_	
219-24	41501-41503	to	_	
219-25	41504-41514	facilitate	_	
219-26	41515-41523	positive	_	
219-27	41524-41532	behavior	_	
219-28	41533-41539	change	_	
219-29	41540-41543	for	_	
219-30	41544-41555	adolescents	_	
219-31	41555-41556	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
220-1	41557-41570	Supplementary	_	
220-2	41571-41579	Material	_	
220-3	41580-41584	This	_	
220-4	41585-41587	is	_	
220-5	41588-41589	a	_	
220-6	41590-41593	PDF	_	
220-7	41594-41598	file	_	
220-8	41599-41601	of	_	
220-9	41602-41604	an	_	
220-10	41605-41613	unedited	_	
220-11	41614-41624	manuscript	_	
220-12	41625-41629	that	_	
220-13	41630-41633	has	_	
220-14	41634-41638	been	_	
220-15	41639-41647	accepted	_	
220-16	41648-41651	for	_	
220-17	41652-41663	publication	_	
220-18	41663-41664	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
221-1	41665-41667	As	_	
221-2	41668-41669	a	_	
221-3	41670-41677	service	_	
221-4	41678-41680	to	_	
221-5	41681-41684	our	_	
221-6	41685-41694	customers	_	
221-7	41695-41697	we	_	
221-8	41698-41701	are	_	
221-9	41702-41711	providing	_	
221-10	41712-41716	this	_	
221-11	41717-41722	early	_	
221-12	41723-41730	version	_	
221-13	41731-41733	of	_	
221-14	41734-41737	the	_	
221-15	41738-41748	manuscript	_	
221-16	41748-41749	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
222-1	41750-41753	The	_	
222-2	41754-41764	manuscript	_	
222-3	41765-41769	will	_	
222-4	41770-41777	undergo	_	
222-5	41778-41789	copyediting	_	
222-6	41789-41790	,	_	
222-7	41791-41802	typesetting	_	
222-8	41802-41803	,	_	
222-9	41804-41807	and	_	
222-10	41808-41814	review	_	
222-11	41815-41817	of	_	
222-12	41818-41821	the	_	
222-13	41822-41831	resulting	_	
222-14	41832-41837	proof	_	
222-15	41838-41844	before	_	
222-16	41845-41847	it	_	
222-17	41848-41850	is	_	
222-18	41851-41860	published	_	
222-19	41861-41863	in	_	
222-20	41864-41867	its	_	
222-21	41868-41873	final	_	
222-22	41874-41881	citable	_	
222-23	41882-41886	form	_	
222-24	41886-41887	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
223-1	41888-41894	Please	_	
223-2	41895-41899	note	_	
223-3	41900-41904	that	_	
223-4	41905-41911	during	_	
223-5	41912-41915	the	_	
223-6	41916-41926	production	_	
223-7	41927-41934	process	_	
223-8	41935-41941	errors	_	
223-9	41942-41945	may	_	
223-10	41946-41948	be	_	
223-11	41949-41959	discovered	_	
223-12	41960-41965	which	_	
223-13	41966-41971	could	_	
223-14	41972-41978	affect	_	
223-15	41979-41982	the	_	
223-16	41983-41990	content	_	
223-17	41990-41991	,	_	
223-18	41992-41995	and	_	
223-19	41996-41999	all	_	
223-20	42000-42005	legal	_	
223-21	42006-42017	disclaimers	_	
223-22	42018-42022	that	_	
223-23	42023-42028	apply	_	
223-24	42029-42031	to	_	
223-25	42032-42035	the	_	
223-26	42036-42043	journal	_	
223-27	42044-42051	pertain	_	
223-28	42051-42052	.	_	

#Text=Conflict of Interest:         
#Text=The authors have no competing financial or other conflicts of interest relating to the data included in the manuscript.
224-1	42064-42072	Conflict	_	
224-2	42073-42075	of	_	
224-3	42076-42084	Interest	_	
224-4	42084-42085	:	_	
224-5	42095-42098	The	_	
224-6	42099-42106	authors	_	
224-7	42107-42111	have	_	
224-8	42112-42114	no	_	
224-9	42115-42124	competing	_	
224-10	42125-42134	financial	_	
224-11	42135-42137	or	_	
224-12	42138-42143	other	_	
224-13	42144-42153	conflicts	_	
224-14	42154-42156	of	_	
224-15	42157-42165	interest	_	
224-16	42166-42174	relating	_	
224-17	42175-42177	to	_	
224-18	42178-42181	the	_	
224-19	42182-42186	data	_	
224-20	42187-42195	included	_	
224-21	42196-42198	in	_	
224-22	42199-42202	the	_	
224-23	42203-42213	manuscript	_	
224-24	42213-42214	.	_	

#Text=References
#Text=
#Text=
#Text=
#Text=Gender and racial/ethnic differences in patterns of adolescent alcohol use and associations with adolescent and adult illicit drug use
#Text=Association among different measures of alcohol use across adolescence and emerging adulthood
#Text=Adolescents’ Perceptions of Risks and Benefits of Conventional Cigarettes, E-cigarettes, and Marijuana: A Qualitative Analysis
#Text=
#Text=Short-term effects of a brief motivational intervention to reduce alcohol and drug risk among homeless adolescents
#Text=Randomized controlled trial of motivational interviewing compared with drug information and advice for early intervention among young cannabis users
#Text=Brief motivational interviewing for teens at risk of substance use consequences: A randomized pilot study in a primary care clinic
#Text=Project CHAT: A brief motivational substance abuse intervention for teens in primary care
#Text=Developing a group motivational interviewing intervention for first-time adolescent offenders at-risk for an alcohol or drug use disorder
#Text=Effectiveness of motivational interviewing interventions for adolescent substance use behavior change: A meta-analytic review
#Text=Mechanisms of change in adolescent substance use treatment: How does treatment work?
225-1	42215-42225	References	_	
225-2	42229-42235	Gender	_	
225-3	42236-42239	and	_	
225-4	42240-42246	racial	_	
225-5	42246-42247	/	_	
225-6	42247-42253	ethnic	_	
225-7	42254-42265	differences	_	
225-8	42266-42268	in	_	
225-9	42269-42277	patterns	_	
225-10	42278-42280	of	_	
225-11	42281-42291	adolescent	_	
225-12	42292-42299	alcohol	_	
225-13	42300-42303	use	_	
225-14	42304-42307	and	_	
225-15	42308-42320	associations	_	
225-16	42321-42325	with	_	
225-17	42326-42336	adolescent	_	
225-18	42337-42340	and	_	
225-19	42341-42346	adult	_	
225-20	42347-42354	illicit	_	
225-21	42355-42359	drug	_	
225-22	42360-42363	use	_	
225-23	42364-42375	Association	_	
225-24	42376-42381	among	_	
225-25	42382-42391	different	_	
225-26	42392-42400	measures	_	
225-27	42401-42403	of	_	
225-28	42404-42411	alcohol	_	
225-29	42412-42415	use	_	
225-30	42416-42422	across	_	
225-31	42423-42434	adolescence	_	
225-32	42435-42438	and	_	
225-33	42439-42447	emerging	_	
225-34	42448-42457	adulthood	_	
225-35	42458-42469	Adolescents	_	
225-36	42469-42470	’	_	
225-37	42471-42482	Perceptions	_	
225-38	42483-42485	of	_	
225-39	42486-42491	Risks	_	
225-40	42492-42495	and	_	
225-41	42496-42504	Benefits	_	
225-42	42505-42507	of	_	
225-43	42508-42520	Conventional	_	
225-44	42521-42531	Cigarettes	_	
225-45	42531-42532	,	_	
225-46	42533-42545	E-cigarettes	_	
225-47	42545-42546	,	_	
225-48	42547-42550	and	_	
225-49	42551-42560	Marijuana	_	
225-50	42560-42561	:	_	
225-51	42562-42563	A	_	
225-52	42564-42575	Qualitative	_	
225-53	42576-42584	Analysis	_	
225-54	42586-42596	Short-term	_	
225-55	42597-42604	effects	_	
225-56	42605-42607	of	_	
225-57	42608-42609	a	_	
225-58	42610-42615	brief	_	
225-59	42616-42628	motivational	_	
225-60	42629-42641	intervention	_	
225-61	42642-42644	to	_	
225-62	42645-42651	reduce	_	
225-63	42652-42659	alcohol	_	
225-64	42660-42663	and	_	
225-65	42664-42668	drug	_	
225-66	42669-42673	risk	_	
225-67	42674-42679	among	_	
225-68	42680-42688	homeless	_	
225-69	42689-42700	adolescents	_	
225-70	42701-42711	Randomized	_	
225-71	42712-42722	controlled	_	
225-72	42723-42728	trial	_	
225-73	42729-42731	of	_	
225-74	42732-42744	motivational	_	
225-75	42745-42757	interviewing	_	
225-76	42758-42766	compared	_	
225-77	42767-42771	with	_	
225-78	42772-42776	drug	_	
225-79	42777-42788	information	_	
225-80	42789-42792	and	_	
225-81	42793-42799	advice	_	
225-82	42800-42803	for	_	
225-83	42804-42809	early	_	
225-84	42810-42822	intervention	_	
225-85	42823-42828	among	_	
225-86	42829-42834	young	_	
225-87	42835-42843	cannabis	_	
225-88	42844-42849	users	_	
225-89	42850-42855	Brief	_	
225-90	42856-42868	motivational	_	
225-91	42869-42881	interviewing	_	
225-92	42882-42885	for	_	
225-93	42886-42891	teens	_	
225-94	42892-42894	at	_	
225-95	42895-42899	risk	_	
225-96	42900-42902	of	_	
225-97	42903-42912	substance	_	
225-98	42913-42916	use	_	
225-99	42917-42929	consequences	_	
225-100	42929-42930	:	_	
225-101	42931-42932	A	_	
225-102	42933-42943	randomized	_	
225-103	42944-42949	pilot	_	
225-104	42950-42955	study	_	
225-105	42956-42958	in	_	
225-106	42959-42960	a	_	
225-107	42961-42968	primary	_	
225-108	42969-42973	care	_	
225-109	42974-42980	clinic	_	
225-110	42981-42988	Project	_	
225-111	42989-42993	CHAT	_	
225-112	42993-42994	:	_	
225-113	42995-42996	A	_	
225-114	42997-43002	brief	_	
225-115	43003-43015	motivational	_	
225-116	43016-43025	substance	_	
225-117	43026-43031	abuse	_	
225-118	43032-43044	intervention	_	
225-119	43045-43048	for	_	
225-120	43049-43054	teens	_	
225-121	43055-43057	in	_	
225-122	43058-43065	primary	_	
225-123	43066-43070	care	_	
225-124	43071-43081	Developing	_	
225-125	43082-43083	a	_	
225-126	43084-43089	group	_	
225-127	43090-43102	motivational	_	
225-128	43103-43115	interviewing	_	
225-129	43116-43128	intervention	_	
225-130	43129-43132	for	_	
225-131	43133-43143	first-time	_	
225-132	43144-43154	adolescent	_	
225-133	43155-43164	offenders	_	
225-134	43165-43172	at-risk	_	
225-135	43173-43176	for	_	
225-136	43177-43179	an	_	
225-137	43180-43187	alcohol	_	
225-138	43188-43190	or	_	
225-139	43191-43195	drug	_	
225-140	43196-43199	use	_	
225-141	43200-43208	disorder	_	
225-142	43209-43222	Effectiveness	_	
225-143	43223-43225	of	_	
225-144	43226-43238	motivational	_	
225-145	43239-43251	interviewing	_	
225-146	43252-43265	interventions	_	
225-147	43266-43269	for	_	
225-148	43270-43280	adolescent	_	
225-149	43281-43290	substance	_	
225-150	43291-43294	use	_	
225-151	43295-43303	behavior	_	
225-152	43304-43310	change	_	
225-153	43310-43311	:	_	
225-154	43312-43313	A	_	
225-155	43314-43327	meta-analytic	_	
225-156	43328-43334	review	_	
225-157	43335-43345	Mechanisms	_	
225-158	43346-43348	of	_	
225-159	43349-43355	change	_	
225-160	43356-43358	in	_	
225-161	43359-43369	adolescent	_	
225-162	43370-43379	substance	_	
225-163	43380-43383	use	_	
225-164	43384-43393	treatment	_	
225-165	43393-43394	:	_	
225-166	43395-43398	How	_	
225-167	43399-43403	does	_	
225-168	43404-43413	treatment	_	
225-169	43414-43418	work	_	
225-170	43418-43419	?	_	

#Text=Ambivalence: Prerequisite for success in motivational interviewing with adolescents?
226-1	43420-43431	Ambivalence	_	
226-2	43431-43432	:	_	
226-3	43433-43445	Prerequisite	_	
226-4	43446-43449	for	_	
226-5	43450-43457	success	_	
226-6	43458-43460	in	_	
226-7	43461-43473	motivational	_	
226-8	43474-43486	interviewing	_	
226-9	43487-43491	with	_	
226-10	43492-43503	adolescents	_	
226-11	43503-43504	?	_	

#Text=Toward a theory of motivational interviewing
#Text=Combined pharmacotherapies and behavioral interventions for alcohol dependence, the COMBINE Study: A randomized control trial
#Text=Matching alcoholism treatments to client heterogeneity: Project MATCH Posttreatment drinking outcomes
#Text=Effectiveness of treatment for alcohol problems: Findings of the randomised UK alcohol treatment trial (UKATT)
#Text=Individual and family motivational interventions for alcohol-positive adolescents treated in an emergency department: results of a randomized clinical trial
#Text=Group motivational interviewing for adolescents: Change talk and alcohol and marijuana outcomes
#Text=Motivational interviewing to reduce substance-related consequences: Effects for incarcerated adolescents with depressed mood
#Text=Randomized controlled trial of motivational enhancement therapy with nontreatment-seeking adolescent cannabis users: A further test of the teen marijuana check-up
#Text=
#Text=Meta-Analysis of Motivational Interviewing for Adolescent Health Behavior: Efficacy Beyond Substance Use
#Text=A meta-analysis of motivational interviewing interventions for pediatric health behavior change
#Text=Motivational interviewing: a pilot test of active ingredients and mechanisms of change
#Text=Matching alcoholism treatments to client heterogeneity: treatment main effects matching effects on drinking during treatment.
227-1	43505-43511	Toward	_	
227-2	43512-43513	a	_	
227-3	43514-43520	theory	_	
227-4	43521-43523	of	_	
227-5	43524-43536	motivational	_	
227-6	43537-43549	interviewing	_	
227-7	43550-43558	Combined	_	
227-8	43559-43576	pharmacotherapies	_	
227-9	43577-43580	and	_	
227-10	43581-43591	behavioral	_	
227-11	43592-43605	interventions	_	
227-12	43606-43609	for	_	
227-13	43610-43617	alcohol	_	
227-14	43618-43628	dependence	_	
227-15	43628-43629	,	_	
227-16	43630-43633	the	_	
227-17	43634-43641	COMBINE	_	
227-18	43642-43647	Study	_	
227-19	43647-43648	:	_	
227-20	43649-43650	A	_	
227-21	43651-43661	randomized	_	
227-22	43662-43669	control	_	
227-23	43670-43675	trial	_	
227-24	43676-43684	Matching	_	
227-25	43685-43695	alcoholism	_	
227-26	43696-43706	treatments	_	
227-27	43707-43709	to	_	
227-28	43710-43716	client	_	
227-29	43717-43730	heterogeneity	_	
227-30	43730-43731	:	_	
227-31	43732-43739	Project	_	
227-32	43740-43745	MATCH	_	
227-33	43746-43759	Posttreatment	_	
227-34	43760-43768	drinking	_	
227-35	43769-43777	outcomes	_	
227-36	43778-43791	Effectiveness	_	
227-37	43792-43794	of	_	
227-38	43795-43804	treatment	_	
227-39	43805-43808	for	_	
227-40	43809-43816	alcohol	_	
227-41	43817-43825	problems	_	
227-42	43825-43826	:	_	
227-43	43827-43835	Findings	_	
227-44	43836-43838	of	_	
227-45	43839-43842	the	_	
227-46	43843-43853	randomised	_	
227-47	43854-43856	UK	_	
227-48	43857-43864	alcohol	_	
227-49	43865-43874	treatment	_	
227-50	43875-43880	trial	_	
227-51	43881-43882	(	_	
227-52	43882-43887	UKATT	_	
227-53	43887-43888	)	_	
227-54	43889-43899	Individual	_	
227-55	43900-43903	and	_	
227-56	43904-43910	family	_	
227-57	43911-43923	motivational	_	
227-58	43924-43937	interventions	_	
227-59	43938-43941	for	_	
227-60	43942-43958	alcohol-positive	_	
227-61	43959-43970	adolescents	_	
227-62	43971-43978	treated	_	
227-63	43979-43981	in	_	
227-64	43982-43984	an	_	
227-65	43985-43994	emergency	_	
227-66	43995-44005	department	_	
227-67	44005-44006	:	_	
227-68	44007-44014	results	_	
227-69	44015-44017	of	_	
227-70	44018-44019	a	_	
227-71	44020-44030	randomized	_	
227-72	44031-44039	clinical	_	
227-73	44040-44045	trial	_	
227-74	44046-44051	Group	_	
227-75	44052-44064	motivational	_	
227-76	44065-44077	interviewing	_	
227-77	44078-44081	for	_	
227-78	44082-44093	adolescents	_	
227-79	44093-44094	:	_	
227-80	44095-44101	Change	_	
227-81	44102-44106	talk	_	
227-82	44107-44110	and	_	
227-83	44111-44118	alcohol	_	
227-84	44119-44122	and	_	
227-85	44123-44132	marijuana	_	
227-86	44133-44141	outcomes	_	
227-87	44142-44154	Motivational	_	
227-88	44155-44167	interviewing	_	
227-89	44168-44170	to	_	
227-90	44171-44177	reduce	_	
227-91	44178-44195	substance-related	_	
227-92	44196-44208	consequences	_	
227-93	44208-44209	:	_	
227-94	44210-44217	Effects	_	
227-95	44218-44221	for	_	
227-96	44222-44234	incarcerated	_	
227-97	44235-44246	adolescents	_	
227-98	44247-44251	with	_	
227-99	44252-44261	depressed	_	
227-100	44262-44266	mood	_	
227-101	44267-44277	Randomized	_	
227-102	44278-44288	controlled	_	
227-103	44289-44294	trial	_	
227-104	44295-44297	of	_	
227-105	44298-44310	motivational	_	
227-106	44311-44322	enhancement	_	
227-107	44323-44330	therapy	_	
227-108	44331-44335	with	_	
227-109	44336-44356	nontreatment-seeking	_	
227-110	44357-44367	adolescent	_	
227-111	44368-44376	cannabis	_	
227-112	44377-44382	users	_	
227-113	44382-44383	:	_	
227-114	44384-44385	A	_	
227-115	44386-44393	further	_	
227-116	44394-44398	test	_	
227-117	44399-44401	of	_	
227-118	44402-44405	the	_	
227-119	44406-44410	teen	_	
227-120	44411-44420	marijuana	_	
227-121	44421-44429	check-up	_	
227-122	44431-44444	Meta-Analysis	_	
227-123	44445-44447	of	_	
227-124	44448-44460	Motivational	_	
227-125	44461-44473	Interviewing	_	
227-126	44474-44477	for	_	
227-127	44478-44488	Adolescent	_	
227-128	44489-44495	Health	_	
227-129	44496-44504	Behavior	_	
227-130	44504-44505	:	_	
227-131	44506-44514	Efficacy	_	
227-132	44515-44521	Beyond	_	
227-133	44522-44531	Substance	_	
227-134	44532-44535	Use	_	
227-135	44536-44537	A	_	
227-136	44538-44551	meta-analysis	_	
227-137	44552-44554	of	_	
227-138	44555-44567	motivational	_	
227-139	44568-44580	interviewing	_	
227-140	44581-44594	interventions	_	
227-141	44595-44598	for	_	
227-142	44599-44608	pediatric	_	
227-143	44609-44615	health	_	
227-144	44616-44624	behavior	_	
227-145	44625-44631	change	_	
227-146	44632-44644	Motivational	_	
227-147	44645-44657	interviewing	_	
227-148	44657-44658	:	_	
227-149	44659-44660	a	_	
227-150	44661-44666	pilot	_	
227-151	44667-44671	test	_	
227-152	44672-44674	of	_	
227-153	44675-44681	active	_	
227-154	44682-44693	ingredients	_	
227-155	44694-44697	and	_	
227-156	44698-44708	mechanisms	_	
227-157	44709-44711	of	_	
227-158	44712-44718	change	_	
227-159	44719-44727	Matching	_	
227-160	44728-44738	alcoholism	_	
227-161	44739-44749	treatments	_	
227-162	44750-44752	to	_	
227-163	44753-44759	client	_	
227-164	44760-44773	heterogeneity	_	
227-165	44773-44774	:	_	
227-166	44775-44784	treatment	_	
227-167	44785-44789	main	_	
227-168	44790-44797	effects	_	
227-169	44798-44806	matching	_	
227-170	44807-44814	effects	_	
227-171	44815-44817	on	_	
227-172	44818-44826	drinking	_	
227-173	44827-44833	during	_	
227-174	44834-44843	treatment	_	
227-175	44843-44844	.	_	

#Text=Project MATCH Research Group
#Text=Cognitive neuroscience approaches to understanding behavior change in alcohol use disorder treatments
#Text=Beyond Brain Mapping: Using Neural Measures to Predict Real-World Outcomes
#Text=Prediction as a humanitarian and pragmatic contribution from human cognitive neuroscience
#Text=A proposed model of the neurobiolgocial mechanisms underlying psychosocial alcohol interventions: The example of motivational interviewing and functional magnetic resonance imaging
#Text=Integrating brain and behavior: Evaluating adolescents’ response to a cannabis intervention
#Text=The impact of therapists’ words on the adolescent brain: In the context of addiction treatment
#Text=Neural activity during health messaging predicts reductions in smoking above and beyond self-report
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Uniting adolescent neuroimaging and treatment research: Recommendations in pursuit of improved integration
#Text=The impact of therapists’ words on the adolescent brain: In the context of addiction treatment
#Text=Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry
#Text=Measuring risks and outcomes in substance use disorders prevention research
#Text=Screening and brief intervention for high-risk college student drinkers: Results from a 2-year follow-up assessment
#Text=
#Text=The Adolescent Cannabis Problems Questionnaire (CPQ-A): Psychometric properties
#Text=
#Text=Brain-based origins of change language: A beginning
#Text=How psychosocial alcohol interventions work: A preliminary look at what fMRI can tell us
#Text=The forest and the trees: Relational and specific factors in addiction treatment
#Text=Analysis of fMRI time-series revisited
#Text=Nonlinear spatial normalization using basis functions
#Text=A generalized form of context-dependent psychophysiological interactions (gPPI): a comparison to standard approaches
#Text=Psychophysiological and modulatory interactions in neuroimaging
#Text=Valid conjunction interference with the minimum statistic
#Text=Lateralization of resting state networks and relationship to age and gender
#Text=Negative and interactive effects of sex, aging, and alcohol abuse on gray matter morphometry
#Text=Thresholding of statistical maps in functional neuroimaging using the false discovery rate
#Text=Recent progress and outstanding issues in motion correction in resting state fMRI
#Text=What works?
228-1	44845-44852	Project	_	
228-2	44853-44858	MATCH	_	
228-3	44859-44867	Research	_	
228-4	44868-44873	Group	_	
228-5	44874-44883	Cognitive	_	
228-6	44884-44896	neuroscience	_	
228-7	44897-44907	approaches	_	
228-8	44908-44910	to	_	
228-9	44911-44924	understanding	_	
228-10	44925-44933	behavior	_	
228-11	44934-44940	change	_	
228-12	44941-44943	in	_	
228-13	44944-44951	alcohol	_	
228-14	44952-44955	use	_	
228-15	44956-44964	disorder	_	
228-16	44965-44975	treatments	_	
228-17	44976-44982	Beyond	_	
228-18	44983-44988	Brain	_	
228-19	44989-44996	Mapping	_	
228-20	44996-44997	:	_	
228-21	44998-45003	Using	_	
228-22	45004-45010	Neural	_	
228-23	45011-45019	Measures	_	
228-24	45020-45022	to	_	
228-25	45023-45030	Predict	_	
228-26	45031-45041	Real-World	_	
228-27	45042-45050	Outcomes	_	
228-28	45051-45061	Prediction	_	
228-29	45062-45064	as	_	
228-30	45065-45066	a	_	
228-31	45067-45079	humanitarian	_	
228-32	45080-45083	and	_	
228-33	45084-45093	pragmatic	_	
228-34	45094-45106	contribution	_	
228-35	45107-45111	from	_	
228-36	45112-45117	human	_	
228-37	45118-45127	cognitive	_	
228-38	45128-45140	neuroscience	_	
228-39	45141-45142	A	_	
228-40	45143-45151	proposed	_	
228-41	45152-45157	model	_	
228-42	45158-45160	of	_	
228-43	45161-45164	the	_	
228-44	45165-45180	neurobiolgocial	_	
228-45	45181-45191	mechanisms	_	
228-46	45192-45202	underlying	_	
228-47	45203-45215	psychosocial	_	
228-48	45216-45223	alcohol	_	
228-49	45224-45237	interventions	_	
228-50	45237-45238	:	_	
228-51	45239-45242	The	_	
228-52	45243-45250	example	_	
228-53	45251-45253	of	_	
228-54	45254-45266	motivational	_	
228-55	45267-45279	interviewing	_	
228-56	45280-45283	and	_	
228-57	45284-45294	functional	_	
228-58	45295-45303	magnetic	_	
228-59	45304-45313	resonance	_	
228-60	45314-45321	imaging	_	
228-61	45322-45333	Integrating	_	
228-62	45334-45339	brain	_	
228-63	45340-45343	and	_	
228-64	45344-45352	behavior	_	
228-65	45352-45353	:	_	
228-66	45354-45364	Evaluating	_	
228-67	45365-45376	adolescents	_	
228-68	45376-45377	’	_	
228-69	45378-45386	response	_	
228-70	45387-45389	to	_	
228-71	45390-45391	a	_	
228-72	45392-45400	cannabis	_	
228-73	45401-45413	intervention	_	
228-74	45414-45417	The	_	
228-75	45418-45424	impact	_	
228-76	45425-45427	of	_	
228-77	45428-45438	therapists	_	
228-78	45438-45439	’	_	
228-79	45440-45445	words	_	
228-80	45446-45448	on	_	
228-81	45449-45452	the	_	
228-82	45453-45463	adolescent	_	
228-83	45464-45469	brain	_	
228-84	45469-45470	:	_	
228-85	45471-45473	In	_	
228-86	45474-45477	the	_	
228-87	45478-45485	context	_	
228-88	45486-45488	of	_	
228-89	45489-45498	addiction	_	
228-90	45499-45508	treatment	_	
228-91	45509-45515	Neural	_	
228-92	45516-45524	activity	_	
228-93	45525-45531	during	_	
228-94	45532-45538	health	_	
228-95	45539-45548	messaging	_	
228-96	45549-45557	predicts	_	
228-97	45558-45568	reductions	_	
228-98	45569-45571	in	_	
228-99	45572-45579	smoking	_	
228-100	45580-45585	above	_	
228-101	45586-45589	and	_	
228-102	45590-45596	beyond	_	
228-103	45597-45608	self-report	_	
228-104	45609-45616	Factors	_	
228-105	45617-45627	modulating	_	
228-106	45628-45634	neural	_	
228-107	45635-45645	reactivity	_	
228-108	45646-45648	to	_	
228-109	45649-45653	drug	_	
228-110	45654-45658	cues	_	
228-111	45659-45661	in	_	
228-112	45662-45671	addiction	_	
228-113	45671-45672	:	_	
228-114	45673-45674	a	_	
228-115	45675-45681	survey	_	
228-116	45682-45684	of	_	
228-117	45685-45690	human	_	
228-118	45691-45703	neuroimaging	_	
228-119	45704-45711	studies	_	
228-120	45712-45719	Uniting	_	
228-121	45720-45730	adolescent	_	
228-122	45731-45743	neuroimaging	_	
228-123	45744-45747	and	_	
228-124	45748-45757	treatment	_	
228-125	45758-45766	research	_	
228-126	45766-45767	:	_	
228-127	45768-45783	Recommendations	_	
228-128	45784-45786	in	_	
228-129	45787-45794	pursuit	_	
228-130	45795-45797	of	_	
228-131	45798-45806	improved	_	
228-132	45807-45818	integration	_	
228-133	45819-45822	The	_	
228-134	45823-45829	impact	_	
228-135	45830-45832	of	_	
228-136	45833-45843	therapists	_	
228-137	45843-45844	’	_	
228-138	45845-45850	words	_	
228-139	45851-45853	on	_	
228-140	45854-45857	the	_	
228-141	45858-45868	adolescent	_	
228-142	45869-45874	brain	_	
228-143	45874-45875	:	_	
228-144	45876-45878	In	_	
228-145	45879-45882	the	_	
228-146	45883-45890	context	_	
228-147	45891-45893	of	_	
228-148	45894-45903	addiction	_	
228-149	45904-45913	treatment	_	
228-150	45914-45922	Exposure	_	
228-151	45923-45925	to	_	
228-152	45926-45929	the	_	
228-153	45930-45935	taste	_	
228-154	45936-45938	of	_	
228-155	45939-45946	alcohol	_	
228-156	45947-45954	elicits	_	
228-157	45955-45965	activation	_	
228-158	45966-45968	of	_	
228-159	45969-45972	the	_	
228-160	45973-45990	mesocorticolimbic	_	
228-161	45991-46005	neurocircuitry	_	
228-162	46006-46015	Measuring	_	
228-163	46016-46021	risks	_	
228-164	46022-46025	and	_	
228-165	46026-46034	outcomes	_	
228-166	46035-46037	in	_	
228-167	46038-46047	substance	_	
228-168	46048-46051	use	_	
228-169	46052-46061	disorders	_	
228-170	46062-46072	prevention	_	
228-171	46073-46081	research	_	
228-172	46082-46091	Screening	_	
228-173	46092-46095	and	_	
228-174	46096-46101	brief	_	
228-175	46102-46114	intervention	_	
228-176	46115-46118	for	_	
228-177	46119-46128	high-risk	_	
228-178	46129-46136	college	_	
228-179	46137-46144	student	_	
228-180	46145-46153	drinkers	_	
228-181	46153-46154	:	_	
228-182	46155-46162	Results	_	
228-183	46163-46167	from	_	
228-184	46168-46169	a	_	
228-185	46170-46171	2	_	
228-186	46171-46172	-	_	
228-187	46172-46176	year	_	
228-188	46177-46186	follow-up	_	
228-189	46187-46197	assessment	_	
228-190	46199-46202	The	_	
228-191	46203-46213	Adolescent	_	
228-192	46214-46222	Cannabis	_	
228-193	46223-46231	Problems	_	
228-194	46232-46245	Questionnaire	_	
228-195	46246-46247	(	_	
228-196	46247-46252	CPQ-A	_	
228-197	46252-46253	)	_	
228-198	46253-46254	:	_	
228-199	46255-46267	Psychometric	_	
228-200	46268-46278	properties	_	
228-201	46280-46291	Brain-based	_	
228-202	46292-46299	origins	_	
228-203	46300-46302	of	_	
228-204	46303-46309	change	_	
228-205	46310-46318	language	_	
228-206	46318-46319	:	_	
228-207	46320-46321	A	_	
228-208	46322-46331	beginning	_	
228-209	46332-46335	How	_	
228-210	46336-46348	psychosocial	_	
228-211	46349-46356	alcohol	_	
228-212	46357-46370	interventions	_	
228-213	46371-46375	work	_	
228-214	46375-46376	:	_	
228-215	46377-46378	A	_	
228-216	46379-46390	preliminary	_	
228-217	46391-46395	look	_	
228-218	46396-46398	at	_	
228-219	46399-46403	what	_	
228-220	46404-46408	fMRI	_	
228-221	46409-46412	can	_	
228-222	46413-46417	tell	_	
228-223	46418-46420	us	_	
228-224	46421-46424	The	_	
228-225	46425-46431	forest	_	
228-226	46432-46435	and	_	
228-227	46436-46439	the	_	
228-228	46440-46445	trees	_	
228-229	46445-46446	:	_	
228-230	46447-46457	Relational	_	
228-231	46458-46461	and	_	
228-232	46462-46470	specific	_	
228-233	46471-46478	factors	_	
228-234	46479-46481	in	_	
228-235	46482-46491	addiction	_	
228-236	46492-46501	treatment	_	
228-237	46502-46510	Analysis	_	
228-238	46511-46513	of	_	
228-239	46514-46518	fMRI	_	
228-240	46519-46530	time-series	_	
228-241	46531-46540	revisited	_	
228-242	46541-46550	Nonlinear	_	
228-243	46551-46558	spatial	_	
228-244	46559-46572	normalization	_	
228-245	46573-46578	using	_	
228-246	46579-46584	basis	_	
228-247	46585-46594	functions	_	
228-248	46595-46596	A	_	
228-249	46597-46608	generalized	_	
228-250	46609-46613	form	_	
228-251	46614-46616	of	_	
228-252	46617-46634	context-dependent	_	
228-253	46635-46654	psychophysiological	_	
228-254	46655-46667	interactions	_	
228-255	46668-46669	(	_	
228-256	46669-46673	gPPI	_	
228-257	46673-46674	)	_	
228-258	46674-46675	:	_	
228-259	46676-46677	a	_	
228-260	46678-46688	comparison	_	
228-261	46689-46691	to	_	
228-262	46692-46700	standard	_	
228-263	46701-46711	approaches	_	
228-264	46712-46731	Psychophysiological	_	
228-265	46732-46735	and	_	
228-266	46736-46746	modulatory	_	
228-267	46747-46759	interactions	_	
228-268	46760-46762	in	_	
228-269	46763-46775	neuroimaging	_	
228-270	46776-46781	Valid	_	
228-271	46782-46793	conjunction	_	
228-272	46794-46806	interference	_	
228-273	46807-46811	with	_	
228-274	46812-46815	the	_	
228-275	46816-46823	minimum	_	
228-276	46824-46833	statistic	_	
228-277	46834-46848	Lateralization	_	
228-278	46849-46851	of	_	
228-279	46852-46859	resting	_	
228-280	46860-46865	state	_	
228-281	46866-46874	networks	_	
228-282	46875-46878	and	_	
228-283	46879-46891	relationship	_	
228-284	46892-46894	to	_	
228-285	46895-46898	age	_	
228-286	46899-46902	and	_	
228-287	46903-46909	gender	_	
228-288	46910-46918	Negative	_	
228-289	46919-46922	and	_	
228-290	46923-46934	interactive	_	
228-291	46935-46942	effects	_	
228-292	46943-46945	of	_	
228-293	46946-46949	sex	_	
228-294	46949-46950	,	_	
228-295	46951-46956	aging	_	
228-296	46956-46957	,	_	
228-297	46958-46961	and	_	
228-298	46962-46969	alcohol	_	
228-299	46970-46975	abuse	_	
228-300	46976-46978	on	_	
228-301	46979-46983	gray	_	
228-302	46984-46990	matter	_	
228-303	46991-47002	morphometry	_	
228-304	47003-47015	Thresholding	_	
228-305	47016-47018	of	_	
228-306	47019-47030	statistical	_	
228-307	47031-47035	maps	_	
228-308	47036-47038	in	_	
228-309	47039-47049	functional	_	
228-310	47050-47062	neuroimaging	_	
228-311	47063-47068	using	_	
228-312	47069-47072	the	_	
228-313	47073-47078	false	_	
228-314	47079-47088	discovery	_	
228-315	47089-47093	rate	_	
228-316	47094-47100	Recent	_	
228-317	47101-47109	progress	_	
228-318	47110-47113	and	_	
228-319	47114-47125	outstanding	_	
228-320	47126-47132	issues	_	
228-321	47133-47135	in	_	
228-322	47136-47142	motion	_	
228-323	47143-47153	correction	_	
228-324	47154-47156	in	_	
228-325	47157-47164	resting	_	
228-326	47165-47170	state	_	
228-327	47171-47175	fMRI	_	
228-328	47176-47180	What	_	
228-329	47181-47186	works	_	
228-330	47186-47187	?	_	

#Text=An empirical perspective on how to retain youth in longitudinal HIV and substance risk reduction studies
#Text=Aberrant orbitofrontal connectivity in marijuana smoking adolescents
#Text=Large-scale brain network dynamics supporting adolescent cognitive control
#Text=A developmental shift from positive to negative connectivity in human amygdala-prefrontal circuitry
#Text=Association between nicotine dependence severity, BOLD response to smoking cues, and functional connectivity
#Text=Accumbens functional connectivity during reward mediates sensation-seeking and alcohol use in high-risk youth
#Text=Differential reward network functional connectivity in cannabis dependent and non-dependent users
#Text=Change talk during motivational intervention with young adult males: strength matters
#Text=fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users
#Text=Long-term effects of marijuana use on the brain
#Text=Abnormal reward circuitry in anorexia nervosa: A longitudinal, multi-modal MRI study
#Text=Anxiety evokes hypofrontality and disrupts rule-relevant encoding by dorsomedial prefrontal cortex neurons
#Text=Regional homogeneity of spontaneous brain activity in adult patients with obsessive-compulsive disorder before and after cognitive behavioural therapy
#Text=The technical hypothesis of motivational interviewing: A meta-analysis of MI’s key causal model
#Text=From in-session behaviors to drinking outcomes: A causal chain for motivational interviewing
#Text=How treatment affects the brain: meta-analysis evidence of neural substrates underpinning drug therapy and psychotherapy in major depression
#Text=Enhancing decision-making and cognitive impulse control with transcranial direct current stimulation (tDCS) applied over the orbitofrontal cortex (OFC): A randomized and sham-controlled exploratory study
#Text=Social reward improves the voluntary control over localized brain activity in fMRI-based neurofeedback training
#Text=Adolescent development of inhibition as a function of SES and gender: Converging evidence from behavior and fMRI
#Text=Altered neural processing to social exclusion in young adult marijuana users
#Text=Neural responses to maternal criticism in healthy youth
#Text=Multi-level models of internalizing disorders and translational developmental science: Seeking etiolgoical insights that can inform early intervention strategies
#Text=Evaluating an integrative theoretical framework for HIV sexual risk among juvenile justice involved adolescents
#Text=Uniting adolescent neuroimaging and treatment research: Recommendations in pursuit of improved integration
#Text=The Cannabis Youth Treatment (CYT) study: Main findings from two randomized trials
#Text=Task schematic
#Text=Main Effects
#Text=Regions having increased connectivity strength with OFC seed, during change talk compared to baseline (cannabis users, n=30).
229-1	47188-47190	An	_	
229-2	47191-47200	empirical	_	
229-3	47201-47212	perspective	_	
229-4	47213-47215	on	_	
229-5	47216-47219	how	_	
229-6	47220-47222	to	_	
229-7	47223-47229	retain	_	
229-8	47230-47235	youth	_	
229-9	47236-47238	in	_	
229-10	47239-47251	longitudinal	_	
229-11	47252-47255	HIV	_	
229-12	47256-47259	and	_	
229-13	47260-47269	substance	_	
229-14	47270-47274	risk	_	
229-15	47275-47284	reduction	_	
229-16	47285-47292	studies	_	
229-17	47293-47301	Aberrant	_	
229-18	47302-47315	orbitofrontal	_	
229-19	47316-47328	connectivity	_	
229-20	47329-47331	in	_	
229-21	47332-47341	marijuana	_	
229-22	47342-47349	smoking	_	
229-23	47350-47361	adolescents	_	
229-24	47362-47373	Large-scale	_	
229-25	47374-47379	brain	_	
229-26	47380-47387	network	_	
229-27	47388-47396	dynamics	_	
229-28	47397-47407	supporting	_	
229-29	47408-47418	adolescent	_	
229-30	47419-47428	cognitive	_	
229-31	47429-47436	control	_	
229-32	47437-47438	A	_	
229-33	47439-47452	developmental	_	
229-34	47453-47458	shift	_	
229-35	47459-47463	from	_	
229-36	47464-47472	positive	_	
229-37	47473-47475	to	_	
229-38	47476-47484	negative	_	
229-39	47485-47497	connectivity	_	
229-40	47498-47500	in	_	
229-41	47501-47506	human	_	
229-42	47507-47526	amygdala-prefrontal	_	
229-43	47527-47536	circuitry	_	
229-44	47537-47548	Association	_	
229-45	47549-47556	between	_	
229-46	47557-47565	nicotine	_	
229-47	47566-47576	dependence	_	
229-48	47577-47585	severity	_	
229-49	47585-47586	,	_	
229-50	47587-47591	BOLD	_	
229-51	47592-47600	response	_	
229-52	47601-47603	to	_	
229-53	47604-47611	smoking	_	
229-54	47612-47616	cues	_	
229-55	47616-47617	,	_	
229-56	47618-47621	and	_	
229-57	47622-47632	functional	_	
229-58	47633-47645	connectivity	_	
229-59	47646-47655	Accumbens	_	
229-60	47656-47666	functional	_	
229-61	47667-47679	connectivity	_	
229-62	47680-47686	during	_	
229-63	47687-47693	reward	_	
229-64	47694-47702	mediates	_	
229-65	47703-47720	sensation-seeking	_	
229-66	47721-47724	and	_	
229-67	47725-47732	alcohol	_	
229-68	47733-47736	use	_	
229-69	47737-47739	in	_	
229-70	47740-47749	high-risk	_	
229-71	47750-47755	youth	_	
229-72	47756-47768	Differential	_	
229-73	47769-47775	reward	_	
229-74	47776-47783	network	_	
229-75	47784-47794	functional	_	
229-76	47795-47807	connectivity	_	
229-77	47808-47810	in	_	
229-78	47811-47819	cannabis	_	
229-79	47820-47829	dependent	_	
229-80	47830-47833	and	_	
229-81	47834-47847	non-dependent	_	
229-82	47848-47853	users	_	
229-83	47854-47860	Change	_	
229-84	47861-47865	talk	_	
229-85	47866-47872	during	_	
229-86	47873-47885	motivational	_	
229-87	47886-47898	intervention	_	
229-88	47899-47903	with	_	
229-89	47904-47909	young	_	
229-90	47910-47915	adult	_	
229-91	47916-47921	males	_	
229-92	47921-47922	:	_	
229-93	47923-47931	strength	_	
229-94	47932-47939	matters	_	
229-95	47940-47944	fMRI	_	
229-96	47945-47950	study	_	
229-97	47951-47953	of	_	
229-98	47954-47960	neural	_	
229-99	47961-47974	sensitization	_	
229-100	47975-47977	to	_	
229-101	47978-47985	hedonic	_	
229-102	47986-47993	stimuli	_	
229-103	47994-47996	in	_	
229-104	47997-48006	long-term	_	
229-105	48006-48007	,	_	
229-106	48008-48013	daily	_	
229-107	48014-48022	cannabis	_	
229-108	48023-48028	users	_	
229-109	48029-48038	Long-term	_	
229-110	48039-48046	effects	_	
229-111	48047-48049	of	_	
229-112	48050-48059	marijuana	_	
229-113	48060-48063	use	_	
229-114	48064-48066	on	_	
229-115	48067-48070	the	_	
229-116	48071-48076	brain	_	
229-117	48077-48085	Abnormal	_	
229-118	48086-48092	reward	_	
229-119	48093-48102	circuitry	_	
229-120	48103-48105	in	_	
229-121	48106-48114	anorexia	_	
229-122	48115-48122	nervosa	_	
229-123	48122-48123	:	_	
229-124	48124-48125	A	_	
229-125	48126-48138	longitudinal	_	
229-126	48138-48139	,	_	
229-127	48140-48151	multi-modal	_	
229-128	48152-48155	MRI	_	
229-129	48156-48161	study	_	
229-130	48162-48169	Anxiety	_	
229-131	48170-48176	evokes	_	
229-132	48177-48191	hypofrontality	_	
229-133	48192-48195	and	_	
229-134	48196-48204	disrupts	_	
229-135	48205-48218	rule-relevant	_	
229-136	48219-48227	encoding	_	
229-137	48228-48230	by	_	
229-138	48231-48242	dorsomedial	_	
229-139	48243-48253	prefrontal	_	
229-140	48254-48260	cortex	_	
229-141	48261-48268	neurons	_	
229-142	48269-48277	Regional	_	
229-143	48278-48289	homogeneity	_	
229-144	48290-48292	of	_	
229-145	48293-48304	spontaneous	_	
229-146	48305-48310	brain	_	
229-147	48311-48319	activity	_	
229-148	48320-48322	in	_	
229-149	48323-48328	adult	_	
229-150	48329-48337	patients	_	
229-151	48338-48342	with	_	
229-152	48343-48363	obsessive-compulsive	_	
229-153	48364-48372	disorder	_	
229-154	48373-48379	before	_	
229-155	48380-48383	and	_	
229-156	48384-48389	after	_	
229-157	48390-48399	cognitive	_	
229-158	48400-48411	behavioural	_	
229-159	48412-48419	therapy	_	
229-160	48420-48423	The	_	
229-161	48424-48433	technical	_	
229-162	48434-48444	hypothesis	_	
229-163	48445-48447	of	_	
229-164	48448-48460	motivational	_	
229-165	48461-48473	interviewing	_	
229-166	48473-48474	:	_	
229-167	48475-48476	A	_	
229-168	48477-48490	meta-analysis	_	
229-169	48491-48493	of	_	
229-170	48494-48496	MI	_	
229-171	48496-48497	’	_	
229-172	48497-48498	s	_	
229-173	48499-48502	key	_	
229-174	48503-48509	causal	_	
229-175	48510-48515	model	_	
229-176	48516-48520	From	_	
229-177	48521-48531	in-session	_	
229-178	48532-48541	behaviors	_	
229-179	48542-48544	to	_	
229-180	48545-48553	drinking	_	
229-181	48554-48562	outcomes	_	
229-182	48562-48563	:	_	
229-183	48564-48565	A	_	
229-184	48566-48572	causal	_	
229-185	48573-48578	chain	_	
229-186	48579-48582	for	_	
229-187	48583-48595	motivational	_	
229-188	48596-48608	interviewing	_	
229-189	48609-48612	How	_	
229-190	48613-48622	treatment	_	
229-191	48623-48630	affects	_	
229-192	48631-48634	the	_	
229-193	48635-48640	brain	_	
229-194	48640-48641	:	_	
229-195	48642-48655	meta-analysis	_	
229-196	48656-48664	evidence	_	
229-197	48665-48667	of	_	
229-198	48668-48674	neural	_	
229-199	48675-48685	substrates	_	
229-200	48686-48698	underpinning	_	
229-201	48699-48703	drug	_	
229-202	48704-48711	therapy	_	
229-203	48712-48715	and	_	
229-204	48716-48729	psychotherapy	_	
229-205	48730-48732	in	_	
229-206	48733-48738	major	_	
229-207	48739-48749	depression	_	
229-208	48750-48759	Enhancing	_	
229-209	48760-48775	decision-making	_	
229-210	48776-48779	and	_	
229-211	48780-48789	cognitive	_	
229-212	48790-48797	impulse	_	
229-213	48798-48805	control	_	
229-214	48806-48810	with	_	
229-215	48811-48823	transcranial	_	
229-216	48824-48830	direct	_	
229-217	48831-48838	current	_	
229-218	48839-48850	stimulation	_	
229-219	48851-48852	(	_	
229-220	48852-48856	tDCS	_	
229-221	48856-48857	)	_	
229-222	48858-48865	applied	_	
229-223	48866-48870	over	_	
229-224	48871-48874	the	_	
229-225	48875-48888	orbitofrontal	_	
229-226	48889-48895	cortex	_	
229-227	48896-48897	(	_	
229-228	48897-48900	OFC	_	
229-229	48900-48901	)	_	
229-230	48901-48902	:	_	
229-231	48903-48904	A	_	
229-232	48905-48915	randomized	_	
229-233	48916-48919	and	_	
229-234	48920-48935	sham-controlled	_	
229-235	48936-48947	exploratory	_	
229-236	48948-48953	study	_	
229-237	48954-48960	Social	_	
229-238	48961-48967	reward	_	
229-239	48968-48976	improves	_	
229-240	48977-48980	the	_	
229-241	48981-48990	voluntary	_	
229-242	48991-48998	control	_	
229-243	48999-49003	over	_	
229-244	49004-49013	localized	_	
229-245	49014-49019	brain	_	
229-246	49020-49028	activity	_	
229-247	49029-49031	in	_	
229-248	49032-49042	fMRI-based	_	
229-249	49043-49056	neurofeedback	_	
229-250	49057-49065	training	_	
229-251	49066-49076	Adolescent	_	
229-252	49077-49088	development	_	
229-253	49089-49091	of	_	
229-254	49092-49102	inhibition	_	
229-255	49103-49105	as	_	
229-256	49106-49107	a	_	
229-257	49108-49116	function	_	
229-258	49117-49119	of	_	
229-259	49120-49123	SES	_	
229-260	49124-49127	and	_	
229-261	49128-49134	gender	_	
229-262	49134-49135	:	_	
229-263	49136-49146	Converging	_	
229-264	49147-49155	evidence	_	
229-265	49156-49160	from	_	
229-266	49161-49169	behavior	_	
229-267	49170-49173	and	_	
229-268	49174-49178	fMRI	_	
229-269	49179-49186	Altered	_	
229-270	49187-49193	neural	_	
229-271	49194-49204	processing	_	
229-272	49205-49207	to	_	
229-273	49208-49214	social	_	
229-274	49215-49224	exclusion	_	
229-275	49225-49227	in	_	
229-276	49228-49233	young	_	
229-277	49234-49239	adult	_	
229-278	49240-49249	marijuana	_	
229-279	49250-49255	users	_	
229-280	49256-49262	Neural	_	
229-281	49263-49272	responses	_	
229-282	49273-49275	to	_	
229-283	49276-49284	maternal	_	
229-284	49285-49294	criticism	_	
229-285	49295-49297	in	_	
229-286	49298-49305	healthy	_	
229-287	49306-49311	youth	_	
229-288	49312-49323	Multi-level	_	
229-289	49324-49330	models	_	
229-290	49331-49333	of	_	
229-291	49334-49347	internalizing	_	
229-292	49348-49357	disorders	_	
229-293	49358-49361	and	_	
229-294	49362-49375	translational	_	
229-295	49376-49389	developmental	_	
229-296	49390-49397	science	_	
229-297	49397-49398	:	_	
229-298	49399-49406	Seeking	_	
229-299	49407-49418	etiolgoical	_	
229-300	49419-49427	insights	_	
229-301	49428-49432	that	_	
229-302	49433-49436	can	_	
229-303	49437-49443	inform	_	
229-304	49444-49449	early	_	
229-305	49450-49462	intervention	_	
229-306	49463-49473	strategies	_	
229-307	49474-49484	Evaluating	_	
229-308	49485-49487	an	_	
229-309	49488-49499	integrative	_	
229-310	49500-49511	theoretical	_	
229-311	49512-49521	framework	_	
229-312	49522-49525	for	_	
229-313	49526-49529	HIV	_	
229-314	49530-49536	sexual	_	
229-315	49537-49541	risk	_	
229-316	49542-49547	among	_	
229-317	49548-49556	juvenile	_	
229-318	49557-49564	justice	_	
229-319	49565-49573	involved	_	
229-320	49574-49585	adolescents	_	
229-321	49586-49593	Uniting	_	
229-322	49594-49604	adolescent	_	
229-323	49605-49617	neuroimaging	_	
229-324	49618-49621	and	_	
229-325	49622-49631	treatment	_	
229-326	49632-49640	research	_	
229-327	49640-49641	:	_	
229-328	49642-49657	Recommendations	_	
229-329	49658-49660	in	_	
229-330	49661-49668	pursuit	_	
229-331	49669-49671	of	_	
229-332	49672-49680	improved	_	
229-333	49681-49692	integration	_	
229-334	49693-49696	The	_	
229-335	49697-49705	Cannabis	_	
229-336	49706-49711	Youth	_	
229-337	49712-49721	Treatment	_	
229-338	49722-49723	(	_	
229-339	49723-49726	CYT	_	
229-340	49726-49727	)	_	
229-341	49728-49733	study	_	
229-342	49733-49734	:	_	
229-343	49735-49739	Main	_	
229-344	49740-49748	findings	_	
229-345	49749-49753	from	_	
229-346	49754-49757	two	_	
229-347	49758-49768	randomized	_	
229-348	49769-49775	trials	_	
229-349	49776-49780	Task	_	
229-350	49781-49790	schematic	_	
229-351	49791-49795	Main	_	
229-352	49796-49803	Effects	_	
229-353	49804-49811	Regions	_	
229-354	49812-49818	having	_	
229-355	49819-49828	increased	_	
229-356	49829-49841	connectivity	_	
229-357	49842-49850	strength	_	
229-358	49851-49855	with	_	
229-359	49856-49859	OFC	_	
229-360	49860-49864	seed	_	
229-361	49864-49865	,	_	
229-362	49866-49872	during	_	
229-363	49873-49879	change	_	
229-364	49880-49884	talk	_	
229-365	49885-49893	compared	_	
229-366	49894-49896	to	_	
229-367	49897-49905	baseline	_	
229-368	49906-49907	(	_	
229-369	49907-49915	cannabis	_	
229-370	49916-49921	users	_	
229-371	49921-49922	,	_	
229-372	49923-49924	n	_	
229-373	49924-49925	=	_	
229-374	49925-49927	30	_	
229-375	49927-49928	)	_	
229-376	49928-49929	.	_	

#Text=Activations (FDR corrected p<0.05, k>50) are displayed on contiguous slices of the EPI template.
230-1	49930-49941	Activations	_	
230-2	49942-49943	(	_	
230-3	49943-49946	FDR	_	
230-4	49947-49956	corrected	_	
230-5	49957-49958	p	_	
230-6	49958-49959	<	_	
230-7	49959-49963	0.05	_	
230-8	49963-49964	,	_	
230-9	49965-49966	k	_	
230-10	49966-49967	>	_	
230-11	49967-49969	50	_	
230-12	49969-49970	)	_	
230-13	49971-49974	are	_	
230-14	49975-49984	displayed	_	
230-15	49985-49987	on	_	
230-16	49988-49998	contiguous	_	
230-17	49999-50005	slices	_	
230-18	50006-50008	of	_	
230-19	50009-50012	the	_	
230-20	50013-50016	EPI	_	
230-21	50017-50025	template	_	
230-22	50025-50026	.	_	

#Text=The color bar indicates t range.
231-1	50027-50030	The	_	
231-2	50031-50036	color	_	
231-3	50037-50040	bar	_	
231-4	50041-50050	indicates	_	
231-5	50051-50052	t	_	
231-6	50053-50058	range	_	
231-7	50058-50059	.	_	

#Text=Orientation: Right=Right.
232-1	50060-50071	Orientation	_	
232-2	50071-50072	:	_	
232-3	50073-50078	Right	_	
232-4	50078-50079	=	_	
232-5	50079-50084	Right	_	
232-6	50084-50085	.	_	

#Text=Positive correlation between OFC network connectivity strength and treatment response
#Text=Maximum loci of activation between connectivity during change talk (relative to baseline) and post-treatment behavior change for the adolescent cannabis using sample (FDR corrected p<0.05).
233-1	50086-50094	Positive	_	
233-2	50095-50106	correlation	_	
233-3	50107-50114	between	_	
233-4	50115-50118	OFC	_	
233-5	50119-50126	network	_	
233-6	50127-50139	connectivity	_	
233-7	50140-50148	strength	_	
233-8	50149-50152	and	_	
233-9	50153-50162	treatment	_	
233-10	50163-50171	response	_	
233-11	50172-50179	Maximum	_	
233-12	50180-50184	loci	_	
233-13	50185-50187	of	_	
233-14	50188-50198	activation	_	
233-15	50199-50206	between	_	
233-16	50207-50219	connectivity	_	
233-17	50220-50226	during	_	
233-18	50227-50233	change	_	
233-19	50234-50238	talk	_	
233-20	50239-50240	(	_	
233-21	50240-50248	relative	_	
233-22	50249-50251	to	_	
233-23	50252-50260	baseline	_	
233-24	50260-50261	)	_	
233-25	50262-50265	and	_	
233-26	50266-50280	post-treatment	_	
233-27	50281-50289	behavior	_	
233-28	50290-50296	change	_	
233-29	50297-50300	for	_	
233-30	50301-50304	the	_	
233-31	50305-50315	adolescent	_	
233-32	50316-50324	cannabis	_	
233-33	50325-50330	using	_	
233-34	50331-50337	sample	_	
233-35	50338-50339	(	_	
233-36	50339-50342	FDR	_	
233-37	50343-50352	corrected	_	
233-38	50353-50354	p	_	
233-39	50354-50355	<	_	
233-40	50355-50359	0.05	_	
233-41	50359-50360	)	_	
233-42	50360-50361	.	_	

#Text=(a) Activations have been overlaid onto the single subject template.
234-1	50362-50363	(	_	
234-2	50363-50364	a	_	
234-3	50364-50365	)	_	
234-4	50366-50377	Activations	_	
234-5	50378-50382	have	_	
234-6	50383-50387	been	_	
234-7	50388-50396	overlaid	_	
234-8	50397-50401	onto	_	
234-9	50402-50405	the	_	
234-10	50406-50412	single	_	
234-11	50413-50420	subject	_	
234-12	50421-50429	template	_	
234-13	50429-50430	.	_	

#Text=The color bar indicates t values.
235-1	50431-50434	The	_	
235-2	50435-50440	color	_	
235-3	50441-50444	bar	_	
235-4	50445-50454	indicates	_	
235-5	50455-50456	t	_	
235-6	50457-50463	values	_	
235-7	50463-50464	.	_	

#Text=Orientation: Right=Right.
236-1	50465-50476	Orientation	_	
236-2	50476-50477	:	_	
236-3	50478-50483	Right	_	
236-4	50483-50484	=	_	
236-5	50484-50489	Right	_	
236-6	50489-50490	.	_	

#Text=(b) Scatter plot of parameter estimates for connectivity strength between this ROI and the seed region have also been shown.
237-1	50491-50492	(	_	
237-2	50492-50493	b	_	
237-3	50493-50494	)	_	
237-4	50495-50502	Scatter	_	
237-5	50503-50507	plot	_	
237-6	50508-50510	of	_	
237-7	50511-50520	parameter	_	
237-8	50521-50530	estimates	_	
237-9	50531-50534	for	_	
237-10	50535-50547	connectivity	_	
237-11	50548-50556	strength	_	
237-12	50557-50564	between	_	
237-13	50565-50569	this	_	
237-14	50570-50573	ROI	_	
237-15	50574-50577	and	_	
237-16	50578-50581	the	_	
237-17	50582-50586	seed	_	
237-18	50587-50593	region	_	
237-19	50594-50598	have	_	
237-20	50599-50603	also	_	
237-21	50604-50608	been	_	
237-22	50609-50614	shown	_	
237-23	50614-50615	.	_	

#Text=Demographic Characteristics of Participating Samples
#Text=Variable\tCannabissample(n = 30)Mean\tAlcohol sample(n = 15)Mean\t \tGender\t\t\t \t    Male (n)\t25\t7\t \t    Female (n)\t5\t8\t \tRace/Ethnicity\t\t\t \t    Hispanic American\t16\t7\t \t    Bi/Multi-racial\t4\t4\t \t    Asian American\t0\t2\t \t    Native American\t0\t1\t \t    African American\t1\t0\t \t    Caucasian\t9\t1\t \tAge (years)\t16.09\t16.62\t \tAge at first drink (years)\t--\t13.86\t \tAge at first cannabis use (years)\t12.30\t--\t \tBaseline past-month drinking days\t1.74\t4.07\t \tFollow-up past month drinking days\t1.76\t0.86\t \tBaseline past-month cannabis days\t18.33\t6.36\t \tFollow-up past month cannabis days\t11.05\t5.29\t \t
#Text=Functional connectivity and treatment mechanisms: PPI results for change talk
#Text=Maximum loci of regions that showed change in connectivity with the OFC (seed region) during change talk (relative to baseline) for the adolescent cannabis using sample.
238-1	50616-50627	Demographic	_	
238-2	50628-50643	Characteristics	_	
238-3	50644-50646	of	_	
238-4	50647-50660	Participating	_	
238-5	50661-50668	Samples	_	
238-6	50669-50677	Variable	_	
238-7	50678-50692	Cannabissample	_	
238-8	50692-50693	(	_	
238-9	50693-50694	n	_	
238-10	50695-50696	=	_	
238-11	50697-50699	30	_	
238-12	50699-50700	)	_	
238-13	50700-50704	Mean	_	
238-14	50705-50712	Alcohol	_	
238-15	50713-50719	sample	_	
238-16	50719-50720	(	_	
238-17	50720-50721	n	_	
238-18	50722-50723	=	_	
238-19	50724-50726	15	_	
238-20	50726-50727	)	_	
238-21	50727-50731	Mean	_	
238-22	50734-50740	Gender	_	
238-23	50745-50749	    	_	
238-24	50749-50753	Male	_	
238-25	50754-50755	(	_	
238-26	50755-50756	n	_	
238-27	50756-50757	)	_	
238-28	50758-50760	25	_	
238-29	50761-50762	7	_	
238-30	50765-50769	    	_	
238-31	50769-50775	Female	_	
238-32	50776-50777	(	_	
238-33	50777-50778	n	_	
238-34	50778-50779	)	_	
238-35	50780-50781	5	_	
238-36	50782-50783	8	_	
238-37	50786-50790	Race	_	
238-38	50790-50791	/	_	
238-39	50791-50800	Ethnicity	_	
238-40	50805-50809	    	_	
238-41	50809-50817	Hispanic	_	
238-42	50818-50826	American	_	
238-43	50827-50829	16	_	
238-44	50830-50831	7	_	
238-45	50834-50838	    	_	
238-46	50838-50840	Bi	_	
238-47	50840-50841	/	_	
238-48	50841-50853	Multi-racial	_	
238-49	50854-50855	4	_	
238-50	50856-50857	4	_	
238-51	50860-50864	    	_	
238-52	50864-50869	Asian	_	
238-53	50870-50878	American	_	
238-54	50879-50880	0	_	
238-55	50881-50882	2	_	
238-56	50885-50889	    	_	
238-57	50889-50895	Native	_	
238-58	50896-50904	American	_	
238-59	50905-50906	0	_	
238-60	50907-50908	1	_	
238-61	50911-50915	    	_	
238-62	50915-50922	African	_	
238-63	50923-50931	American	_	
238-64	50932-50933	1	_	
238-65	50934-50935	0	_	
238-66	50938-50942	    	_	
238-67	50942-50951	Caucasian	_	
238-68	50952-50953	9	_	
238-69	50954-50955	1	_	
238-70	50958-50961	Age	_	
238-71	50962-50963	(	_	
238-72	50963-50968	years	_	
238-73	50968-50969	)	_	
238-74	50970-50975	16.09	_	
238-75	50976-50981	16.62	_	
238-76	50984-50987	Age	_	
238-77	50988-50990	at	_	
238-78	50991-50996	first	_	
238-79	50997-51002	drink	_	
238-80	51003-51004	(	_	
238-81	51004-51009	years	_	
238-82	51009-51010	)	_	
238-83	51011-51012	-	_	
238-84	51012-51013	-	_	
238-85	51014-51019	13.86	_	
238-86	51022-51025	Age	_	
238-87	51026-51028	at	_	
238-88	51029-51034	first	_	
238-89	51035-51043	cannabis	_	
238-90	51044-51047	use	_	
238-91	51048-51049	(	_	
238-92	51049-51054	years	_	
238-93	51054-51055	)	_	
238-94	51056-51061	12.30	_	
238-95	51062-51063	-	_	
238-96	51063-51064	-	_	
238-97	51067-51075	Baseline	_	
238-98	51076-51086	past-month	_	
238-99	51087-51095	drinking	_	
238-100	51096-51100	days	_	
238-101	51101-51105	1.74	_	
238-102	51106-51110	4.07	_	
238-103	51113-51122	Follow-up	_	
238-104	51123-51127	past	_	
238-105	51128-51133	month	_	
238-106	51134-51142	drinking	_	
238-107	51143-51147	days	_	
238-108	51148-51152	1.76	_	
238-109	51153-51157	0.86	_	
238-110	51160-51168	Baseline	_	
238-111	51169-51179	past-month	_	
238-112	51180-51188	cannabis	_	
238-113	51189-51193	days	_	
238-114	51194-51199	18.33	_	
238-115	51200-51204	6.36	_	
238-116	51207-51216	Follow-up	_	
238-117	51217-51221	past	_	
238-118	51222-51227	month	_	
238-119	51228-51236	cannabis	_	
238-120	51237-51241	days	_	
238-121	51242-51247	11.05	_	
238-122	51248-51252	5.29	_	
238-123	51256-51266	Functional	_	
238-124	51267-51279	connectivity	_	
238-125	51280-51283	and	_	
238-126	51284-51293	treatment	_	
238-127	51294-51304	mechanisms	_	
238-128	51304-51305	:	_	
238-129	51306-51309	PPI	_	
238-130	51310-51317	results	_	
238-131	51318-51321	for	_	
238-132	51322-51328	change	_	
238-133	51329-51333	talk	_	
238-134	51334-51341	Maximum	_	
238-135	51342-51346	loci	_	
238-136	51347-51349	of	_	
238-137	51350-51357	regions	_	
238-138	51358-51362	that	_	
238-139	51363-51369	showed	_	
238-140	51370-51376	change	_	
238-141	51377-51379	in	_	
238-142	51380-51392	connectivity	_	
238-143	51393-51397	with	_	
238-144	51398-51401	the	_	
238-145	51402-51405	OFC	_	
238-146	51406-51407	(	_	
238-147	51407-51411	seed	_	
238-148	51412-51418	region	_	
238-149	51418-51419	)	_	
238-150	51420-51426	during	_	
238-151	51427-51433	change	_	
238-152	51434-51438	talk	_	
238-153	51439-51440	(	_	
238-154	51440-51448	relative	_	
238-155	51449-51451	to	_	
238-156	51452-51460	baseline	_	
238-157	51460-51461	)	_	
238-158	51462-51465	for	_	
238-159	51466-51469	the	_	
238-160	51470-51480	adolescent	_	
238-161	51481-51489	cannabis	_	
238-162	51490-51495	using	_	
238-163	51496-51502	sample	_	
238-164	51502-51503	.	_	

#Text=Activations have been thresholded at FDR p< 0.05, k>50 voxels.
239-1	51504-51515	Activations	_	
239-2	51516-51520	have	_	
239-3	51521-51525	been	_	
239-4	51526-51537	thresholded	_	
239-5	51538-51540	at	_	
239-6	51541-51544	FDR	_	
239-7	51545-51546	p	_	
239-8	51546-51547	<	_	
239-9	51548-51552	0.05	_	
239-10	51552-51553	,	_	
239-11	51554-51555	k	_	
239-12	51555-51556	>	_	
239-13	51556-51558	50	_	
239-14	51559-51565	voxels	_	
239-15	51565-51566	.	_	

#Text=R= right; L = left.
#Text=# voxels\tLocalization\tt value\tx (mm)\ty (mm)\tz (mm)\t \t(a) Regions of increased connectivity\t \t1466\tL.
240-1	51567-51568	R	_	
240-2	51568-51569	=	_	
240-3	51570-51575	right	_	
240-4	51575-51576	;	_	
240-5	51577-51578	L	_	
240-6	51579-51580	=	_	
240-7	51581-51585	left	_	
240-8	51585-51586	.	_	
240-9	51587-51588	#	_	
240-10	51589-51595	voxels	_	
240-11	51596-51608	Localization	_	
240-12	51609-51610	t	_	
240-13	51611-51616	value	_	
240-14	51617-51618	x	_	
240-15	51619-51620	(	_	
240-16	51620-51622	mm	_	
240-17	51622-51623	)	_	
240-18	51624-51625	y	_	
240-19	51626-51627	(	_	
240-20	51627-51629	mm	_	
240-21	51629-51630	)	_	
240-22	51631-51632	z	_	
240-23	51633-51634	(	_	
240-24	51634-51636	mm	_	
240-25	51636-51637	)	_	
240-26	51640-51641	(	_	
240-27	51641-51642	a	_	
240-28	51642-51643	)	_	
240-29	51644-51651	Regions	_	
240-30	51652-51654	of	_	
240-31	51655-51664	increased	_	
240-32	51665-51677	connectivity	_	
240-33	51680-51684	1466	_	
240-34	51685-51686	L	_	
240-35	51686-51687	.	_	

#Text=Inferior frontal gyrus (Pars orbitalis)\t11.58\t−44\t26\t−8\t \t\tL.
241-1	51688-51696	Inferior	_	
241-2	51697-51704	frontal	_	
241-3	51705-51710	gyrus	_	
241-4	51711-51712	(	_	
241-5	51712-51716	Pars	_	
241-6	51717-51726	orbitalis	_	
241-7	51726-51727	)	_	
241-8	51728-51733	11.58	_	
241-9	51734-51735	−	_	
241-10	51735-51737	44	_	
241-11	51738-51740	26	_	
241-12	51741-51742	−	_	
241-13	51742-51743	8	_	
241-14	51747-51748	L	_	
241-15	51748-51749	.	_	

#Text=Precentral gyrus\t8.41\t−42\t6\t50\t \t2467\tL.
242-1	51750-51760	Precentral	_	
242-2	51761-51766	gyrus	_	
242-3	51767-51771	8.41	_	
242-4	51772-51773	−	_	
242-5	51773-51775	42	_	
242-6	51776-51777	6	_	
242-7	51778-51780	50	_	
242-8	51783-51787	2467	_	
242-9	51788-51789	L	_	
242-10	51789-51790	.	_	

#Text=Middle Temporal Gyrus\t10.2\t−60\t−32\t−6\t \t\tL.
243-1	51791-51797	Middle	_	
243-2	51798-51806	Temporal	_	
243-3	51807-51812	Gyrus	_	
243-4	51813-51817	10.2	_	
243-5	51818-51819	−	_	
243-6	51819-51821	60	_	
243-7	51822-51823	−	_	
243-8	51823-51825	32	_	
243-9	51826-51827	−	_	
243-10	51827-51828	6	_	
243-11	51832-51833	L	_	
243-12	51833-51834	.	_	

#Text=Middle Temporal Gyrus\t9.22\t−52\t−36\t−2\t \t1379\tL.
244-1	51835-51841	Middle	_	
244-2	51842-51850	Temporal	_	
244-3	51851-51856	Gyrus	_	
244-4	51857-51861	9.22	_	
244-5	51862-51863	−	_	
244-6	51863-51865	52	_	
244-7	51866-51867	−	_	
244-8	51867-51869	36	_	
244-9	51870-51871	−	_	
244-10	51871-51872	2	_	
244-11	51875-51879	1379	_	
244-12	51880-51881	L	_	
244-13	51881-51882	.	_	

#Text=Supplementary motor area\t9.38\t−4\t16\t62\t \t\tL.
245-1	51883-51896	Supplementary	_	
245-2	51897-51902	motor	_	
245-3	51903-51907	area	_	
245-4	51908-51912	9.38	_	
245-5	51913-51914	−	_	
245-6	51914-51915	4	_	
245-7	51916-51918	16	_	
245-8	51919-51921	62	_	
245-9	51925-51926	L	_	
245-10	51926-51927	.	_	

#Text=Medial superior frontal gyrus\t7.27\t−8\t34\t56\t \t1148\tR.
246-1	51928-51934	Medial	_	
246-2	51935-51943	superior	_	
246-3	51944-51951	frontal	_	
246-4	51952-51957	gyrus	_	
246-5	51958-51962	7.27	_	
246-6	51963-51964	−	_	
246-7	51964-51965	8	_	
246-8	51966-51968	34	_	
246-9	51969-51971	56	_	
246-10	51974-51978	1148	_	
246-11	51979-51980	R	_	
246-12	51980-51981	.	_	

#Text=Middle Temporal Gyrus\t7.66\t52\t−34\t2\t \t\tR.
247-1	51982-51988	Middle	_	
247-2	51989-51997	Temporal	_	
247-3	51998-52003	Gyrus	_	
247-4	52004-52008	7.66	_	
247-5	52009-52011	52	_	
247-6	52012-52013	−	_	
247-7	52013-52015	34	_	
247-8	52016-52017	2	_	
247-9	52021-52022	R	_	
247-10	52022-52023	.	_	

#Text=Superior temporal gyrus\t5.96\t62\t−24\t−2\t \t137\tR.
248-1	52024-52032	Superior	_	
248-2	52033-52041	temporal	_	
248-3	52042-52047	gyrus	_	
248-4	52048-52052	5.96	_	
248-5	52053-52055	62	_	
248-6	52056-52057	−	_	
248-7	52057-52059	24	_	
248-8	52060-52061	−	_	
248-9	52061-52062	2	_	
248-10	52065-52068	137	_	
248-11	52069-52070	R	_	
248-12	52070-52071	.	_	

#Text=Inferior Occipital Gyrus\t7.06\t26\t−98\t−4\t \t\tR.
249-1	52072-52080	Inferior	_	
249-2	52081-52090	Occipital	_	
249-3	52091-52096	Gyrus	_	
249-4	52097-52101	7.06	_	
249-5	52102-52104	26	_	
249-6	52105-52106	−	_	
249-7	52106-52108	98	_	
249-8	52109-52110	−	_	
249-9	52110-52111	4	_	
249-10	52115-52116	R	_	
249-11	52116-52117	.	_	

#Text=Calcarine gyrus\t5.43\t18\t−96\t−4\t \t798\tL.
250-1	52118-52127	Calcarine	_	
250-2	52128-52133	gyrus	_	
250-3	52134-52138	5.43	_	
250-4	52139-52141	18	_	
250-5	52142-52143	−	_	
250-6	52143-52145	96	_	
250-7	52146-52147	−	_	
250-8	52147-52148	4	_	
250-9	52151-52154	798	_	
250-10	52155-52156	L	_	
250-11	52156-52157	.	_	

#Text=Posterior cingulate gyrus\t6.5\t−6\t−50\t28\t \t\tR.
251-1	52158-52167	Posterior	_	
251-2	52168-52177	cingulate	_	
251-3	52178-52183	gyrus	_	
251-4	52184-52187	6.5	_	
251-5	52188-52189	−	_	
251-6	52189-52190	6	_	
251-7	52191-52192	−	_	
251-8	52192-52194	50	_	
251-9	52195-52197	28	_	
251-10	52201-52202	R	_	
251-11	52202-52203	.	_	

#Text=Posterior cingulate gyrus\t4.39\t2\t−48\t26\t \t96\tL.
252-1	52204-52213	Posterior	_	
252-2	52214-52223	cingulate	_	
252-3	52224-52229	gyrus	_	
252-4	52230-52234	4.39	_	
252-5	52235-52236	2	_	
252-6	52237-52238	−	_	
252-7	52238-52240	48	_	
252-8	52241-52243	26	_	
252-9	52246-52248	96	_	
252-10	52249-52250	L	_	
252-11	52250-52251	.	_	

#Text=Inferior occipital gyrus\t6.32\t−26\t−94\t−6\t \t350\tR.
253-1	52252-52260	Inferior	_	
253-2	52261-52270	occipital	_	
253-3	52271-52276	gyrus	_	
253-4	52277-52281	6.32	_	
253-5	52282-52283	−	_	
253-6	52283-52285	26	_	
253-7	52286-52287	−	_	
253-8	52287-52289	94	_	
253-9	52290-52291	−	_	
253-10	52291-52292	6	_	
253-11	52295-52298	350	_	
253-12	52299-52300	R	_	
253-13	52300-52301	.	_	

#Text=Medial superior frontal gyrus\t6.29\t8\t62\t24\t \t193\tL.
254-1	52302-52308	Medial	_	
254-2	52309-52317	superior	_	
254-3	52318-52325	frontal	_	
254-4	52326-52331	gyrus	_	
254-5	52332-52336	6.29	_	
254-6	52337-52338	8	_	
254-7	52339-52341	62	_	
254-8	52342-52344	24	_	
254-9	52347-52350	193	_	
254-10	52351-52352	L	_	
254-11	52352-52353	.	_	

#Text=Pallidum\t5.36\t−18\t4\t−4\t \t\tL.
255-1	52354-52362	Pallidum	_	
255-2	52363-52367	5.36	_	
255-3	52368-52369	−	_	
255-4	52369-52371	18	_	
255-5	52372-52373	4	_	
255-6	52374-52375	−	_	
255-7	52375-52376	4	_	
255-8	52380-52381	L	_	
255-9	52381-52382	.	_	

#Text=Caudate\t3.75\t−8\t4\t4\t \t418\tL.
256-1	52383-52390	Caudate	_	
256-2	52391-52395	3.75	_	
256-3	52396-52397	−	_	
256-4	52397-52398	8	_	
256-5	52399-52400	4	_	
256-6	52401-52402	4	_	
256-7	52405-52408	418	_	
256-8	52409-52410	L	_	
256-9	52410-52411	.	_	

#Text=Middle temporal pole\t5.1\t−46\t14\t−30\t \t\tL.
257-1	52412-52418	Middle	_	
257-2	52419-52427	temporal	_	
257-3	52428-52432	pole	_	
257-4	52433-52436	5.1	_	
257-5	52437-52438	−	_	
257-6	52438-52440	46	_	
257-7	52441-52443	14	_	
257-8	52444-52445	−	_	
257-9	52445-52447	30	_	
257-10	52451-52452	L	_	
257-11	52452-52453	.	_	

#Text=Inferior temporal gyrus\t4.78\t−44\t2\t−40\t \t140\tL.
258-1	52454-52462	Inferior	_	
258-2	52463-52471	temporal	_	
258-3	52472-52477	gyrus	_	
258-4	52478-52482	4.78	_	
258-5	52483-52484	−	_	
258-6	52484-52486	44	_	
258-7	52487-52488	2	_	
258-8	52489-52490	−	_	
258-9	52490-52492	40	_	
258-10	52495-52498	140	_	
258-11	52499-52500	L	_	
258-12	52500-52501	.	_	

#Text=Middle cingulate gyrus\t5.04\t−2\t−16\t40\t \t\tL.
259-1	52502-52508	Middle	_	
259-2	52509-52518	cingulate	_	
259-3	52519-52524	gyrus	_	
259-4	52525-52529	5.04	_	
259-5	52530-52531	−	_	
259-6	52531-52532	2	_	
259-7	52533-52534	−	_	
259-8	52534-52536	16	_	
259-9	52537-52539	40	_	
259-10	52543-52544	L	_	
259-11	52544-52545	.	_	

#Text=Anterior cingulate gyrus\t2.57\t−2\t−4\t30\t \t134\tL.
260-1	52546-52554	Anterior	_	
260-2	52555-52564	cingulate	_	
260-3	52565-52570	gyrus	_	
260-4	52571-52575	2.57	_	
260-5	52576-52577	−	_	
260-6	52577-52578	2	_	
260-7	52579-52580	−	_	
260-8	52580-52581	4	_	
260-9	52582-52584	30	_	
260-10	52587-52590	134	_	
260-11	52591-52592	L	_	
260-12	52592-52593	.	_	

#Text=Parahippocampal Gyrus\t3.96\t−16\t−14\t−14\t \t202\tR.
261-1	52594-52609	Parahippocampal	_	
261-2	52610-52615	Gyrus	_	
261-3	52616-52620	3.96	_	
261-4	52621-52622	−	_	
261-5	52622-52624	16	_	
261-6	52625-52626	−	_	
261-7	52626-52628	14	_	
261-8	52629-52630	−	_	
261-9	52630-52632	14	_	
261-10	52635-52638	202	_	
261-11	52639-52640	R	_	
261-12	52640-52641	.	_	

#Text=Inferior Frontal Gyrus (Parstriangularis)\t3.87\t52\t24\t2\t \t\tR.
262-1	52642-52650	Inferior	_	
262-2	52651-52658	Frontal	_	
262-3	52659-52664	Gyrus	_	
262-4	52665-52666	(	_	
262-5	52666-52682	Parstriangularis	_	
262-6	52682-52683	)	_	
262-7	52684-52688	3.87	_	
262-8	52689-52691	52	_	
262-9	52692-52694	24	_	
262-10	52695-52696	2	_	
262-11	52700-52701	R	_	
262-12	52701-52702	.	_	

#Text=Inferior Frontal Gyrus (Parstriangularis)\t3.72\t58\t28\t14\t \t68\tR.
263-1	52703-52711	Inferior	_	
263-2	52712-52719	Frontal	_	
263-3	52720-52725	Gyrus	_	
263-4	52726-52727	(	_	
263-5	52727-52743	Parstriangularis	_	
263-6	52743-52744	)	_	
263-7	52745-52749	3.72	_	
263-8	52750-52752	58	_	
263-9	52753-52755	28	_	
263-10	52756-52758	14	_	
263-11	52761-52763	68	_	
263-12	52764-52765	R	_	
263-13	52765-52766	.	_	

#Text=Caudate\t3.83\t14\t10\t8\t \t\tR.
264-1	52767-52774	Caudate	_	
264-2	52775-52779	3.83	_	
264-3	52780-52782	14	_	
264-4	52783-52785	10	_	
264-5	52786-52787	8	_	
264-6	52791-52792	R	_	
264-7	52792-52793	.	_	

#Text=Pallidum\t3.79\t18\t4\t−6\t \t112\tL.
265-1	52794-52802	Pallidum	_	
265-2	52803-52807	3.79	_	
265-3	52808-52810	18	_	
265-4	52811-52812	4	_	
265-5	52813-52814	−	_	
265-6	52814-52815	6	_	
265-7	52818-52821	112	_	
265-8	52822-52823	L	_	
265-9	52823-52824	.	_	

#Text=Rectus\t3.55\t−6\t46\t−16\t \t\tL.
266-1	52825-52831	Rectus	_	
266-2	52832-52836	3.55	_	
266-3	52837-52838	−	_	
266-4	52838-52839	6	_	
266-5	52840-52842	46	_	
266-6	52843-52844	−	_	
266-7	52844-52846	16	_	
266-8	52850-52851	L	_	
266-9	52851-52852	.	_	

#Text=Rectus\t3.24\t−2\t38\t−20\t \t\t \t(b) Regions of decreased connectivity\t \t\t \t1201\tR.
267-1	52853-52859	Rectus	_	
267-2	52860-52864	3.24	_	
267-3	52865-52866	−	_	
267-4	52866-52867	2	_	
267-5	52868-52870	38	_	
267-6	52871-52872	−	_	
267-7	52872-52874	20	_	
267-8	52880-52881	(	_	
267-9	52881-52882	b	_	
267-10	52882-52883	)	_	
267-11	52884-52891	Regions	_	
267-12	52892-52894	of	_	
267-13	52895-52904	decreased	_	
267-14	52905-52917	connectivity	_	
267-15	52923-52927	1201	_	
267-16	52928-52929	R	_	
267-17	52929-52930	.	_	

#Text=Middle frontal gyrus\t7.12\t34\t34\t40\t \t\tR.
268-1	52931-52937	Middle	_	
268-2	52938-52945	frontal	_	
268-3	52946-52951	gyrus	_	
268-4	52952-52956	7.12	_	
268-5	52957-52959	34	_	
268-6	52960-52962	34	_	
268-7	52963-52965	40	_	
268-8	52969-52970	R	_	
268-9	52970-52971	.	_	

#Text=Superior frontal gyrus\t6.01\t24\t4\t68\t \t2604\tR.
269-1	52972-52980	Superior	_	
269-2	52981-52988	frontal	_	
269-3	52989-52994	gyrus	_	
269-4	52995-52999	6.01	_	
269-5	53000-53002	24	_	
269-6	53003-53004	4	_	
269-7	53005-53007	68	_	
269-8	53010-53014	2604	_	
269-9	53015-53016	R	_	
269-10	53016-53017	.	_	

#Text=Middle temporal gyrus\t6.98\t52\t−62\t2\t \t\tR.
270-1	53018-53024	Middle	_	
270-2	53025-53033	temporal	_	
270-3	53034-53039	gyrus	_	
270-4	53040-53044	6.98	_	
270-5	53045-53047	52	_	
270-6	53048-53049	−	_	
270-7	53049-53051	62	_	
270-8	53052-53053	2	_	
270-9	53057-53058	R	_	
270-10	53058-53059	.	_	

#Text=Precuneus\t6.63\t10\t−58\t62\t \t1429\tL.
271-1	53060-53069	Precuneus	_	
271-2	53070-53074	6.63	_	
271-3	53075-53077	10	_	
271-4	53078-53079	−	_	
271-5	53079-53081	58	_	
271-6	53082-53084	62	_	
271-7	53087-53091	1429	_	
271-8	53092-53093	L	_	
271-9	53093-53094	.	_	

#Text=Precuneus\t6.89\t−8\t−60\t60\t \t\tL.
272-1	53095-53104	Precuneus	_	
272-2	53105-53109	6.89	_	
272-3	53110-53111	−	_	
272-4	53111-53112	8	_	
272-5	53113-53114	−	_	
272-6	53114-53116	60	_	
272-7	53117-53119	60	_	
272-8	53123-53124	L	_	
272-9	53124-53125	.	_	

#Text=Midde temporal gyrus\t6.61\t−50\t−68\t6\t \t1230\tL.
273-1	53126-53131	Midde	_	
273-2	53132-53140	temporal	_	
273-3	53141-53146	gyrus	_	
273-4	53147-53151	6.61	_	
273-5	53152-53153	−	_	
273-6	53153-53155	50	_	
273-7	53156-53157	−	_	
273-8	53157-53159	68	_	
273-9	53160-53161	6	_	
273-10	53164-53168	1230	_	
273-11	53169-53170	L	_	
273-12	53170-53171	.	_	

#Text=Lingual gyrus\t6.39\t−16\t−78\t−8\t \t\tL.
274-1	53172-53179	Lingual	_	
274-2	53180-53185	gyrus	_	
274-3	53186-53190	6.39	_	
274-4	53191-53192	−	_	
274-5	53192-53194	16	_	
274-6	53195-53196	−	_	
274-7	53196-53198	78	_	
274-8	53199-53200	−	_	
274-9	53200-53201	8	_	
274-10	53205-53206	L	_	
274-11	53206-53207	.	_	

#Text=Parahippocampal gyrus\t5.66\t−32\t−26\t−24\t \t551\tR.
275-1	53208-53223	Parahippocampal	_	
275-2	53224-53229	gyrus	_	
275-3	53230-53234	5.66	_	
275-4	53235-53236	−	_	
275-5	53236-53238	32	_	
275-6	53239-53240	−	_	
275-7	53240-53242	26	_	
275-8	53243-53244	−	_	
275-9	53244-53246	24	_	
275-10	53249-53252	551	_	
275-11	53253-53254	R	_	
275-12	53254-53255	.	_	

#Text=Supramarginal gyrus\t5.91\t60\t−32\t30\t \t\tR.
276-1	53256-53269	Supramarginal	_	
276-2	53270-53275	gyrus	_	
276-3	53276-53280	5.91	_	
276-4	53281-53283	60	_	
276-5	53284-53285	−	_	
276-6	53285-53287	32	_	
276-7	53288-53290	30	_	
276-8	53294-53295	R	_	
276-9	53295-53296	.	_	

#Text=Postcentral gyrus\t4.39\t54\t−24\t52\t \t939\tR.
277-1	53297-53308	Postcentral	_	
277-2	53309-53314	gyrus	_	
277-3	53315-53319	4.39	_	
277-4	53320-53322	54	_	
277-5	53323-53324	−	_	
277-6	53324-53326	24	_	
277-7	53327-53329	52	_	
277-8	53332-53335	939	_	
277-9	53336-53337	R	_	
277-10	53337-53338	.	_	

#Text=Inferior temporal gyrus\t5.77\t50\t−46\t−18\t \t\tR.
278-1	53339-53347	Inferior	_	
278-2	53348-53356	temporal	_	
278-3	53357-53362	gyrus	_	
278-4	53363-53367	5.77	_	
278-5	53368-53370	50	_	
278-6	53371-53372	−	_	
278-7	53372-53374	46	_	
278-8	53375-53376	−	_	
278-9	53376-53378	18	_	
278-10	53382-53383	R	_	
278-11	53383-53384	.	_	

#Text=Fusiform gyrus\t4.44\t38\t−30\t−18\t \t62\tR.
279-1	53385-53393	Fusiform	_	
279-2	53394-53399	gyrus	_	
279-3	53400-53404	4.44	_	
279-4	53405-53407	38	_	
279-5	53408-53409	−	_	
279-6	53409-53411	30	_	
279-7	53412-53413	−	_	
279-8	53413-53415	18	_	
279-9	53418-53420	62	_	
279-10	53421-53422	R	_	
279-11	53422-53423	.	_	

#Text=Superior occipital gyrus\t5.47\t16\t−100\t16\t \t61\tL.
280-1	53424-53432	Superior	_	
280-2	53433-53442	occipital	_	
280-3	53443-53448	gyrus	_	
280-4	53449-53453	5.47	_	
280-5	53454-53456	16	_	
280-6	53457-53458	−	_	
280-7	53458-53461	100	_	
280-8	53462-53464	16	_	
280-9	53467-53469	61	_	
280-10	53470-53471	L	_	
280-11	53471-53472	.	_	

#Text=Superior occipital gyrus\t5.39\t−18\t−100\t14\t \t83\tR.
281-1	53473-53481	Superior	_	
281-2	53482-53491	occipital	_	
281-3	53492-53497	gyrus	_	
281-4	53498-53502	5.39	_	
281-5	53503-53504	−	_	
281-6	53504-53506	18	_	
281-7	53507-53508	−	_	
281-8	53508-53511	100	_	
281-9	53512-53514	14	_	
281-10	53517-53519	83	_	
281-11	53520-53521	R	_	
281-12	53521-53522	.	_	

#Text=Thalamus\t5.27\t14\t−26\t10\t \t52\tL.
282-1	53523-53531	Thalamus	_	
282-2	53532-53536	5.27	_	
282-3	53537-53539	14	_	
282-4	53540-53541	−	_	
282-5	53541-53543	26	_	
282-6	53544-53546	10	_	
282-7	53549-53551	52	_	
282-8	53552-53553	L	_	
282-9	53553-53554	.	_	

#Text=Thalamus\t4.91\t−14\t−30\t12\t \t261\tL.
283-1	53555-53563	Thalamus	_	
283-2	53564-53568	4.91	_	
283-3	53569-53570	−	_	
283-4	53570-53572	14	_	
283-5	53573-53574	−	_	
283-6	53574-53576	30	_	
283-7	53577-53579	12	_	
283-8	53582-53585	261	_	
283-9	53586-53587	L	_	
283-10	53587-53588	.	_	

#Text=Supramarginal gyrus\t4.9\t−62\t−30\t40\t \t\tL.
284-1	53589-53602	Supramarginal	_	
284-2	53603-53608	gyrus	_	
284-3	53609-53612	4.9	_	
284-4	53613-53614	−	_	
284-5	53614-53616	62	_	
284-6	53617-53618	−	_	
284-7	53618-53620	30	_	
284-8	53621-53623	40	_	
284-9	53627-53628	L	_	
284-10	53628-53629	.	_	

#Text=Inferior parietal lobule\t3.39\t−52\t−36\t52\t \t55\tL.
285-1	53630-53638	Inferior	_	
285-2	53639-53647	parietal	_	
285-3	53648-53654	lobule	_	
285-4	53655-53659	3.39	_	
285-5	53660-53661	−	_	
285-6	53661-53663	52	_	
285-7	53664-53665	−	_	
285-8	53665-53667	36	_	
285-9	53668-53670	52	_	
285-10	53673-53675	55	_	
285-11	53676-53677	L	_	
285-12	53677-53678	.	_	

#Text=Middle frontal gyrus\t4.69\t−22\t2\t68\t \t\tL.
286-1	53679-53685	Middle	_	
286-2	53686-53693	frontal	_	
286-3	53694-53699	gyrus	_	
286-4	53700-53704	4.69	_	
286-5	53705-53706	−	_	
286-6	53706-53708	22	_	
286-7	53709-53710	2	_	
286-8	53711-53713	68	_	
286-9	53717-53718	L	_	
286-10	53718-53719	.	_	

#Text=Superior frontal gyrus\t3.88\t−22\t4\t58\t \t158\tR.
287-1	53720-53728	Superior	_	
287-2	53729-53736	frontal	_	
287-3	53737-53742	gyrus	_	
287-4	53743-53747	3.88	_	
287-5	53748-53749	−	_	
287-6	53749-53751	22	_	
287-7	53752-53753	4	_	
287-8	53754-53756	58	_	
287-9	53759-53762	158	_	
287-10	53763-53764	R	_	
287-11	53764-53765	.	_	

#Text=Olfactory gyrus\t4.65\t4\t14\t−10\t \t89\tL.
288-1	53766-53775	Olfactory	_	
288-2	53776-53781	gyrus	_	
288-3	53782-53786	4.65	_	
288-4	53787-53788	4	_	
288-5	53789-53791	14	_	
288-6	53792-53793	−	_	
288-7	53793-53795	10	_	
288-8	53798-53800	89	_	
288-9	53801-53802	L	_	
288-10	53802-53803	.	_	

#Text=Middle cingulate gyrus\t4.02\t−10\t4\t40\t \t212\tL.
289-1	53804-53810	Middle	_	
289-2	53811-53820	cingulate	_	
289-3	53821-53826	gyrus	_	
289-4	53827-53831	4.02	_	
289-5	53832-53833	−	_	
289-6	53833-53835	10	_	
289-7	53836-53837	4	_	
289-8	53838-53840	40	_	
289-9	53843-53846	212	_	
289-10	53847-53848	L	_	
289-11	53848-53849	.	_	

#Text=Middle frontal gyrus\t4\t−32\t36\t40\t \t\tL.
290-1	53850-53856	Middle	_	
290-2	53857-53864	frontal	_	
290-3	53865-53870	gyrus	_	
290-4	53871-53872	4	_	
290-5	53873-53874	−	_	
290-6	53874-53876	32	_	
290-7	53877-53879	36	_	
290-8	53880-53882	40	_	
290-9	53886-53887	L	_	
290-10	53887-53888	.	_	

#Text=Middle frontal gyrus\t3.79\t−30\t30\t32\t \t101\tR.
291-1	53889-53895	Middle	_	
291-2	53896-53903	frontal	_	
291-3	53904-53909	gyrus	_	
291-4	53910-53914	3.79	_	
291-5	53915-53916	−	_	
291-6	53916-53918	30	_	
291-7	53919-53921	30	_	
291-8	53922-53924	32	_	
291-9	53927-53930	101	_	
291-10	53931-53932	R	_	
291-11	53932-53933	.	_	

#Text=Superior temporal pole\t3.81\t46\t6\t−12\t \t(c) Correlations between OFC network connectivity strength and treatment response\t \t87\tL.
292-1	53934-53942	Superior	_	
292-2	53943-53951	temporal	_	
292-3	53952-53956	pole	_	
292-4	53957-53961	3.81	_	
292-5	53962-53964	46	_	
292-6	53965-53966	6	_	
292-7	53967-53968	−	_	
292-8	53968-53970	12	_	
292-9	53973-53974	(	_	
292-10	53974-53975	c	_	
292-11	53975-53976	)	_	
292-12	53977-53989	Correlations	_	
292-13	53990-53997	between	_	
292-14	53998-54001	OFC	_	
292-15	54002-54009	network	_	
292-16	54010-54022	connectivity	_	
292-17	54023-54031	strength	_	
292-18	54032-54035	and	_	
292-19	54036-54045	treatment	_	
292-20	54046-54054	response	_	
292-21	54057-54059	87	_	
292-22	54060-54061	L	_	
292-23	54061-54062	.	_	

#Text=Anterior cingulate gyrus/Medial frontalgyrus\t6.26\t−2\t40\t26\t \t\tL.
293-1	54063-54071	Anterior	_	
293-2	54072-54081	cingulate	_	
293-3	54082-54087	gyrus	_	
293-4	54087-54088	/	_	
293-5	54088-54094	Medial	_	
293-6	54095-54107	frontalgyrus	_	
293-7	54108-54112	6.26	_	
293-8	54113-54114	−	_	
293-9	54114-54115	2	_	
293-10	54116-54118	40	_	
293-11	54119-54121	26	_	
293-12	54125-54126	L	_	
293-13	54126-54127	.	_	

#Text=Medial frontal gyrus\t5.46\t−2\t48\t30\t \t50\tR.
294-1	54128-54134	Medial	_	
294-2	54135-54142	frontal	_	
294-3	54143-54148	gyrus	_	
294-4	54149-54153	5.46	_	
294-5	54154-54155	−	_	
294-6	54155-54156	2	_	
294-7	54157-54159	48	_	
294-8	54160-54162	30	_	
294-9	54165-54167	50	_	
294-10	54168-54169	R	_	
294-11	54169-54170	.	_	

#Text=Anterior cingulate gyrus\t5.88\t4\t36\t24\t \t
#Text=Highlights
#Text=Functional connectivity has been associated with addiction.
295-1	54171-54179	Anterior	_	
295-2	54180-54189	cingulate	_	
295-3	54190-54195	gyrus	_	
295-4	54196-54200	5.88	_	
295-5	54201-54202	4	_	
295-6	54203-54205	36	_	
295-7	54206-54208	24	_	
295-8	54212-54222	Highlights	_	
295-9	54223-54233	Functional	_	
295-10	54234-54246	connectivity	_	
295-11	54247-54250	has	_	
295-12	54251-54255	been	_	
295-13	54256-54266	associated	_	
295-14	54267-54271	with	_	
295-15	54272-54281	addiction	_	
295-16	54281-54282	.	_	

#Text=We examined functional connectivity as a mechanism of treatment response.
296-1	54283-54285	We	_	
296-2	54286-54294	examined	_	
296-3	54295-54305	functional	_	
296-4	54306-54318	connectivity	_	
296-5	54319-54321	as	_	
296-6	54322-54323	a	_	
296-7	54324-54333	mechanism	_	
296-8	54334-54336	of	_	
296-9	54337-54346	treatment	_	
296-10	54347-54355	response	_	
296-11	54355-54356	.	_	

#Text=We found network cohesion seeded on the OFC.
297-1	54357-54359	We	_	
297-2	54360-54365	found	_	
297-3	54366-54373	network	_	
297-4	54374-54382	cohesion	_	
297-5	54383-54389	seeded	_	
297-6	54390-54392	on	_	
297-7	54393-54396	the	_	
297-8	54397-54400	OFC	_	
297-9	54400-54401	.	_	

#Text=OFC functional connectivity was associated with behavior change.
298-1	54402-54405	OFC	_	
298-2	54406-54416	functional	_	
298-3	54417-54429	connectivity	_	
298-4	54430-54433	was	_	
298-5	54434-54444	associated	_	
298-6	54445-54449	with	_	
298-7	54450-54458	behavior	_	
298-8	54459-54465	change	_	
298-9	54465-54466	.	_	
